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Abstract 
Multicellular organisms have the ability to produce and maintain several cell 
types despite the DNA molecule being the same in all cells. For that, a complex 
network of cis-regulatory elements (CRE) and transcription factors is involved in 
controlling cellular fate. Among the different approaches that allow the identification 
of CREs, the novel ATAC-sequencing is becoming an increasingly used tool due to 
its easy-to-perform protocol. In this study, this technique has been optimized to be 
used in two species (Xenopus laevis and Schmidtea mediterranea) to elucidate (1) 
the epigenetic mechanism behind Xenopus neural crest (NC) specification and 
differentiation, and (2) the establishment of anteroposterior identity during planarian 
regeneration.  
ATAC-sequencing has been carried out on Xenopus animal caps induced to 
give rise to NC or neural tissue. Comparison of this data along with non-injected 
ectodermal animal caps has led to the characterization of the epigenome involved in 
Xenopus neural crest formation. Results show that 4,528 NC open regions or 
potential enhancers are present during specification whereas 852 NC potential 
enhancers are specific for differentiation. In these NC open regions, the 
transcription factors Zic, Meis and Sox10 play an important role. Five enhancers 
driving expression of key neural crest genes (cmyc, foxd3, id3, snai2 and sox10) 
have been identified. 
ATAC-sequencing has also been successfully validated on dissected 
blastemas from 48h regenerating planarians. The analysis has revealed nervous 
system-related transcription factor motifs such as Prep or NeuroD-1 present in 
anterior specific open regions whereas posterior polarity-related transcription factor 
binding sites such as Islet or HoxD3 are present in posterior open regions.  
 
Key words: ATAC-sequencing, enhancer, transcription factor, Xenopus neural crest, 
planarian, anteroposterior polarity. 
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1.1. Genome architecture 
With the origin of multicellular organisms, the control of gene expression 
gets more sophisticated as such organisms have to produce and maintain different 
cell types with the same genome information. Moreover, the eukaryotic genome has 
to be tightly compact to fit inside the nuclei and, at the same time, to allow the 
accessibility of the DNA at regulatory regions to ensure proper gene expression 
(Perino & Veenstra 2016). The 3D organization of the genome acquires, then, more 
importance as it has an impact on transcription, DNA replication, chromatin stability 
and splicing. The different hierarchies of organization involve: (1) chromosome 
territories, (2) chromatin compartments, (3) topological associated domains (TADs), 
(4) chromatin/histone modifications and (5) enhancer-promoter loops (Figure 1). 
 
Figure 1: Genome architecture. The chromosome territories, chromatin compartments, 
TADs, histone modifications and enhancer-promoter loops are shown. 
The chromosomes have a preferred location in the nuclei: active regions 
tend to be in the periphery physically separated from permanently silence regions 
(Figure 1). However, the location of the genome in the nuclei seems to be cell-
specific rather than having a role in gene expression (Cremer & Cremer 2001). 
Genomic regions of approximately 5Mb determine the chromatin compartments: the 
active A compartment and the inactive B compartment. Within compartments, the 
topological associated domains are defined. Unlike the A/B compartments, TADs 
are very rigid and do not change between different cell types and developmental 
stages. TADs determine the regulatory space within which genes and regulatory 
elements such as enhancer, promoters and insulators interact forming loops. The 
loops that define TADs are highly enriched in CTCF and cohesin proteins (Perino & 
Veenstra 2016; Sewitz et al. 2017). At a lower scale, chromatin is a highly dynamic 
and regulated macromolecular complex comprised of DNA and nucleosomes, 
which are octamers containing two each of the histone proteins H2A, H2B, H3 
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and H4. 146 base pairs of genomic DNA are wrapped around each nucleosome 
with a 20-50bp link between them. The repetition of nucleosomes builds up the 
chromatin, which can be subdivided into two main domains regarding its 
activity: the heterochromatin, tightly packed and primarily containing inactive 
genes, and the euchromatin, which has a relaxed conformation and is where 
active transcription takes place. The N-terminal tail of the histone proteins can 
be post-translationally modified. These modifications include among others: 
acetylation, methylation, phosphorylation and ubiquitination (Sawan et al. 2008; 
Dawson & Kouzarides 2012). The last level of gene regulation is composed of 
cis-regulatory elements (CREs). CREs are sequences present in the DNA 
molecule that regulate gene expression. The most common elements are the 
promoters, at the transcription start site (TSS), and the enhancers. The 
regulatory landscapes of a gene is composed of all the distal cis-regulatory 
elements that regulate a specific promoter (Maeso et al. 2017).  
As this study focuses on identifying cis-regulatory elements in two 
different scenarios, here, histone modifications and regulatory elements such as 
enhancers and promoters are going to be further explained.  
1.1.1. Histone modifications 
Histone proteins can be post-transcriptional modified by several 
chemical groups. Histone modifications are dynamically added and removed by 
chromatin-modifying enzymes in a highly regulated manner (Figure 2). These 
can (1) enhance or weaken non-covalent interactions between DNA and 
histones, due to changes in the net charge of nucleosomes, and (2) act as a 
platform for recruitment of other proteins with domains that specifically 
recognize these modifications. For these reasons, histone modifications 
modulate the accessibility to certain loci and therefore play a critical role in all 
DNA-based regulation processes such as transcription, DNA repair and 
replication (Lawrence et al. 2016).  
The chromatin-modifying enzymes can be divided into three classes 
regarding their role: (1) writers, capable of adding chemical modifications to 
DNA or histones; (2) erasers, able to remove these chemical modifications and 
finally (3) readers, which bind to specific modifications. The specificity of the 
readers is due to critical residues in their binding pocket, which confer 
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selectivity for particular modifications, as well as residues outside the binding 
pocket that confer histone-sequence preferences (Berger et al. 2009).  
The best-characterized epigenetic modifications are DNA methylation, 
histone methylation and histone acetylation (Figure 2). First, the methylation of the 
fifth position of cytosine (5-methylcitosine, 5mC) at CpG islands on the promoters is 
associated with silenced coding and non-coding genes during cell linage. DNA 
methyltransferases (DNMT) are the enzymes responsible of adding the methyl 
group whereas a complex cascade of TET enzymes is required for removing the 
methyl group. Secondly, lysine methylation of histone residues can be associated 
with activation or repression of genes depending on the position: methylation of 
H3K4, H3K36 and H3K79 are modifications associated with activation whereas 
methylation of H3K9, H3K27 and H3K20 mark repression. The enzyme families 
lysine methyltransferase (KMT) and lysine demethylase (KDM) are responsible of 
adding and removing the methyl group, respectively. On the other side, proteins 
with chromo and PHD domains bind specifically to lysine methylated positions, such 
as polycomb proteins, which binds to H3K27me to repress gene expression. Finally, 
acetylation of histone residues is associated with activation of transcription since 
this modification affects the electrical charge of histones. The histone proteins are 
negatively charged, and therefore this modification weakens the interaction between 
histone and DNA allowing the accessibility of transcription factors. Histone 
acetyltransferases (HAT) and histone deacetylases (HDAC) are responsible of this 
modification and proteins with bromo domains can bind specifically to acetylated 
histones, such as the transcription initiation factor TAF1 which binds to H4K5ac to 
stabilize TBP-TATA box complex (Kouzarides 2007). 
                  
Figure 2: Scheme of the main histone modifications involved in gene regulation. 
Me=methylation, Ac=acetylation, P=phosphorylation and Ub=ubiquitination. Modified from 
Promega website.  
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1.1.2. Genomic regulatory elements 
1.1.2.1. Enhancers 
Enhancers are defined as small sequences of DNA, about a few hundred 
base pairs that act as a platform for transcription factors, which in turn can recruit 
other cofactors and nucleosome-remodeling complexes, thus regulating gene 
expression. Enhancers can be located 3’, 5’, intronically or even exonically relative 
to their target genes (Suryamohan & Halfon 2015). Different enhancers can exhibit 
different regulatory behaviors. Some genes have multiple enhancers each 
controlling specific spatiotemporal aspects of their target gene expression; some 
other genes have secondary enhancers, which drive similar expression conferring 
robustness; some other genes are regulated by so-called superenhancers, which 
contain several motifs for important transcription factors such as Oct4, Sox2, and 
Nanog as well as the coactivator Mediator. Superenhancers are composed by 
multiple concatenated enhancers within 12.5kb and have the ability to activate high 
levels of transcription of the target genes, usually key cell-type specific genes 
(Whyte et al. 2013; Spitz & Furlong 2012; Maeso et al. 2017).  
Transcription factors (TFs) are an important player in cis-regulation. TFs 
recognize a 6-12 degenerate DNA sequence, called a motif. Enhancers often 
contain several TFs motifs and the cooperation between TFs is necessary to 
activate gene expression. There are several mechanisms whereby TFs cooperate 
and increase the retention time of the TFs at the enhancer: (1) direct protein-protein 
binding of TFs that binds to adjacent DNA sequences; (2) several TFs co-bind to an 
enhancer regulator (i.e. p300); (3) the binding of the first TF produces a 
conformational change which expose the binding site for a second TF, the first TF 
acts therefore as a pioneer factor; (4) the binding of the first TF prevents the 
remodeling of the nucleosome allowing the second TF to bind to the enhancer; and 
finally (5) the binding of the first TF bends the DNA in a way that the second TF is 
then able to bind to its motif. Despite the importance of TFs in activating enhancers, 
the majority of TF binding events are not directly affecting gene activation but rather 
with nucleosome positioning (Spitz & Furlong 2012).  
Developmental enhancers, in order to ensure accuracy on gene expression, 
undergo progressive changes to become active. Enhancer activation involves 
transition from inactive to primed and then from primed to active or poised stage 
(Figure 3). Before enhancer activation, these are in a compact state and, therefore, 
inaccessible. Enhancer priming facilitate activation as decreases the remodeling 
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time upon activation signals (Figure 3A). The key element is the pioneer factor 
which binds directly to DNA and triggers nucleosome repositioning, chromatin 
remodeling and prevent DNA methylation, which is related to gene silencing. 
Examples of pioneer factors are FoxA1, involved in liver specification, and Zelda, 
only present in Drosophila and required for maternal to zygotic transition. (Caravaca 
et al. 2013; Liang et al. 2008). Primed enhancers are enriched in H3K4me1, which 
serves as a platform for Tip60/400 that catalyzes replacement of H2A with H2A.Z. 
Histone variants H2A.Z and H3.3, opposite to canonical histones are hyper dynamic 
and the DNA-histone binding of such histone variants is less tight. Both primed and 
active enhancers contain 5- hydroximethylcytosine (5hmC). Silenced regions 
contain 5-methylcytosine; to transform them into active regions the methyl group 
needs to be removed through TET enzymes generating 5hmC (Calo & Wysocka 
2013; Spitz & Furlong 2012)  
Active enhancers (Figure 3C) are characterized by several histone 
modifications such as H3K4me1, H3K79me3 and H3K27ac. The histone 
acetyltransferase p300/CBP, often used as a marker for active enhancers, 
acetylates H3K27, which recruit proteins with a bromodomain such as chromatin 
remodelers and transcription regulators. H3K27ac not only acts as a platform for 
proteins with bromodomain but also decreases nucleosome stability and chromatin 
decompactation due to changes in net charge of histones. Multiple cell-type specific 
and generic transcription factors bind to the enhancers together with cofactors, such 
as histone modifiers, chromatin remodeling complexes and mediators of long-range 
crosstalk with basal transcription machinery in the promoters. By looping, enhancer 
associated factors are directly delivered to the promoter, helped by CTCF and 
cohesion, in order to potentiate either the formation of the preinitiation complex 
or the transition from initiation to elongation (Plank & Dean 2014; Calo & 
Wysocka 2013). 
During differentiation, the enhancers are poised to ensure rapid activation 
upon TFs binding or cellular signals. Poised enhancers (Figure 3B) are 
characterized by the presence of p300, H3K4me1 and H3K27me3, preventing 
acetylation of H3K27ac related with activation. Polycomb repressive complex 2 
(PRC2), also present in poised enhancers, triggers H3K27 methylation (Calo & 
Wysocka 2013; Spitz & Furlong 2012).  
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Figure 3: Epigenetic features of primed, poised and active enhancers. Modified from 
Calo & Wysocka (2013). 
1.1.2.2. Promoters 
Promoters are defined as DNA sequences proximal to the TSS 
(transcription start site) of a gene where the RNA polymerase binds to the DNA 
to initiate the transcription. About 70% of the annotated promoters in 
vertebrates contain CpG islands, an enrichment of C and G bases in the DNA 
sequence which are predominantly non-methylated (Deaton & Bird 2011).  
Active promoters are characterized by H3K4me3 and H3K4me2, RNA 
polymerase II (RNAP II) deposition, histone acetylation such as H3K9ac or 
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H3K14ac, hypersensivity to DNAse I digestion and hypomethylation at the DNA 
level (Figure 4A). H3K4me3 is a key mark for identifying promoters, acting as a 
docking site for (1) transcription machinery; (2) histone acetyltransferases, 
needed for making the chromatin accessible; (3) histone demethylases that 
remove repressive marks such as H3K36me3 or H3K9me3 typical from 
heterochromatin; and (4) metyltransferases that add new H3K4me3 to the next 
nucleosomes (Li et al. 2007; Wozniak & Strahl 2014). The histone modification 
H3K27me3, triggered by the PRC2, defines repressed promoters together with 
H3K9me3 (Figure 4C). Inactive promoters also contain DNA methylated regions 
(Zhou et al. 2011). Some developmental genes show both active (H3K4me3) 
and repressive (H3K27me3) marks so they can be rapidly induced by 
extracellular signals; these are so-called poised promoters. RNAP II can be 
present but they do not produce mature mRNAs (Figure 4B)(Zhou et al. 2011). 
    
Figure 4: Key chromatin marks involved in active, poised and repressed promoters. 
Modified from Zhou et al. (2011). 
 
 9 
1.1.3. Evolution and conservation of cis-regulatory elements 
Gene regulatory networks involved in Hox genes patterning, establishment 
of body axes or nervous system regionalization are well conserved during evolution. 
Unlike the high degree of coding sequence conservation, cis-regulatory elements do 
not display a great conservation among phyla. Nevertheless, there are a few highly 
conserved non-coding regions (HCNRs) (Maeso et al. 2013). 
HCNRs are enhancers present in vertebrate genomes involved in regulating 
key developmental genes. They are characterized by being short (75-100bp) and 
with low similarity among species (60-70%), making them technically difficult to 
identify. In the chordate phylum, there have only been identified 50 HCNRs 
common between amphioxus, the ancestor of the vertebrates, and human 
genomes, despite the similarities in body plan organization (Putnam et al. 2008; 
Woolfe et al. 2005).  
Studies performed in several organisms, from flies to mammalian, reveal 
that regardless of the low sequence conservation of cis-regulatory elements, the 
signatures of enhancers are evolutionary conserved. Active enhancers correlate 
with H3K27ac, H3K4me1, high DNA hypersensitive sites and p300/CBP. 
Techniques to identify such regions include: chromatin immunoprecipitation using 
H2K27ac or p300 antibodies or DNAse I or ATAC-sequencing that identify 
hypersensitive regions. Moreover, the transcription binding sites present in the 
enhancers are more conserved than the broader sequence that contains them 
(Heintzman et al. 2007; Bogdanović et al. 2012; Neph et al. 2012). 
Also relevant are enhancers turned on during late gastrula that drive 
expression of genes during the phylotypic stages, where the maximum 
morphological similarities between vertebrates are found (Irie & Kuratani 2011). It 
has been demonstrated that these putative enhancers display the highest sequence 
conservation compared with enhancers active at other stages (Maeso et al. 2013).  
When talking about evolution of cis-regulatory elements, mention has to be 
made on the conservation of TADs. TADs are present in bilaterian animals; plants 
or yeast either do not contain this 3D genome organization or it is not regulated by 
the same molecular mechanism (Dekker & Heard 2015). The appearance of TADs 
correlates with the presence of CTCFs facilitating enhancer-promoter interactions 
(Heger et al. 2012). Alteration of TAD boundaries, either by mutation, insertion or 
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deletion, can change the integrity of the regulatory landscape creating or eliminating 
enhancers-promoter contacts thus activating or repressing genes. In fact, whole 
sequence analysis of cancer cells reveals high degree of mutations in CTCF sites 
(Hnisz et al. 2016). Studies of microsynteny (gene order) conservation show also a 
high degree of conservation in bilaterians. This is due to the presence of CREs in 
the introns of neighboring genes forcing the conservation of the regulatory 
landscape (Irimia et al. 2012). 
The high frequency of interactions inside a TAD promotes the formation of 
new CREs through (1) de novo formation, (2) modification of preexisting CREs or 
(3) insertion and exaptation of transposable elements. Nevertheless, not all the 
new-formed potential CREs can act as functional CREs: the new enhancers need to 
connect to a promoter within the same TAD that would respond to new enhancers. 
Those enhancers driving the expression in similar pattern as the preexisting 
enhancers, have more chances of affecting gene expression thus (1) quantitatively 
affecting gene expression or (2) refining a preexisting expression pattern (Maeso et 
al. 2017).  
An example of how changes in TADs can influence evolution is the role of 
the HoxD in limb formation. In vertebrates there are two hox clusters flanked by 
several CREs organized in two TADs: one at 3’ of the gene cluster and another at 
5’. The 3’ CREs become active first and are involved in proximal structures whereas 
the 5’ CREs are related with distal structures such as the hands and the digits. The 
central part of the cluster (hoxd8-hoxd11) switches from being influenced for one 
TAD to the other, and thus allowing the formation of the wrist and ankle. 
Interestingly, in amphioxus there is just one hox cluster regulated by a single TAD 
located at 3’ CREs. This suggests that the incorporation of the inputs coming from 
the 5’ regulatory region has allowed the formation of new structures in higher 
vertebrates such as the digits (Lonfat & Duboule 2015; Acemel et al. 2016).  
1.1.4. Empirical approaches to study cis-regulatory elements 
The main experimental methods for whole genome CREs discovery are 
based on chromatin-immunoprecipitation (ChIP) or chromatin accessibility 
techniques (DNase- MNase- FAIRE- and ATAC-sequencing). Subsequently, the 
potential CREs identified by next-generation sequencing can be validated by low 
throughput (reporter gene assay) or high throughput (enhancer-FACS-sequencing 
and CRE-sequencing) reporter assays. Also, to demonstrate the physical interaction 
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of enhancers and promoters image based (FISH) and chromatin conformation (3C, 
4C, 5C and HiC) techniques can be used (Suryamohan & Halfon 2015). 
1.1.4.1. Identification of cis-regulatory elements 
The most frequently used technique to identify enhancers is ChIP-
sequencing. This technique is based in the in vivo crosslinking of DNA-protein 
complexes followed by pull-down using a specific antibody and high throughput 
DNA sequencing. This method allows the detection of both direct and indirect whole 
genome binding sites events. The key point of this technique lies on the antibody 
selection: the use of an antibody recognizing a specific TF of interest would reveal 
this TFs binding sites on the genome, even though the binding might be not 
functional, whereas the use of an antibody against the co-factor p300 or the histone 
modifications H3K4me1 and H3K27ac would unravel the active (and poised) 
enhancers on the genome without any prior knowledge of the TFs involved (Visel et 
al. 2009; Rada-Iglesias et al. 2012).  
One of the characteristics of active enhancers is that they are depleted of 
nucleosomes and therefore the DNA is accessible. This is the rationale behind 
several techniques based on open chromatin. The DNAase-sequencing technique 
is based on the enzymatic activity of DNase I to cleave accessible DNA (Boyle et al. 
2008). MNase-sequencing relies on micrococcal nuclease activity that reveals 
nucleosome position therefore indirectly the accessible regions (Barski et al. 2007). 
Alternatively, formaldehyde-assisted isolation of regulatory elements (FAIRE-
seq) isolates nucleosome-free DNA by a phenol extraction step (Giresi et al. 2007). 
Each of these techniques followed by deep sequencing allow the identification of 
open chromatin regions and the transcription factors footprint (Neph et al. 2012). 
However, not all open regions are active enhancers; accessible regions can also be 
found on primed enhancers, promoter regions, CTCF binding sites and in regions 
bound by repressive transcription factors. Because of that, it is advisable to 
combine the two different types of CRE identification for a more conclusive result 
(Shlyueva et al. 2014).  
Also based on open chromatin, the assay for transposase-accessible 
chromatin using sequencing (ATAC-sequencing) stands out compared to the above 
mentioned methods because of the simplicity of its protocol and the small amount of 
material that it requires (Buenrostro et al. 2015; Buenrostro et al. 2013). ATAC-
sequencing is based on a modified Tn5 transposase enzyme that in vivo fragments 
open regions of the DNA and at the same time tags these fragments for sequencing 
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(Figure 5). This technique can be performed in 500 to 50,000 nuclei, which makes it 
very appealing for certain model organisms or cell subpopulation. Unlike other high 
throughput techniques, the library preparation is performed with a simple PCR and 
purification. Tn5 cuts around nucleosomes therefore the expected fragment size to 
sequence is about 300bp.  
 
Figure 5: Representation of the ATAC-sequencing protocol. Modified from Abcam 
website.  
1.1.4.2. Validation of cis-regulatory elements 
After identification of candidate CREs, in vivo validation can be carried out 
using reporter gene assays. The idea behind this is to interrogate the ability of a 
certain sequence to direct transcription. The reporter gene vector contains: (1) CRE 
to test, (2) minimal promoter that alone drive little or no transcription and (3) reporter 
gene whose expression should be easy to detect such as gfp, luciferase, lacZ or β-
galactosidase (Suryamohan & Halfon 2015).  
Traditionally, cloned sequences were tested in model organisms such as 
zebrafish, flies or mice. The vector is randomly integrated in the genome and the 
enhancer activity is determined by the localization and the presence of the reporter 
gene at RNA or protein level. There are several modifications of this technique such 
as the enhancer-FACS-sequencing design for Drosophila that allows the 
identification of the cell type the enhancer is acting in (Gisselbrecht et al. 2013). 
This low throughput method is not suitable for enhancer screening and requires a 
small selection of CREs to test (Shlyueva et al. 2014). With the introduction of next 
generation sequencing strategies, a lot of effort has been made to adapt reporter 
gene assays. Techniques such as CRE-sequencing incorporate a barcode in the 
vector and the amounts of reads sequenced indicate the activity of the potential 
enhancer (Mogno et al. 2013). 
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1.1.4.3. Validation of promoter-enhancer interaction 
Enhancers are known to directly contact promoters. Although it is assumed 
that enhancers drive the expression of neighboring genes it is necessary to 
experimentally address this question. The first method is the fluorescence in situ 
hybridization (FISH), which uses probes against the promoter and the enhancer to 
test the co-localization of both elements. This technique allows single cell resolution 
but is a low throughput technique limited by the resolution of the microscopy 
(Ronshaugen & Levine 2004).  
Another set of techniques that aim to identify promoter-enhancer interactions 
in a high throughput manner is the so-called chromosome conformation capture-
based methods (3C, 4C, 5C and HiC). The idea behind these techniques is to 
crosslink the chromosomal contacts generating a chimeric DNA molecule of 
promoter-enhancers that reflect long-range contacts. The sequencing of this 
molecule using specific primers is called 3C or 4C; depending if primers for 
promoter and enhancer or only primers for enhancers are used, respectively. These 
allow the validation of specific enhancer-promoter interactions. Moreover, the 
development of 5C and HiC reveals all the interactions in a region or in the whole 
genome, respectively (van Steensel & Dekker 2010). A variant of this method is the 
Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET), which 
identifies the enhancer-promoter contacts in which a specific transcription factor is 
involved. HiC is currently used to detect TADs within the genome (Fullwood et al. 
2009). 
 
1.2. Xenopus as a model organism 
Xenopus, and in particular X. laevis and X. tropicalis, are African clawed 
frogs commonly used to study developmental biology. Since the 1950s, X. laevis 
has been widely used in research as these organisms can produce thousands of 
easy-to-maintain eggs that develop synchronically. The eggs are relatively large 
(1.4-1.5mm) and can tolerate dissections and injections, even into specific 
blastomeres, of large amounts of material; thus making it a good model to examine 
gene function (Harland & Grainger, 2011). In the mid-1990s, X. tropicalis became 
more popular for genetic studies because of its diploid genome unlike the X. laevis 
pseudotetraploid genome (Schmitt et al. 2014). 
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Figure 6: Xenopus life cycle. The embryos are stages based on the standard Niewkoop 
and Faber fate map. Timing of Xenopus development is temperature dependent. Modified 
from Schmitt et al. (2014). 
An unfertilized egg of Xenopus has two easy-to-distinguish regions: (1) the 
animal pole, darkly pigmented, and (2) the vegetal pole, lightly pigmented and 
containing high amount of maternal messenger RNA (Sive et al. 2000). Xenopus 
development starts after the fertilization has occurred on the animal pole of the 
embryo (Figure 6). 90 minutes after fertilization, the first cleavage takes place giving 
rise to two identical blastomeres followed by 12 rapid synchronous cell divisions 
consisting in DNA replication and mitosis. Until the so-called mid-blastula transition 
(MBT) coinciding with stage 8-9 according to the Nieuwkoop and Faber atlas, the 
embryo relies on maternal RNA and proteins. Following MBT, zygotic gene 
transcription takes over and the cell cycle is desynchronized by adding the gap 
phases G1 and G2 of the cell cycle (Schmitt et al. 2014).  
After fertilization, the embryonic cells divide generating a cavity inside called 
blastocoel. At stage 10, the blastula embryo begins to undergo gastrulation, a 
complex process of cell rearrangements that includes the invagination of the dorsal 
cells, opposite to the sperm entry point, and epiboly of the cells from the animal pole 
thus giving rise to the three germ layers (endoderm, mesoderm, ectoderm) that will 
form different tissues in the embryo (Gilbert & Barresi 2016). Shortly after 
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gastrulation, neurulation takes place to form the central nervous system (Figure 6). 
The dorsal part of the gastrula embryo, the neural plate, folds to form the neural 
tube while the cells on the edge of the neural plate will give rise to the preplacodal 
regions and the neural crest. Following neurulation, organogenesis occurs to form 
the different organs of the embryo such as the heart, the liver or the kidney (Sive et 
al. 2000). 
1.2.1. Xenopus neural crest formation 
The neural crest (NC) cells are a multipotent and highly migratory cell 
population unique to vertebrates that give rise to several derivatives such as enteric 
ganglia, neuroendocrine cells, melanocytes, neurons, craniofacial skeleton and 
connective tissue. This cell population arises from the neural plate border, which is 
elevated by the neural folds and finally forms the dorsal part of the neural tube. The 
NC then undergo epithelial to mesenchymal transition (EMT) and migrate away to 
their correct destination where they differentiate into the several NC-derivatives 
(Pegoraro & Monsoro-Burq 2013) (Figure 7). Recently, the NC has been defined as 
a subset of blastula cells that retain pluripotency properties whereas other cells 
become fate-restricted. Evidence suggests that neural crest key genes are 
expressed at pluripotent (blastula) stage. Also the induction of NC is sufficient to 
confer pluripotency capabilities (Buitrago-Delgado et al. 2015; Hoppler & Wheeler 
2015).  
                          
Figure 7: Xenopus neural crest formation processes.  
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Neural crest cells are induced in the neural plate border during gastrulation 
thanks to the interaction of several signaling pathways such as BMP, FGF and Wnt 
together with Notch/Delta, Retinoic acid, Hedgehog and Endothelin. These signals 
come from the neural plate, non-neural ectoderm and the underlying mesoderm. As 
a result, the neural plate border (NPB) is induced. The NPB contains a multi-
progenitor cell population that is capable of giving rise to neural crest cells as well 
as ectodermal placodes, epidermal cells, roof plate cells and sensory neurons of the 
central nervous system (Simões-Costa & Bronner 2015). The ectodermal placodes 
generate different components of the sensory organs of the head together with the 
cranial NC derivatives. The NPB specifiers (msx, pax3/7, zic, dlx5/6, hairy, tfap2a, 
gbx2 and meis3) are expressed in the prospective NC cells. Later on, during 
neurulation (stage 15-20), the interactions between neural plate border specifiers 
and the initial signaling pathways lead to the specification of the NC located in the 
elevating neural folds and dorsal neural tube. These cells are characterized by the 
expression of NC specifiers (snai2, foxd3, sox9/10, twist, cmyc and tfap2a) that 
drive the expression of genes involved in EMT, delamination, migration and, 
differentiation into the several NC derivatives (Stuhlmiller & García-Castro 2012; 
Pegoraro & Monsoro-Burq 2013) (Figure 7).  
1.2.1.1. Neural crest induction  
 In order to induce the NC cells, simultaneous gradients of mainly BMP, FGF 
and Wnt are required in two different phases. During gastrulation, Wnt sourced from 
the underlying mesoderm and non-neural ectoderm and FGF also from the 
mesoderm must be present together with low levels of BMP, due to the presence of 
BMP antagonists, thus allowing NC induction (Figure 8A). Later during neurulation, 
BMP from the underlying mesoderm, Wnt and Notch are required to maintain the 
NC population (Stuhlmiller & García-Castro 2012). 
 Bone morphogenetic proteins (BMPs) are secreted proteins that bind to their 
cellular receptor activating gene expression through the canonical Smad signaling 
pathway. A dual function of bmp4/7 is required: a first inhibition during gastrulation 
to induce the NC cells and intermediate levels during neurulation to maintain them. 
The BMP gradient is generated during neurulation, with high levels at the non-
neural ectoderm and low levels the neural plate, promoted by BMP antagonists 
(Chordin, Follistatin and Noggin) secreted from the mesoderm (Steventon et al. 
2009; Stuhlmiller & García-Castro 2012). Other BMP regulators in the neural-NC 
border have been described: snw1 and tumor necrosis-factor receptor associated 
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factor 4 (traf4) activate BMP whereas tsukushi is a negative regulator (Kuriyama et 
al. 2006; Wu et al. 2011). 
 Wnt signaling involving both the canonical and non-canonical pathway is 
required for the NC induction. Canonical wnt1, wnt3a, expressed in the neural plate 
and wnt8, expressed in the mesoderm, can induce the neural plate border and the 
neural crest markers when combined with BMP antagonists (Saint-Jeannet et al. 
1997; Chang & Hem 1998; LaBonne & Bronner-Fraser 1998). frizzled7 initially and 
later frizzled3 are the Wnt receptors involved in NC specification (Abu-Elmagd et al. 
2006; Deardorff et al. 2001). On the other hand, the non-canonical wnt11 acts 
through microtubule-associated regulatory kinase and it is also required for the NC 
formation (Ossipova & Sokol 2011).  
 Fibroblast growth factors (FGFs) can activate several intracellular signaling 
cascades. fgf8 secreted from the mesoderm is sufficient to induce neural crest 
(Monsoro-Burq et al. 2003). Fgf signaling can also induce wnt8 in the mesodermal 
tissues during gastrulation (Hong et al. 2008).  
 The interactions between these signaling pathways turn on the expression of 
specific NPB genes. These transcription factors positively regulate each other to 
define the neural plate border domain and stabilize this regulatory state to ensure 
their continued expression (Figure 8B). tfap2a activates the expression of pax3 and 
msx1 in the border with the neural plate (de Crozé et al. 2011). pax3 and zic1 are 
independently regulated but synergize in a Wnt dependent manner to induce the 
neural crest cells. The expression of these genes also regulates the initial signaling 
pathways: hairy and msx1 are needed for FGF and BMP signaling and pax3 and 
tfap2a are required for FGF and Wnt signaling allowing NC formation (Pegoraro & 
Monsoro-Burq 2013; Monsoro-Burq et al. 2005). All these interactions between NPB 
markers and signaling pathways are required for the correct NC induction.  
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Figure 8: Gene regulatory network controlling the formation of the neural plate 
border. (A) Wnt, BMP and FGF signals induction of NPB. (B) Interaction between NPB 
required for the maintenance of NPB genes. Direct interactions are indicated with solid lines, 
whereas dashed lines show possible direct interactions inferred from gain- and loss-of-
function studies. Modified from Simões-Costa & Bronner (2015). 
1.2.1.2. Neural crest specification 
 The interaction between NPB markers together with Wnt and BMP signaling 
from surrounding tissues leads to the specification of the NC characterized by the 
expression of neural crest specifiers (Figure 9). These genes are involved in three 
main processes that characterize the NC cells. NC specifiers: (1) regulate the 
balance between proliferation and specification. hairy2 and stat3 are known to 
enhance proliferation at the expense of specification and subsequent differentiation 
the NC cells. To keep a balance, these genes also activate id3, which in turn 
promote differentiation and negatively regulates hairy2 and stat3 (Nichane et al. 
2008; Nichane et al. 2009). sox9 has also been involved in survival as lost of 
function experiments lead to the downregulation of snail1, an anti-apoptotic factor, 
causing massive apoptosis of trunk NC cells (Cheung et al. 2005). 
NC specifiers also (2) maintain their expression by activating each other so 
that the regulatory system is stabilized (Figure 9) (Simões-Costa & Bronner 2015; 
Sauka-Spengler & Bronner-Fraser 2008; Pegoraro & Monsoro-Burq 2013). A subset 
of NC specifiers (foxd3, ets1, snail1/2) are first expressed to define NC identity. 
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These transcription factors are epigenetically activated by the neural plate border 
genes pax3, zic, msx and tfap2a. It has been hypothesized that tfap2a together with 
nrf1/2 would bind NC enhancers inducing the chromatin to open allowing pax3, zic 
and msx to bind the regulatory regions of the NC genes for their proper expression 
(Rada-Iglesias et al. 2012; Plouhinec et al. 2014).  
Due to the interaction between NPB markers, initial signaling pathways and 
cross-activation between NC specifiers, a full suite of genes is expressed (foxd3, 
snail1/2, twist, pax3/7, sox9/10, ets1, cmyc, tfap2a and id3) in the neural crest 
population, some of which are newly expressed and others whose expression is 
maintained form NPB cells (Simões-Costa & Bronner 2015).  
Finally, NC specifiers (3) activate the expression of genes that change the 
adhesive properties, shape and motility of NC cells thus allowing delamination from 
the neuroepithelium and migration through highly regulated pathways to their final 
destination where these cells will differentiate (Simões-Costa & Bronner 2015; 
Sauka-Spengler & Bronner-Fraser 2008; Pegoraro & Monsoro-Burq 2013). 
            
Figure 9: Gene regulatory network controlling the specification of NC cells. Direct 
interactions are indicated with solid lines, whereas dashed lines show possible direct 
interactions inferred from gain- and loss-of-function studies. Modified from Simões-Costa & 
Bronner (2015). 
1.2.1.3. Neural crest migration  
 Premigratory NC cells are polarized in the dorsal neural tube. To achieve 
EMT, a loss of apical-basal polarity and tight junctions is required along with a shift 
from cadherins type I, associated with adhesion, to type II (Figure 10) (Sauka-
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Spengler & Bronner-Fraser 2008). Several NC transcription factors have been 
associated with the switch form type I (E-cadherin, N-cadherin, cadherin-6b) to type 
II (cadherin7/11) cadherins. snai2 can bind to E-cadherin promoter to repress its 
expression and it also inhibits cadherin-6b. Also, foxd3 can inhibit N-cadherin 
expression (Taneyhill et al. 2007; Cano et al. 2000). Conversely, type II cadherin 7 
is upregulated by foxd3 and snai2 (Chu et al. 2006). The delamination process also 
involves downregulation of tight-junctions by snai2 and increase of gap-junctions 
(Ikenouchi et al. 2003). Besides delamination from the neural tube, the NC cells 
also have to disaggregate into individual cells. This is regulated by twist and its 
regulator hif1α, which represses E-cadherin in the delaminating cells (Barriga et al. 
2013).  
 To allow migration, cells must also disturb basement membrane and invade 
the extracellular matrix, which consist of collagens, fibronectin, laminins, vitronectin 
and proteoglycans. To do this, NC cells express matrix metalloproteinases (MMPs) 
on their surface or secrete them. In order to regulate the disruption of the cell matrix 
whilst keeping a balance, the NC cells express mmps and their inhibitors (Sauka-
Spengler & Bronner-Fraser 2008). In that sense, there have been identified several 
mmps involved in the NC cells migration. For example, mmpP17b is involved in 
general NC migration; adam13, in migrating cranial NC cells and mmp2 in NC-
derived cardiac cells. (Leigh et al. 2013; Alfandari et al. 2001; Cai et al. 2000). While 
cells are migrating, they respond to their environment therefore neighboring cells 
are involved in directing migration and targeting the correct position (Sauka-
Spengler & Bronner-Fraser 2008). 
           
Figure 10: Gene regulatory network controlling the EMT of NC cells. Direct interactions 
are indicated with solid lines, whereas dashed lines show possible direct interactions 
inferred from gain- and loss-of-function studies. Modified from Simões-Costa & Bronner 
(2015). 
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1.2.1.4. Neural crest differentiation 
Migrating neural crest cells express transcription factors involved in both 
migration and differentiation that will lead to the formation of several derivatives. 
There are four main NC-derivatives: (1) cephalic NC cells that give rise to 
craniofacial structures such as bones, cartilage, connective tissue, pigment cells 
and cephalic peripheral nervous system (PNS), (2) cardiac NC cells that contribute 
to the heart outflow track, (3) truck NC cells that contribute to pigment cells, PNS 
and adrenal glands, and (4) enteric NC cells that form the gut PNS (Mayor & 
Theveneau 2013). 
1.2.2. Epigenetic regulation of the neural crest cells 
1.2.2.1. DNA and chromatin modifications related with NC 
Several modifications have been associated with NC formation in either 
chicken, mice, zebrafish or Xenopus. Table 1 summarizes the main bibliographic 
evidences for each of them. A couple of examples include the lysine demethylase 
jmjD2a, the adapter phd12 that directly interact with HDAC and finally, the DNA 
methyltransferase dnmt3. 
The lysine demethylase jmjD2a is expressed in the neural plate, neural 
border and the NC cells, and removes H3K9me3 and H3K36me3 in vivo. By 
inhibiting jmjD2a, the expression of sox10 is down regulated suggesting that jmjD2A 
is required for H3K9me3 demethylation at sox10 locus to activate its expression 
(Strobl-Mazzulla et al. 2010). Also, snai2 represses cadherin-6b expression in 
premigratory NC cells through an epigenetic mechanism. snai2 binds to phd12 
recruiting hdac/sin3a at the cadherin-6b promoter to repress its expression. Hence, 
normal levels of cadherin-6b are found allowing the NC cells to undergo EMT 
(Strobl-Mazzulla & Bronner 2012). Moreover, there is cooperation between DNA 
methyltransferase and Histone methyltransferase in zebrafish development. The 
DNMT dnmt3 together with the HMT g9a bind to the lef1 promoter allowing the 
correct neural and eye differentiation (Rai et al. 2010) (Table 1). 
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Table 1: Bibliographic summary of the chromatin modifiers involved in NC formation. 
 Enzyme ON/ OFF 
Downstream targets 
(role in NC 
development) 
Organism Reference 
N
C
 s
pe
ci
fic
at
io
n 
aepb2 
(PRC2) 
(KMT) 
Off 
snai2 (migration), sox10 
(NC specification) 
Mice 
Kim et al. 
(2011) 
brg1 
(SWI/SNF 
family) 
On snai2 (NC specification) Zebrafish 
Eroglu et al. 
(2006) 
chd7 
(chromo) 
On foxd3 (NC specification) 
Mice NC-
derived stem 
cells 
Fujita et al. 
(2016) 
chd7-pbaf 
(chromo) 
On 
sox9, twist, slug  (NC 
specification) 
Xenopus 
Bajpai et al. 
(2010) 
ezh2 
(PRC2) 
(KMT) 
Off 
Cooperation with snai2 
(NC specification, 
migration, craniofacial and 
cartilage formation) 
Xenopus 
Tien et al. 
(2015) 
hdac Off 
bmp4, cadherin 6B, sox9, 
sox10,hnk1 (Neural tube 
closure and NC 
specification 
Chicken 
Murko et al. 
(2013) 
hdac1-ets1 Off id3 (NC formation) Xenopus 
Wang et al. 
(2015) 
jmjD2A 
(KDM) 
On sox10 (NC specification) Chicken 
Strobl-
Mazzulla et al. 
(2010) 
prd12 
(HMT) 
Off 
foxd3, slug, sox8 (NC 
formation) 
Xenopus 
Matsukawa et 
al. (2015) 
N
C
 m
ig
ra
tio
n dnmt3B Off 
sox10 (NC migration) 
 
Chicken 
Hu et al. 
(2014) 
hdac-sin3a-
phd12 
Off 
cadherin-6b (EMT) 
 
Chicken 
Strobl-
Mazzulla & 
Bronner 
(2012) 
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 Enzyme ON/ OFF 
Downstream targets 
(role in NC 
development) 
Organism Reference 
N
C
 d
iff
er
en
tia
tio
n 
dnmt3A Off gbx2 (Ear formation) Chicken Roellig & Bronner (2016) 
ezh2 
(PRC2) 
(KMT) 
Off hox genes (craniofacial formation) Mice 
Schwarz et al. 
(2014) 
g9a 
(KMT)/dnmt
3 
Off lef1 (craniofacial, brain and retina formation) Zebrafish 
Rai et al. 
(2010) 
hdac1 Off foxd3 (melanophore formation) Zebrafish 
Ignatius et al. 
(2008) 
hdac1 Off dlx2/3, hoxb3a (craniofacial formation) Zebrafish 
Ignatius et al. 
(2013) 
hdac3 Off Cardiac smooth muscle differentiation Mice 
Singh et al. 
(2011) 
hdac4 Off Craniofacial formation Zebrafish DeLaurier et al. (2012) 
hdac8 Off otx2, lhx1 (craniofacial formation) Mice 
Haberland et 
al. (2009) 
kat6a On Nitric Oxide  (craniofacial formation) Zebrafish 
Kong et al. 
(2014) 
kat6a On hox genes (craniofacial formation) Zebrafish 
Miller et al. 
(2004) 
kdm6a On msx (craniofacial formation) Zebrafish Qi et al. (2010) 
ring1b/rnf2 
(PRC1) Off 
(Chondrocyte 
differentiation) Zebrafish 
van der Velden 
et al. (2013) 
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1.2.2.2. Cis-regulatory elements associated with NC 
Enhancers are cis-regulatory elements required for cell specification and 
differentiation. Enhancers (1) coordinate the expression of important genes for a 
given cell type, and (2) act as a transcription factor-binding platform recognized by 
major lineage specifiers and effectors of signaling pathways (Remeseiro et al. 
2016). It is not surprising then that the NC cells, as a major feature in vertebrates, 
have an extensive network of cis-regulatory elements. A general in silico study of 
human induced neural crest cells (hNCCs) identified tfap2a and nrf1/2 as important 
transcription factors found in most active NC enhancers, alongside p300 and 
H3K24ac in the surrounding nucleosomes, thus allowing permissive chromatin in 
hNC enhancers and therefore transcription activation of NC genes (Rada-Iglesias et 
al. 2012).  
Since the first study in 1994, which characterized the mouse wnt1 enhancer 
driving expression in cranial and trunk NC cells (Echelard et al. 1994), more 
research has been done aiming to identify enhancers important for the expression 
of key NC genes. For instance, an ets1 enhancer (ECR1) was found to be a 694bp 
sequence located upstream of the ets1 TSS and conserved in birds and mammals. 
This region can drive expression of ets1 in cranial NC cells and contains TF binding 
sites for sox9, ets1, tfpa2a, foxd3, pax7 and msx1/2, all involved in activating ets1. 
Interestingly, it contains a cmyc binding site that represses ets1 expression in the 
hindbrain (Barembaum & Bronner 2013). gbx2 is an important gene required for NC 
induction. Analysis of the Xenopus gbx2 upstream landscape revealed a 500bp 
regulatory region that contains a ß-catenin/TCF binding site, indicating the role of 
Wnt signaling in gbx2 activation (Li et al. 2009). The pax3 enhancer is conserved 
between mouse and human and is located within the 1.6kb region upstream pax3 
TSS. It is formed by two 200bp regulatory regions (NCE1 and NCE2) spaced by 
156bp. NCE2 has the ability to drive pax3 expression in the dorsal neural tube and 
neural crest cells and contains a tead2 binding site (Milewski et al. 2004). Another 
study identified pax3 enhancers in zebrafish. IR1 and IR2 are two regulatory regions 
found in pax3 introns that drive gene expression in the neural plate border and 
dorsal tube. The response to signaling pathways was analysed revealing that 
whereas IR1 requires Wnt and FGF for its function and it is upregulated by BMPs, 
IR2 is FGF dependent but its function is inhibited by BMP (Garnett et al. 2012). The 
pax7 enhancer (P7eNBPE) directs expression of pax7 in neural plate border, neural 
folds and early migrating NC, but it is not responsible for its later expression. 
P7eNBPE has been described in chicken and has very little conservation with other 
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organisms, being postulated as a specie-specific enhancer. It is located upstream of 
pax7 and contains a cmyb binding site, revealing a new role for cmyb as a pax7 
regulator (Vadasz et al. 2013). foxd3 contains two regulatory elements (NC1 and 
NC2) conserved in chicken, mice, human and Xenopus that together recapitulate 
foxd3 expression but they show differences in regulation: NC1 drives expression in 
cranial neural crest cells and contains binding sites for pax7, msx1/2 and ets1 
whereas NC2 is necessary for trunk foxd3 expression and is regulated by pax7, 
msx1/2 and zic1 (Simões-Costa et al. 2012). Several regulatory regions for sox10 
have been identified: Sox10E1 and Sox10E2 located 1.1kb and 2.1kb downstream 
of sox10, respectively, and Sox10L8 6.1kb upstream of the TSS. Both Sox10E1 and 
Sox10E2 regulate sox10 expression in cranial NC cells in a rostocaudal temporal 
manner. These regulatory regions are conserved in chicken, opossum, mouse, rat, 
human but not in Xenopus or zebrafish. Considerable analyses have been carried 
out on Sox10E2 regulatory region. sox9, ets1 and cmyb are required for initial 
sox10 expression but cmyb, pea3, sox8 are necessary for ear formation at later 
stages (Betancur et al. 2010b; Betancur et al. 2011). The Mef2c-F10N enhancer 
conserved in mice, human, rat, rabbit and chicken but not in aquatic species, drives 
the expression of ß-galactosidase in migrating NC cells during early stages and 
later in cranial NC cells, peripheral nervous system and melanocytes overlapping 
with msx1/2 and pax3/7 (Aoto et al. 2015). Finally, the mitf enhancer is a 298bp 
located 14.5kb from the TSS containing two functional sox10 binding sites. It is 
known to be conserved in mice and human and can drive the expression of mitf 
gene in pigment cells (Watanabe et al. 2002). As very few studies report enhancers 
conserved in Xenopus, it would be required to identify cis-regulatory elements 
involved in Xenopus neural crest formation.  
 
1.3. Schmidtea mediterranea as a model organism 
The ability to regenerate body structures, studied for the first time by 
Ferchault de Réaumur in 1712, is a widespread phenomenon across the animal 
kingdom. In each phyla there are animals with the ability to regenerate limbs, 
organs and/or other appendices (Li et al. 2015). Schimdtea mediterranea are 
freshwater planarians extensively used in biological studies in order to understand 
regenerative body processes. Several characteristics make of S. mediterranea a 
great model to study regeneration: (1) this species can regenerate a whole new 
organism within days, and (2) they are the only species able to regenerate a 
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complete and functional nervous system de novo (Cebrià 2007). Moreover, (3) their 
genome is partially sequenced, there are available transcriptomes, and a wide 
range of molecular techniques such as RNA interference, in situ hybridization, 
immunohistochemistry and cell sorting are easy to carry out in these organisms 
(Pearson et al. 2009; Sanchez Alvarado & Newmark 1999; Hayashi et al. 2006). 
Planarians are Platyhelminthes belonging to the lophotrochozoa clade 
(Baguñà & Riutort 2004). They are acoelomates and possess the three germ layers. 
Planarians have anteroposterior and dorsoventral well-defined body axis and 
bilateral symmetry. The main organs and tissues present in the organism are 
(Figure 11): (1) a central nervous system (CNS), which consists of two cephalic 
ganglia and two longitudinal nerve cords connected by commissural neurons, (2) a 
digestive system composed by three blind gut branches and a pharynx that allows 
ingestion and ejection of food, (3) a muscular system formed by longitudinal, 
diagonal and circular fibres, (4) an excretory system, a dorsal network of flame 
cells, (5) a multiciliar epithelium that allows locomotion, and (6) the parenchyma, i.e. 
the space between the gut and the epidermis (Saló 2006).  
 
 
 
 
 
 
Figure 11: Planarian anatomy. An image of a wild type organism and a schematic 
representation of the nervous system, digestive system and muscular system are shown. 
1.3.1. Neoblasts, the planarian stem cells 
The regeneration of the planarian S. mediterranea occurs thanks to the 
induction of neoblast proliferation, which forms a non-pigmented tissue, called 
blastema, where cells differentiate in order to form all missing structures. The 
neoblasts represent 20-30% of the cells present in an organism and are located in 
the parenchyma surrounding the intestinal branches except in the region anterior to 
the photoreceptors and the pharynx. Neoblasts have a large nucleus/cytoplasm 
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ratio and they are the only mitotic cells in the organism; therefore when they are 
depleted by irradiation, regeneration is impaired (Zhu & Pearson 2016; Saló 2006).  
There are two models which aim to explain the neoblasts lineage 
development: (1) the ‘naïve model’ suggests that there is an homogeneous 
population of stem cells and the lineage progression occurs in the progeny, 
whereas (2) the ‘specialized model’ sustains that there is a lineage restricted 
population of dividing cells (Rink 2013; Reddien 2013). This question has been 
addressed in the last decades leading to the conclusion that there is a small 
population of pluripotent stem cells together with lineage-restricted neoblasts 
(Figure 12). A recent study has identified a small population of clonogenic neoblasts 
(cNeoblasts) (Wagner et al. 2011). When one cNeoblast is injected into an 
irradiated planarian, it is able to replace all host cells and restore the regeneration 
capabilities of the organism. Other studies analysing the transcription profile of 
neoblasts led to the identification of four populations of linage-restricted neoblasts: 
gamma neoblasts (ϒ) which give rise to intestine progeny; sigma neoblasts (σ) 
which give rise to eyes, pharynx and muscle and massively contribute to the 6h and 
48h proliferation peaks after amputation; zeta neoblasts (ζ) which give rise to the 
epidermis; and finally nu neoblasts (ν) which give rise to the brain. Modelling the 
transition between the different neoblast subpopulations leads to a model where 
cNeoblasts can generate σ-Neoblasts which can produce ϒ- ζ- and ν-neoblasts 
(Molinaro & Pearson 2016; Van Wolfswinkel et al. 2014). 
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Figure 12: Current model of neoblast differentiation. cNeoblasts, characterized by 
piwi1/2 expression, self-renew and give rise to the sigma neoblasts (σNeoblasts), 
characterized by the expression of soxP-1/2, which give rise to the eye, pharynx and muscle 
cells. σNeoblasts can give rise to the gamma neoblasts (ϒNeoblasts) that form the intestine, 
the zeta neoblasts (ζNeoblasts) that give rise to the epidermis and the nu neoblasts 
(νNeoblasts) that give rise to the brain. The ϒ, ζ, ν Neoblasts are characterized by the 
expression of gata4/5/6, zfp1 and ston-2, respectively. 
1.3.2. Planarian regeneration 
It is known that regeneration in S. mediterranea involves several processes, 
taking place all at the same time: (1) wound healing, (2) cell death, (3) neoblast 
proliferation, (4) patterning, and (5) regeneration of organs and tissues (Saló 2006). 
The most relevant processes for the purpose of this thesis are going to be 
described focusing on the specification of anteroposterior patterning.  
1.3.2.1. Wound healing 
Wound healing and scar formation is a common process for all organisms 
after damage. However, not all organisms are able, after that, to restore missing 
structures. In planarians, there is a muscle contraction 30 seconds after injury in 
order to reduce the area and time of exposure of the inner tissues (Saló 2006). 
Following that, the external epithelium extends to cover the wound. Grafting 
experiments conclude that the contact between the dorsal and ventral epithelium 
triggers the regenerative response as well as the contact between areas with 
different anteroposterior identities (Salo & Baguñà 1985; Kato et al. 1999).  
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The kinetics of gene expression during wound healing has lead to the 
identification of four gene populations (Wenemoser et al. 2012). W1 genes are 
expressed within the 30min following amputation and correspond to genes such as 
jun-1, fos-1 and egr-3 known as ‘immediate early response’. W2 genes are induced 
between 3h and 12h and fall under the category of secreted factors involved in cell 
positioning identity such as wnt1, nlg1 and follistatin. W3 genes are induced 
between 6h and 12h and correspond to remodeling matrix factors. Finally, W4 are 
expressed in neoblasts and are necessary for the differentiation of new tissues, for 
example, runt-1 is required for the formation of the nervous system (Sandmann et 
al. 2011).  
It has also been shown that different mechanisms are activated in response 
to different types of injuries, mainly depending on whether tissue is lost (i.e. 
amputation or notching vs incision or puncture). Follistatin inhibiting activin is a 
pathway just activated in response to missing tissues thus activating the second 
wave of neoblast proliferation that allows regeneration of tissues. JNK signaling also 
promotes neoblast proliferation just on tissue-lost injures (Gaviño et al. 2013; 
Almuedo-Castillo et al. 2014).  
1.3.2.2. Cell death  
For the regeneration process to occur it is important to have a balance 
between cell death and proliferation. Cell death is essential for remodeling tissues 
as well as generating proportionate organs and tissues after amputation. On the 
other side, cell proliferation and differentiation are key to generate new tissues. 
Two mechanisms of cell death have been associated with regeneration in 
planarians: apoptosis and autophagy. Regarding apoptosis, there are two main 
peaks of apoptosis after amputation. The first peak occur at 4 hours post-
amputation and it is localized at the wound-site whereas the second peak at 3 days 
post-amputation is a systemic response involved in tissue remodeling. The 
depletion of neoblasts does not affect the kinetics and magnitude of the apoptotic 
response, suggesting that the cell death is on differentiated cells and neoblast-
independent (Pellettieri et al. 2010).  
The second cell death mechanism associated with regeneration is 
autophagy. The study of death-associated protein-1, dap-1, a positive regulator of 
autophagy, let to the conclusion that autophagy is necessary for tissue remodeling. 
dap-1 is expressed in non-mitotic neoblasts and its expression is increased upon 
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amputation. The morphologic analysis of the cells expressing dap-1 indicates that 
these cells are undergoing autophagy and its inhibition affects tissue remodeling 
(González-Estévez et al. 2007). 
1.3.2.3. Neoblasts proliferation 
The proliferation of neoblast is a key process for generating new organs and 
tissues. There is a bimodal proliferation response to damage. The first peak at 6h 
post-injury is a systemic response to any type of damage. It is thought to be 
generated by neoblasts on G2 or late S phase of mitosis. Therefore, the signals 
promoting proliferation affect the transition between G2 to M phase. The second 
proliferation peak at 48h post-injury only occurs when there is tissue loss and it is 
localized on the wound-site. It involves migration of the neobasts close to the 
affected area to the post-blastema where they proliferate, forming the blastema. 
The neoblasts responsible for this second peak are thought to be in G0 or G1 phase 
when the amputation occurs so the second activation of proliferation is associated 
with signals affecting the progression from G0/G1 to M phase. Between these two 
peaks of cell division there is a minimum of 18h post-amputation (Saló & Baguñà 
1984; Wenemoser & Reddien 2010). 
Two signaling pathways have been found to be involved in controlling 
neoblast proliferation after injury. mTOR pathway is necessary to activate the first 
mitotic peak. The JNK pathway determine the transition between G2 to M phase, 
involved in both proliferating peaks, and it is also required to induce the wound-site 
apoptotic peak. Therefore, jnk knockdown organisms have an increase in neoblasts 
proliferating in the first mitotic peak, and an earlier and more sustained second 
peak, together with a decrease in apoptosis resulting in organisms unable to restore 
body proportions (González-Estévez et al. 2012; Almuedo-Castillo et al. 2014).  
1.3.2.4. Head vs tail regeneration 
After amputation, planarians must accomplish three main milestones to 
restore their head or tail: (1) determine the amount of material that is missing and if 
it has anterior or posterior identity; (2) form the anterior and posterior pole de novo, 
which will act as a instructive center; and finally (3) reconstruct tissues and organs 
(Owlarn & Bartscherer 2016).  
Canonical Wnt signaling is the main pathway involved in anteroposterior 
patterning. Wnts are a family of secreted glycoproteins that bind to a Frizzled 
receptor, activate Dishevelled, which inactivates the ß-catenin destruction complex, 
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mainly composed of Axin, APC and GSK-3. This stabilizes ß-catenin, which can 
then translocate to the nucleus and activate transcription of target genes in 
association with TCF/Lef transcription factors. A Wnt morphogen gradient, high 
levels promoting tail and low levels required for head formation, has been proposed 
to be responsible for cell positioning. Inhibition of Wnt signaling produced, for 
example, by silencing ß-catenin, leads to a fully anteriorized organism, the 
phenotype of which is dose dependent: complete inhibition result in a ‘radial-like 
hypercephalized’ animal while lower inhibition result in ‘two-head phenotype’ with or 
without ectopic eyes. Activation of the Wnt pathway by APC or axins knockdowns 
therefore produce a ‘two-tail phenotype’ (Iglesias et al. 2008; Iglesias et al. 2011).  
Although Wnt is essential for anteroposterior polarity, other pathways such 
as the Hedgehog signaling are involved in establishing and maintaining polarity. 
Knockdown of positive regulators of hedgehog (hedgehog, smoothened, gli-1) fails 
to regenerate a tail whereas depletion of negative regulators of Hh (patched, 
suppressor of fused) fails to regenerate the head (Rink et al. 2009; Yazawa et al. 
2009).  
The main elements for the head vs tail decision are wnt1, a Wnt ligand, and 
notum, an inhibitor of the Wnt signaling pathway. wnt1 knockdown produces a ‘two-
head phenotype’. In intact planarians, it is expressed in a row of discreet cells in the 
posterior dorsal midline (Figure 13). After 6h post-amputation, wnt1 is expressed in 
individual cells in both the anterior and posterior wound-sites, but its expression 
gets restricted to the posterior part of the animal at 48h, in a similar pattern to an 
intact organism. notum is a secreted protein that hydrolyzes the Wnt molecule in a 
way that Wnt is unable to bind its receptor. It is expressed in a few cells at the 
anterior pole of the organism. After amputation it is also expressed in both 
blastemas, preferentially in the anterior one, and at 48h its expression gets 
restricted to the most anterior tip of the blastema. Silencing notum generates a ‘two-
tail organism’. The first wnt1 and notum expression in both blastemas is not affected 
by depletion of neoblast, suggesting their expression is stem cell independent and 
wound-induced (Figure 13) (Owlarn & Bartscherer 2016; Petersen & Reddien 
2011).  
The current model to reestablish anteroposteror polarity has two phases: 
first, the identity establishment (0h-24h after amputation) and later, the maintenance 
of the identity, previously determined (from 24h to 72h) (Figure 13). The first gene 
expressed after amputation is hh that activates wnt1 expression in both wound-
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sites. Later wnt1 will be restricted to the posterior wound allowing the formation of a 
tail. wnt1 activate, through ß-catenin, notum, in both wound-sites. In the anterior 
blastema, notum indirectly inhibits ß-catenin allowing head formation whereas in 
posterior, notum expression, through an unknown mechanism, is reduced leading to 
the formation of the tail (Almuedo-Castillo et al. 2012). 
A lot of effort has been put to identify genes involved in the pole formation 
and re-patterning once the identity has been determined. In the posterior wound-
site, islet, a LIM homeobox transcription factor; pbx, a TALE class homeodomain 
protein; and pitx, a paired class homeobox/pituitary homeobox are required for 
maintaining wnt1 expression and the transcription of other posterior Wnts such as 
wnt11.1 and wnt11.2 and posterior Hox genes (hoxD and abd-ba) (Hayashi et al. 
2011; Chen et al. 2013; Blassberg et al. 2013; März et al. 2013). The inhibition of 
any of these fail to regenerate the tail, similar to the phenotypes observed when ß-
catenin or wnt1 are inhibited. Although these genes are important for posterior 
regeneration, they are not only expressed in the posterior pole but also in the 
anterior. Moreover, inhibition of these genes also leads to cyclops planarians, which 
are planarians with one eye, suggesting that these genes are also involved in 
anterior regeneration.   
On the anterior wound-site, pbx and another TALE class homeodomain 
protein, prep; foxD, a Forkhead-family transcription factor; zic1, a member of the 
Zinc finger of the cerebellum protein family; and follistatin, a secreted regulator of 
TGF-β proteins; are involved in anterior pole formation. These genes are co-
expressed in a small subset of cells in the midline regions alongside notum, on the 
new-forming anterior pole, and are important for maintaining the late expression of 
notum and genes involved in maintaining anterior identity such as the frizzled 
receptor, sFRP-1, and ndl-4 (nou darake-like gen 4). The inhibition of any of these 
genes leads to defects in anterior structures such as the brain (Chen et al. 2013; 
Felix & Aboobaker 2010; Scimone et al. 2014; Vásquez-Doorman & Petersen 2014; 
Roberts-Galbraith & Newmark 2013).  
All this positional information is active in the adult, as it is not only important 
for regeneration but also for cellular turnover in intact animals. A recent study 
identified the subepidermal muscle cells as the ‘position control cells’ (PCCs) 
secreting all the positional genes. The muscles cells are therefore involved not only 
in contraction but provide body coordinates for maintaining the adult body plan. 
PCCs are in charge of specifying the identity of new cells during homeostasis and 
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after injury. These cells change the expression of the positional genes, such as prep 
and ndl-4 in anterior and wnt11.1 and wnt11.2 in posterior, they are expressing in 
order to ensure the new cells acquire the correct identity to regenerate the missing 
structures (Witchley et al. 2013). 
 
 
Figure 13: Proposed model for establishment of anteroposterior identities after 
amputation. (A) Identity establishment. After wound-healing, wnt1 activates ß-catenin which 
in turn activates notum. notum inhibits the function of ß-catenin in the anterior pole but not in 
the posterior pole where an unknown element inhibits notum. (B) Maintenance of the 
identity. After 2 days post-amputation, the downstream targets of canonical Wnts such as 
sFRP1 and ndl-4 in anterior and the posterior Wnts and hox are activated. The anterior 
identity is maintained thanks to the action of pbx, foxD, zic1 and follistatin and the posterior 
to islet, pbx and pitx. Anterior to the left and posterior to the right. 
1.3.3. Epigenetic regulation of the regeneration 
The study of the enhancers associated to the regeneration is a novel field. 
Only three enhancers, which activate gene expression after injury, have been 
identified in different organisms. In zebrafish, the len enhancer is located 7kb 
upstream the lepb TSS and activate gene expression after fin or heart amputation 
(Kang et al. 2016). Despite not being conserved in other organisms, a mice 
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transgenic line containing the len enhancer with a minimal promoter is able to drive 
reporter expression in amputated digit and damaged hear ventricles. A bmp5 
enhancer has been identified in mice that drive bmp5 expression only after adult 
bone or soft tissue injury. This region is different from the enhancers that drive 
bmp5 expression during mice development (Guenther et al. 2015). Finally, an 
enhancer close to a Wnt gene-encoding locus in Drosophila has been identified 
which activate expression upon injury, allowing the regeneration of the imaginal 
discs. After L3, polycomb-mediated epigenetic silencing of this enhancer takes 
place impairing the regeneration of mature imaginal discs (Harris et al. 2016). 
In planarians, the CRE involved in regeneration have not been identified yet. 
However, a recent study shows that the epigenetic modifiers and histone 
modifications are conserved in planarians. These are mainly expressed in the 
parenchyma, where the neoblasts are present (i.e. around the digestive system and 
not in the pharynx or anterior to the photoreceptors) or in the neural system (i.e. in 
the brain and nerve cords) (Robb & Sanchez Alvarado 2014). HDAC1-1 is 
expressed in neoblasts and when inhibited the regeneration is impaired. The 
inhibition of HDAC1-1 could be causing cell-cycle arrest preventing neoblast to 
proliferate or differentiate (Robb & Sanchez Alvarado 2014). Furthermore, the role 
of the H3K4 methyltransferases Set1 and MLL1/2 in regeneration have been 
studied (Duncan et al. 2015). The results indicated that Set1 and MLL1/2 have 
different biological roles: whereas Set1 targets promoters of genes involved in 
neoblast maintenance, MLL1/2 targets promoters of genes involved with motility.   
 
1.4. Aims and objectives 
Cis-regulatory elements in the genome are known to control animal 
development. These elements contain multiple target sites for transcription factors 
and collectively control expression of developmental gene regulatory networks. 
Therefore, CRE analysis provides a method to study transcription factor 
interactions. In this study, ATAC-sequencing will be used to identify cis-regulatory 
elements in the genome to answer two biological questions: (1) how NC genes are 
regulated in Xenopus embryos and (2) how the anteroposterior polarity of 
planarians is established during regeneration?  
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The first biological question will be addressed by characterizing the 
epigenome during neural crest formation. For that, the specific objectives are: 
• To identify epigenetic modifiers which specifically affect NC formation. 
• To validate NC-induced animal caps as a method to obtain an enriched 
population of NC cells through transcriptomic analysis. 
• To optimize the ATAC-sequencing protocol for animal cap samples. 
• To identify neural crest exclusive regulatory elements at two different 
stages during NC formation: NC specification (stage 13) and NC 
differentiation (stage18).  
• To identify overrepresented motifs in NC enhancers that could drive 
expression of NC genes. 
• To identify enhancers of key NC genes and test their functionality. 
 
In order to address the second biological question (i.e. to characterize the 
genomic regulation of the anterior and posterior poles of planarians, which define 
head versus tail identity), the specific objectives to accomplish are:  
• To ensure that data analysis of the ATAC-sequencing is relevant in 
planarians. 
• To identify exclusive open regions for anterior and posterior pole 
formation during regeneration. 
• To combine ATAC-sequencing and ChIP-sequencing data to identify 
active enhancers involved in anterior and posterior poles of planarians at 
12 hours regeneration. 
• To identify overrepresented transcription factor DNA-binding sequence 
motifs in anterior vs posterior 12h regenerating blastemas. 
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2.1. Xenopus materials and methods 
2.1.1. X. tropicalis embryo obtainment 
Both male and female X. tropicalis adults were primed 24h before eggs are 
required with 10 units of Chorulon (human Chorionic Gonadotropin) into the dorsal 
lymph sac and let them rest at 26°C overnight without being fed. X. tropicalis males 
were euthanized by immersing it in 1g of ethyl 3-aminobenzoate methane sulfonate 
dissolved in 200ml reversed osmotic water in a 500ml beaker and placed in the dark 
for more than 1 hour at 4°C. The testes were surgically removed just before the egg 
collection and store them in Leibovitz's L-15 Medium supplemented with 10% Calf 
serum at 4°C.  
Females were induced 5-6 hours before the eggs were required by injecting 
200 units of Chorulon (human Chorionic Gonadotropin) into the dorsal lymph sac and 
left at 26°C. X. tropicalis eggs were obtained by gently applying pressure to the 
abdomen to encourage eggs to be released. Immediately, eggs were fertilized with a 
mashed section of testes dissolved in Leibovitz's L-15 Medium supplemented with 
10% Calf serum and let at room temperature for 5 minutes. After that embryos were 
immersed in 0.05x MMR (Marc's Modified Ringer's) (50mM NaCl, 1mM KCl, 0.5mM 
MgCl2, 1mM CaCl2, 2.5mM HEPES pH 7.5) for 20 minutes at room temperature and 
rinsed several times with 0.05x MMR. Embryos were stored in a BSA (bovine serum 
albumin) coated Petri dish in 0.05X MMR at 26°C.  
2.1.2. X. laevis embryo obtainment 
Adult females were primed by injecting 100units of PMSG (pregnant mare 
serum gonadotropin) into one pericardial sac 5-10 days before eggs were required 
and left them isolated at room temperature without being fed. 12-18h before eggs 
collection, adult female were induced by injecting 250units of Chorulon in each 
pericardial sac and left overnight at 18°C. X. laevis eggs were obtained by gently 
squeezing the animals with a massaging action and collecting them in a 25ml petri 
dish every hour over a period of 6 hours.  
Before eggs collection, a X. laevis male were euthanized by immersing in 1g 
of ethyl 3- aminobenzoate methane sulfonate dissolved in 300ml reversed osmotic 
water in a 500ml beaker. The beaker is wrapped in foil and placed in the dark for 
more than 1 hour at 4°C. Then, the testes were surgically removed and stored in 
80% FBS (fetal bovine serum) in 1x MMR (100mM NaCl, 2mM KCl, 1mM MgCl2, 
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2mM CaCl2, 5mM HEPES pH 7.5) at 4°C. Having the X. laevis eggs in a 25ml Petri 
dish, a proportion of testes was dissolved with 1ml of 1xMMR, distributed over the 
embryos and left for 5 minutes at 18°C. Embryos were then immersed in 0.1X MMR 
for 20min at 18°C. After this embryos were rinsed with 0.1X MMR and stored in a 
BSA coated Petri dish in 0.1X MMR.  
2.1.3. Dejellying embryos 
Xenopus embryos are enveloped in a transparent jelly coat, which needs to 
be removed post fertilization. 0.1XMMR (X. laevis) or 0.05X MMR (X. tropicalis) were 
poured off the embryos and replaced with 2% L-Cysteine pH 8 for approximately 7 
minutes. Embryos were subsequently washed in 1x MMR and 0.1x MMR (X. laevis) 
or 0.05X MMR (X. tropicalis).  
2.1.4. Embryo fixation 
Once Xenopus embryos reached the appropriate stage they were fixed using 
MEMFA (3.7% formaldehyde, 1XMEM salts), then washed in PBST (PBS, 0.1% 
Tween) and dehydrate in a serial dilution of Ethanol and kept at 4°C. 
2.1.5. Chemical screen  
The compounds (Table 2) were kept at 10mM with DMSO solvent at 4°C or    
-20°C, depending of the specificities of the compounds. 7 embryos per well were 
placed in a 24 well-plate and incubated with the appropriate drug dilution from stage 
15 to stage 40 or from stage 9 to stage 15 (Tomlinson et al. 2009; Schmitt et al. 
2014).  
Table 2: Epigenetic inhibitors tested in the chemical screen. 
Drug Target Source 
ZM 447439 Aurora Kinase Selleckchem (Prof Rob. Field) 
Danusertib (PHA-739358) Aurora Kinase Selleckchem (Prof Rob. Field) 
AT9283 Aurora Kinase Selleckchem (Prof Rob. Field) 
Barasertib (AZD1152-HQPA) Aurora Kinase Selleckchem (Prof Rob. Field) 
SNS-314 Mesylate Aurora Kinase Selleckchem (Prof Rob. Field) 
CYC116 Aurora Kinase Selleckchem (Prof Rob. Field) 
JNJ-7706621 Aurora Kinase Selleckchem (Prof Rob. Field) 
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PHA-680632 Aurora Kinase Selleckchem (Prof Rob. Field) 
CCT129202 Aurora Kinase Selleckchem (Prof Rob. Field) 
TAK-901 Aurora Kinase Selleckchem (Prof Rob. Field) 
AMG-900 Aurora Kinase Selleckchem (Prof Rob. Field) 
PF-03814735 Aurora Kinase Selleckchem (Prof Rob. Field) 
GSK1070916 Aurora Kinase Selleckchem (Prof Rob. Field) 
CCT137690 Aurora Kinase Selleckchem (Prof Rob. Field) 
M344 Aurora Kinase Selleckchem (Prof Rob. Field) 
Decitabine DNA Methyltransferase 
Selleckchem (Prof 
Rob. Field) 
Azacitidine DNA Methyltransferase 
Selleckchem (Prof 
Rob. Field) 
5-Aza-2-deoxicytidine DNA Methyltransferase Sigma 
5-azacitidine DNA Methyltransferase Prof. A.Ganesan 
PFI-1 (PF-6405761) Epigenetic Reader Domain 
Selleckchem (Prof 
Rob. Field) 
NU9056 HAT Tocris 
L002 HAT Tocris 
PU141 HAT Prof. Jung 
PU139 HAT Prof. Jung 
CPTH2 HAT Prof. A.Ganesan 
(S)-ESBA HAT Santa Cruz Biotecnology 
H3-CoA-20-TAT HAT PhD, David J. Meyers 
M3-3 HAT Sigma 
C626 HAT Abcam 
CPTB HAT Abcam 
MG149 HAT Prof. FJ. Dekker 
Trichostatin A (TSA) HDAC Selleckchem (Prof Rob. Field) 
Vorinostat (SAHA, MK0683) HDAC Selleckchem (Prof Rob. Field) 
Entinostat (MS-275) HDAC Selleckchem (Prof Rob. Field) 
Belinostat (PXD101) HDAC Selleckchem (Prof Rob. Field) 
PCI-24781 (Abexinostat) HDAC Selleckchem (Prof Rob. Field) 
LAQ824 (Dacinostat) HDAC Selleckchem (Prof Rob. Field) 
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Quisinostat (JNJ-26481585) HDAC Selleckchem (Prof Rob. Field) 
Mocetinostat (MGCD0103) HDAC Selleckchem (Prof Rob. Field) 
Valproic acid sodium salt (Sodium 
valproate) HDAC 
Selleckchem (Prof 
Rob. Field) 
CUDC-101 HDAC Selleckchem (Prof Rob. Field) 
Droxinostat HDAC Selleckchem (Prof Rob. Field) 
MC1568 HDAC Selleckchem (Prof Rob. Field) 
Pracinostat (SB939) HDAC Selleckchem (Prof Rob. Field) 
PCI-34051 HDAC Selleckchem (Prof Rob. Field) 
Givinostat (ITF2357) HDAC Selleckchem (Prof Rob. Field) 
AR-42 HDAC Selleckchem (Prof Rob. Field) 
Tubastatin A HCl HDAC Selleckchem (Prof Rob. Field) 
PI3K/HDAC Inhibotor 1 HDAC Selleckchem (Prof Rob. Field) 
CI994 (Tacedinaline) HDAC Selleckchem (Prof Rob. Field) 
Sodium Phenylbutyrate HDAC Selleckchem (Prof Rob. Field) 
Rocilinostat (ACY-1215) HDAC Selleckchem (Prof Rob. Field) 
Scriptaid HDAC Selleckchem (Prof Rob. Field) 
Burkholdac B HDAC Prof. A.Ganesan 
FG-4592 HIF Selleckchem (Prof Rob. Field) 
2-Methoxyestradiol (2-MeOE2) HIF Selleckchem (Prof Rob. Field) 
IOX2 HIF Selleckchem (Prof Rob. Field) 
GSK J4 HCl Histone demethylases 
Selleckchem (Prof 
Rob. Field) 
Entacapone Histone Methyltransferase 
Selleckchem (Prof 
Rob. Field) 
BIX 01294 Histone Methyltransferase Sigma 
Pargiline Histone Methyltransferase Prof. A.Ganesan 
SRT1720 Sirtuin Selleckchem (Prof Rob. Field) 
Resveratrol Sirtuin Selleckchem (Prof Rob. Field) 
EX 527 (Selisistat) Sirtuin Selleckchem (Prof Rob. Field) 
Quercetin Sirtuin Selleckchem (Prof Rob. Field) 
Sirtinol Sirtuin Selleckchem (Prof Rob. Field) 
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2.1.6. Imaging 
Images of embryos were captured using Q imaging 01-MP3.3-RTV-CLR-10 
camera mounted on a Zeiss Stemi 5V6 microscope. Images were then processed 
using Inkscape/Illustrator and Photoshop. 
2.1.7. Transformation using DH5α cells 
1µl of DNA plasmid was added to 100µl of DH5α competent cells and kept on 
ice 30min. After that, cells were incubated 90s at 42°C and incubated again 5min on 
ice. 300µl of LB was added and incubate 1h at 37°C at 200rpm. Finally, 100-200µl 
was plated onto a LB with carbicillin. These were left at 37°C overnight to form 
colonies. 
2.1.8. DNA Midiprep 
Colonies from the transformation were taken to be incubated with 50 ml LB 
with 50µl of carbicillin, or the appropriate antibiotic, shaking overnight at 37°C. 
Plasmid DNA was isolated using the Qiagen Midiprep plasmid purification kit 
according to the manufactures instructions. The concentration was measured with a 
nanodrop (Thermofisher). 
2.1.9. Probe synthesis 
Plasmids containing the gene of interest, foxd3 and zic1 (plasmids obtained 
from Prof. Yoshiki Sasai and Dr. Jung Aruga, respectively), were linearized by 
restriction enzyme using 2µl of the appropriate enzyme (BamHI and EcoRI, 
respectively), 5-10µg of plasmid, 5µl of the restriction enzyme buffer in a total volume 
of 50µl. The reaction was incubated overnight at 37°C. The linearized plasmid was 
then purified through Ethanol precipitation by adding 5µl of NaAc 3M pH 5.2, 250µl of 
Ethanol and let overnight at -20°. The mixture was centrifuged and the pellet was 
resuspended in 15µl of water. 
To synthesis the DIG-probe the following reaction was used: 1µg of purified 
linearized plasmid, 4µl of 5x Transcription Buffer (Promega), 2µl of DTT (100mM), 
1µl of dNTP containing DIG labelled UTP (Roche), 1µl RNAsin (Promega) and 2µl of 
RNA polymerase made to a final volume of 20µl. The polymerases to transcribe the 
probes for foxd3 and zic1 were T7 and T3, respectively. The reaction was incubated 
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3h at 37°C and the probes were purified using G50 column, according to the 
manufacturers instructions.  
2.1.10. Whole mount in situ hybridization (WISH) 
X. tropicalis embryos were rehydrated in PBST (PBS, 0.1% Tween). All the 
washes were performed 5min at room temperature in a rocker. Embryos were then 
incubated with 10µg/ml ProteinaseK for 2min. Embryos were rinse twice 5min in 
0.1M triethanolamine pH 7-8 and then washed 25µl acid anhydride/10ml 0.1M 
triethanolamine and finally in 50µl acid anhydride/10ml 0.1M triethanolamine. 
Embryos were then washed twice in PBST for 5min and incubated in 3.7% 
formaldehyde/PBST for 20min at room temperature after which they were washed 3 
times in PBST for 5min and incubated 1hour at 60°C in hybridization buffer (50% 
Formamide, 5XSSC, 1mg/ml Torula RNA, 100µg/ml Heparin, 1X Debharts solution, 
0.1% Tween, 0.1g/100ml Chaps, 10mM EDTA). Embryos were incubated with the 
probe in hybridization buffer (1/500) overnight at 60°C.  
Probes were removed and stored at -20°C. Embryos were washed 20min at 
60°C three times in 2X SSC and two times in 0.2X SSC (SSC 20X: 175g NaCl, 88.2g 
Sodium citrate total volume 1l and pH 7). Embryos were then washed twice in MABT 
(100mM Maleic acid, 150mM NaCl, pH 7.5, 0.1% Tween) 30min at room temperature 
and then transferred into 2% BMB Blocking/MABT for 1hour at room temperature 
with rocking. Blocking solution was replaced with antibody solution (2% BMB, 20% 
goat serum in 1XMAB) containing anti-digoxigenin (1:2000) and incubated overnight 
at 4°C with rocking. 
Antibody solution was removed and embryos were washed in MABT five 
times for 60min each at room temperature with rocking. Embryos were then washed 
twice in alkaline phosphate buffer (100mM TrisHCl pH 9.5, 50mM MgCl2, 100mM 
NaCl, 0.1% Tween). Embryos were then put in NBT/BCIP with alkaline phosphate 
buffer (67.5µl of 75mg/ml NBT and 52.5µl of 50ml/ml of BCIP made up to 15ml of 
alkaline phosphate buffer) until the desire level of colour was observed. Embryos 
were then put in 5XTBST (125ml 1M TrisHCl pH 7.5, 40g NaCl, 1g KCl 50ml of 
Tween made up to 500ml). Embryos were kept overnight in 5XTBST to remove the 
background and then were photographed. To store them, embryos were kept in 
methanol at 4°C. 
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2.1.11. Capped RNA synthesis 
10µl of plasmid DNA containing X. laevis noggin and wnt1 (plasmids obtained 
from Dr. Dave Hsu and Dr. Oliver Destree, respectively) were digested using 5µl of 
restriction enzyme buffer, 2µl of restriction enzyme (NotI for noggin and XbaI for 
wnt1) made up to 50µl with water. The reaction was incubated overnight at 37°C and 
then purified using Qiagen PCR Purification kit. For capped RNA synthesis, 1µg of 
linearized plasmid, 10µl of NTP/CAP, 2µl of buffer, 2µl of Sp6 RNA polymerase 
made up to 20µl was incubated 2hours at 37°C. 1µl of Turbo DNAse was added for 
15min at 37°C. The capped RNA underwent lithium chloride precipitation and 
quantified.  
2.1.12. Animal cap assay 
Embryos were injected at two cell stage with ether noggin (to induce 
neuroectoderm), noggin and wnt1 (to induce neural crest) or non-injected (which 
gives ectoderm). These were left to develop until stage 9 when the animal pole was 
cut using sharp forceps after removing the vitelline membrane. Caps were cut in 
filtered-sterile 1XMMR and transferred to plates containing 0.7XMMR, 1mg/ml BSA, 
100µg/l gentamycin until non-dissected sibling embryos had reached stage 13 or 18  
(Figure 14). 
 
Figure 14: Animal cap assay. Embryos were injected at two-cell stage and left to develop 
until stage 9 when the animal pole was dissected. Caps were left develop until sibling 
embryos reached stage 13 or 18. 
2.1.13. ATAC-sequencing 
One X. laevis animal cap was incubated in a 1ml eppendorf with 500µl of 
liberase/trypsin solution (1:10) at room temperature for 10 minutes, pipetting every 3 
minutes to dissociate the tissue. The solution was transferred to a 50ml falcon tube 
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containing 4ml Hank’s solution (1xHBSS, 10mM HEPES, 0.25%BSA). The eppenford 
was rinsed with 1ml of Hank’s solution to recover more material. The falcon was 
centrifuged 800g 8min, the supernatant was discarded and the pellet was 
resuspended in 4ml of Hank’s solution. The solution was passed through a 40µm cell 
strainer and centrifuged again 8min at 800g. The supernatant was removed and the 
pellet was resuspended in 1ml of cold 1XPBS and transferred to a new eppendorf. 
The sample was centrifuged 500g, 10min at 4°C, the supernatant was removed and 
the pellet was resuspended in 50µl of cold 1XPBS. The sample was centrifuged 
again 500g, 10min at 4°C, the supernatant was removed and resuspended in 50µl of 
cold lysis buffer (5µl of Tris HCl pH 7.4, 1.5µl of MgCl2, 10µl of 10% NP40, 1µl of 
NaCl 5M made up to 500µl with nuclease free water). 5µl of the resuspended sample 
were taken to count the number of nuclei in a Neubauer chamber. The volume 
corresponding to 50,000cells was transferred into a new eppendorf. The sample was 
centrifuged 500g, 10min at 4°C and resuspended in transposition reaction (10µl of 
2X TD Buffer, 1µl Tn5, 9µl nuclease free water). The reaction was incubated 30min 
at 37°C. 2.4µl EDTA 0.5M were added and incubated at 55°C for 30min. After that, 
1.2µl MgCl2 was added and the samples were purified using Qiagen Mini Cleanup 
Kit, according to the manufacturers, and resuspended in 10µl of nuclease free water. 
The DNA fragments were amplified by carrying out the following PCR reaction: 10µl 
of transposase DNA, 10µl on nuclease free water, 2.5µl of 25µM adapter 1, 2.5µl of 
25µM adapter 2.X and 25µl of NEBNext High Fidelity PCR 2X and cycling as follow: 
75°C for 5min, 98°C for 30s, 16 cycles of 98°C for 10s, 63°C for 30s and 72°C for 
1min, and hold at 4°C. The PCR reaction was purified using Qiagen Mini PCR 
Purification and resuspended in 10µl of nuclease free water. AMPure beads 
purification SRI1X was carried out and the libraries were quantified using Qubit.  
2.1.14. RNA extraction and cDNA synthesis 
Embryos were snap frozen in liquid nitrogen and kept at -80°C before RNA 
extraction. RNA extraction was performed using High Pure RNA Isolation kit (Roche), 
according to the manufacturers and samples were resuspended in 30µl of water. 
DNAse treatment on column was carried out. 1µg of RNA was taken to synthetize 
cDNA using the Maxima First Strand cDNA synthesis (Themofisher). 
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2.1.15. Quantitative PCR 
The quantitative PCR (qPCR) reaction mixture was as follows: 2µl cDNA, 1µl 
of 2.5µM Primer forward and reverse dilution, 5µl of Syber green and 2µl of water. 
The PCR reaction cycled 50°C for 2min, 95°C for 10min, and 40 cycles of 95°C for 
15s and 60°C for 1min. Amplification curves were analysed using 7500 sequence 
detection software. 
Table 3: Xenopus qPCR primers. 
Name Forward primer Reverse primer 
FoxD3 TCTCTGGGGCAATCACACTC GTACATTTGTTGATAAAGGG 
Snai2 TCCCGCCACTGAAAATGCCACGAT
C 
CCGTCCTAAAGATGAAGGGTATTCCTG 
Sox2 GAGGATGGACACTTATGCCCAC GGACATGCTGTAGGTAGGCGA 
Keratin GGAGCTAGCCAACCATGAAC CTGCCAGCTTGGCATTATCT 
Gapdh CTTTGATGCTGATGCTGGAA GAAGAGGGGTTGACAGGTGA 
Xbra GAATGGTGGAGGCCAGATTA TTCATTCTGGTATGCGGTCA 
MyoD TACACTGACAGCCCCAATGA TGCAGAGGAGAACAGGGACT 
Id3 CAAGGGACCAGGTATGGATG CCTGGCACCAACTCTTTCAG 
Ocd CATGGCATTCTCCCTGAAGT TGGTCCCAAGGCTAAAGTTG 
cMyc GAAACACCCATCAGCAGACC CTCTTCCTCGTCGCAGTCT 
cMyc 
promoter 1 
TGGTTCCTAGCTGTCAGTGG TCCATGCAGGAGACAGAGAG 
cMyc 
promoter 2 
GGGCAGGATTTCTCACTTTC ATAGCAGCTCCACGTCTCCT 
cMyc 
promoter 3 
GCTGCTGCTGCTATTACTGC TAAATCCACAGGCTGTCGTG 
cMyc gene 
body 1 
ATCTGAGAAGCTGGCATCCT GTGGACTCTGGCACTGAGAA§ 
cMyc gene 
body 2 
CTCAGTGAAATGCTGGGAGA TAGAAAGCATTTGGCGTCTG 
cMyc gene 
body 3 
CTGAGGCTTGTGGTTCTTCA TTTGAGCAACAGCTGGAAAC 
   
2.1.16. Embryo morpholino injection 
X. tropicalis embryos undergoing injections were placed at two cell stage in 
3% Ficoll PM400 (Sigma). Both blastomeres were injected with 100ng standard 
control morpholino or Cdk9-a morpholino, in the animal pole, using a 14nl calibrated 
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needle and oxygen free nitrogen was used with a Harvard apparatus injector 
(Medical Systems Research products). The injector was set at Pout=90, Pbalance=0.6 
and Pinject=16. 2 hours after injection the ficoll was removed and replaced with 
0.5XMMR with gentamycin (1:1000) and left to develop at 26°C.  
2.1.17. ChIP-sequencing 
Approximately 50 embryos per sample were fixed at stage 16 in 1% 
formaldehyde for 30min. Embryos were then washed in 125mM glycine solution 30 
minutes and then transferred gradually to 0.1X MMR. Embryos were homogenized in 
sonication buffer (20mM TrisHCl pH 8, 70mM KCl, 1mM EDTA, 10% glycerol, 5mM 
DTT, 0.125% NP40, protease inhibitors (Roche #04693132001) and stored at -80C. 
After sonication, chromatin samples were incubated with RNA Pol II antibody 
(diagenode C15200004) 1ug per 15 embryo equivalent in IP buffer overnight (50mM 
TrisHCl pH 8, 100mM NaCl, 2mM EDTA, 1%NP40, 1mM DTT and protease 
inhibitors) followed by incubation with Dynabeads Protein G for 1h. Beads where 
subsequently washed in ChIP 1 buffer (IP buffer + 0.1% deoxycholate), ChIP 2 buffer 
(ChIP 1 buffer + 400mM NaCl), ChIP 3 buffer (ChIP 1 buffer + 250mM LiCl) and TE 
buffer. Material was digested with proteinase K and DNA was purified using a 
QIAGEN kit. Q-PCR was performed pre and post library preparation for quality 
checking and DNA libraries were prepared using Kapa Hyper Prep kit (Kapa 
Biosystems).  
2.1.18. I-SceI meganuclease trangenesis  
The protocol was obtained form Ogino et al. (2006). The plasmid containing 
the enhancer, minimal promoter and the reporter gene were first digested. 2µl of 10X 
I-SceI buffer, 2µl of I-SceI (New England Bio Labs), 8µl of plasmid at 0.1µg/µl and 
8µl of water were incubated at 37°C for 40min. The reaction was injected in 1cell 
stage X. laevis embryos. The embryos were injected in a period of 45min after being 
fertilized. Embryos were kept in 3% Ficoll at 12°C until they reached 4 cell stage and 
then transferred to 0.3X MMR with 50µg/ml gentamycin and kept at 18°C until they 
underwent gastrulation. Then the embryos were placed at 22°C. The injector was set 
at Pout=0.7 and Pinject=10.  
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2.2. Planarians materials and methods 
2.2.1. Organisms maintenance 
Planarians used in these experiments were from a clonal strain of the 
S.mediterranea BCN-10 biotype and were maintained at 18°C in PAM 1X water 
(93.5µg NaCl, 246.5µg MgSO4x7H2O, 100.8µg NaHCO3, 7.5µg KCl, 20.35µg 
MgCl2x6H2O, 147µg CaCl2x2H2O made up in 1l) and feed once-twice a week with 
organic beef liver. Planarians were starved for 1 week and were 4 to 6 mm in length 
when used for experiments. 
2.2.2 Double stranded RNA (dsRNA) synthesis 
dsRNA was prepared from in vitro transcription reactions using PCR-
generated templates. For that primers for notum (TCGAGTGATTTGTGGTCTGG and 
TGAAGCTAGATTTATGTGAAAAACCA) and wnt1 (AACAATCAAATATTCGTCA and 
TGTTAGGAAAGGTCGGTTGC) were used. For the in vitro transcription, 1µg of 
amplified DNA, 2µl of transcription buffer 10X, 2µl of 10mM NTP, 1µl RNAse 
inhibitor, 1µl of RNA polymerase made up to 20µl were incubated 4h at 37°C. This 
reaction was set to transcribe the sense and the antisense RNA. Both strands were 
mixed and the dsRNA was purified through phenol – chlorophorm extraction.  
2.2.3. Injections 
dsRNA was injected in the prepharingeal region using a Drummond Scientific 
Nanoject. 3632-nl of dsRNA was injected for three consecutive days. After that, 
planarians were amputated pre and postpharingeal (one round of injections). Two 
rounds or injections were required. Control animals were injected with water or a 
dsRNA of gfp (see section 4.3). 
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Figure 15: Schematic representation of the dsRNA injection methodology. Planarians 
were injected three days in the prepharyngeal region and then performed a bipolar cut. After 
three days the same protocol was carried out. 
2.2.4. ATAC-sequencing 
The same ATAC-sequencing protocol as for Xenopus (see 2.1.13) was 
followed. The organisms were washed in 2%L-Cystein pH 7 for 2min and then 
transferred to a petri dish containing CMFH (2.56mM NaH2PO4x2H2O, 14.28mM 
NaCl, 10.21mM KCl, 9.42mM NaHCO3, 1%BSA, 0.5%Glucose, 15mM HEPES pH 
7.3). 20 blastemas were cut and transferred into an eppependorf. CMFH was 
removed and blastemas were dissociated in a solution of liberase/CMFH (1:10).  
2.2.5. ChIP-sequencing 
2000 anterior and posterior blastemas were fixed in groups of 100 blastemas. 
For that, organisms were place in 1M MgCl2 for 15-30s rocking and then transferred 
to PBS. Following that, blastemas were fixed in 1.85%formaldehyde for 15mintutes 
rocking at room temperature. Glycine to a final concentration of 0.125M was added 
to quench the formaldehyde and it was incubated 5min at room temperature. 
Blastemas were washed three times in cold PBS1X and the samples were stored at  
-80°C. Samples were homogenize in 5ml of cell lysis buffer (10mM Tris-HCl pH 7.5, 
10mM NaCl, 0.3% NP-40, Complete 1X). Samples were centrifuged at 3500rpm, 
5min at 4°C, the supernatant was discard and the pellet resuspended in 660µl 
Nuclear lysis buffer (50mM Tris-HCl pH 7.5, 10mM EDTA, 1% SDS, Complete 1X) 
diluted by adding 1.340ml of ChIP Dilution buffer (16.7mM Tris-HCl pH 7.5, 1.2mM 
EDTA, 167mM NaCl, 0.01% SDS, 1.1% Triton X-100). Samples were split in 1ml 
aliquots and sonicated in a Covaris M220 with settings: duty factor=10%, PIP=75W, 
100=cycles/burst, time=10’. Samples were centrifuge 5min, max speed at 4°C and 
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the supernatant were collected. 20µl were kept as an input control. 5/3x200µl of 
sonicated chromatin were incubated with 2µl of H2K27ac (ab4729) at 4°C, overnight 
rotating. Samples were incubated with 50µl of Dynabeads protein G resuspended in 
ChIP Dilution Buffer 1h at 4°C. Beads were washed twice in Wash Buffer 1(20mM 
Tris-HCl pH 7.5, 2mM EDTA, 150mM NaCl, 1% SDS, 1% Triton X-100), twice in 
Wash Buffer 2 (20mM Tris-HCl pH 7.5, 2mM EDTA, 500mM NaCl, 0.1% SDS, 1% 
Triton X-100) and twice in Wash Buffer 3 (10mM Tris-HCl pH 7.5, 1mM EDTA, 
250mM LiCl, 1%NP-40, Na-deoxycholate 1%) and twice in 10mM Tris-HCl pH 8. 
Beads were resuspended in TAGmentation reaction mix (10 mM Tris-HCl pH 8.0, 5 
mM MgCl2, 10 % w/v dimethylformamide), 1µl of Tn5 was added and incubated for 
1min. Beads were then washed twice in Wash Buffer 1 and once in TE 1X. The 
samples were eluted 15min in 100µl of Elution Buffer (50mM NaHCO3 pH 8.8, 
1%SDS) and 180µl of Elution Buffer was added to the input sample. 10µl of 4M NaCl 
and 0.5µl of 10mg/ml proteinase K were added to the ChIP and input sample and it 
was incubated 4-6h at 65°C. DNA was purified using Minelute columns (Qiagen). 
The library was prepared by PCR: 19µl of DNA, 1µl of 25µM of adapter1 and 2.X, 
25µl of NEBNext High-Fidelity 2X PCR Master Mix and 4µl of water which was cycled 
98°C for 30s, 98°C for 10s 63°C for 30’s 72°C for 30 and 72°C for 5min. The number 
of cycles was empirically determined. The libraries were purified using Minelute 
columns (Qiagen). 1/100 of each ChIP sample, 1/10, 1/100, 1/1000 of the inputs 
were used in a qPCR with positive and negative primers according to 2.1.15. 
!Table 4: Planarian qPCR primers. 
 
 
 
 
 
Name Forward primer Reverse primer 
neg AATCAAAATTGTTGGGGGTTT TGACTCAGCTGGGTTCTTCA 
Wnt1 TTCCATCTTTTATTCTCAGAGTTTG TTGATTGGATAAAAATGAGGAGTT 
follistatin GACAAAATTATGCAATTCTTTTTACA TTTCCTTTGGTAATCGAAACAA 
notum TATTGCCTATTGCCCCTTTG GAAGCACCCTGCTGCTACTC 
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2.3. In silico methods 
2.3.1. RNA-sequencing data analysis 
Xenopus RNA-sequencing data performed using Kallisto 0.43.0 against the 
XL_9.1_v1.8.3.2.primaryTranscripts.fa transcriptome.  
>kallisto index -i Xl_transcriptome.idx XL_9.1.fa 
>kallisto quant -i Xl_transcriptome.idx -o <output> <R1> <R2>  
 
The TPM were analysed with edgeR. The PCA plot, scatter plot of 
differentially expressed genes according a p-value=0.5, and the selection of 100 top 
differently expressed genes were generated using the following commands: 
> data <- readDGE(files, columns = c(1,4)) 
> keep <- rowSums(cpm(data)>1) >= 2 
> data <- data[keep, , keep.lib.sizes=FALSE] 
> y <- calcNormFactors(data) 
> y$samples 
> plotMDS(y) #PCA plot 
> Stage <- factor(c("st9","st9","st9","st13","st13","st13")) 
> Frog <- factor(c(1,2,3,1,2,3)) 
> design <- model.matrix(~Stage+Frog) 
> rownames(design) <- colnames(y) 
> data <- estimateDisp(y,design) 
> fit <- glmFit(data,design) 
> lrt <- glmLRT(fit,coef=2) 
> topgenes <- topTags(lrt,n=100,sort.by = "PValue", p.value = 0.05) 
> top <- rownames(topgenes) 
> table_topgenes <- cpm(y)[top,] 
> summary(dt<- decideTestsDGE(lrt, p.value = 0.05)) 
> isDE <- as.logical(dt) 
> DEnames <- rownames(data)[isDE] 
> plotSmear(lrt, de.tags = DEnames) # Smear plot of differential 
expressed genes 
> write.table(topgenes, file = "file.txt", sep="\t") #Generate the 
table of top differential expressed genes 
2.3.2. ATAC-sequencing data analysis 
Both Xenopus and planarian data was analysed using the following 
commands. The Xenopus data was analysed using the X. laevis genome 
Xla.v91.repeatMasked.fa and the features file XL_9.1_v1.8.3.2.gff3. The planarian 
data was analysed using the S. mediterranea genome SmedAsxl_genome_v1.1.nt 
and the features file SmedAsxl_genome_v1.1.all.gff. Reads were first analysed using 
bowtie1 with the argument X2000, the distance between the two reads can be up to 
2000bp, as the default is 250bp. For X. laevis the -m1 argument was used to detect 
only reads that map in one place. 
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> bowtie-build <genome.fa> <ebwt_base> 
> bowtie -X2000 –m1 <indexed genome> -1 <R1.fastq>  -2 <R2.fastq> -S 
<output.sam> 
The sam files were converted to bam, the mapped reads were filtered and the 
forward reads were then shifted 4bp and reverse reads, 5bp, due to the Tn5 
properties 
> samtools view -b -T <genome.fa> -o <output.bam> -S <input.sam> 
> samtools sort <input.bam> <outout.bam> 
> samtools view -b -F 4 -o <output.bam> <input.bam> 
> awk '{if($6=="+"){$2=$2+4} else if ($6=="-") {$3=$3-5} 
print$1"\t"$2"\t"$3"\t"$4"\t"$5"\t"$6}' <input.bam> > <output.bam> 
Taking the output of this, the tracks to be visualised on the genome browser 
were generated using F-seq. First individual files for each chromosome/scaffold were 
generated and then combined in a single bigwig file that can be loaded to the UCSC 
genome browser. 
> bedtools bamtobed –i  <input.bam> > <output.bed> 
> fseq -of wig -f 0 -o <output_index> <input.bed> 
> cat 0h/*.wig | grep -v track > <combinedwig.wig> 
> wigToBigWig <combinedwig.wig> <chrom.sizes> <output> 
To perform peak calling using MACS2 the following command was followed. 
The peaks common in the three replicated were selected. Peaks overlapping 50%, 
were considered the same peak. 
>callpeak -t <input.bam> -n <output_index> -f BAM -g <genome_size> 
>intersectBed -wo -a <rep1.narrowPeak> -b <rep2.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21/s1 >= 0.5) || 
($21/s2>= 0.5)) {print $0}}' | cut -f 1-10 | sort | uniq 
|intersectBed -wo -a stdin -b <rep3.narrowPeak> |awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21/s1 >= 0.5) || 
($21/s2 >= 0.5)) {print $0}}' | cut -f 1-10 |sort | uniq > 
<sample.narrowPeak> 
To identify peaks shared between different samples in order to generate the 
Venn diagrams and to identify peaks present in the different gene location the 
following commands were followed: 
a. Peaks present in A and B but not in C: 
>intersectBed -wo -a <A.narrowPeak> -b <B.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21/s1 >= 0.5) 
|| ($21/s2 >= 0.5)) {print $0}}' | cut -f 1-10 | sort | uniq | 
intersectBed -wao -a stdin -b <C.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21 == 0) || 
($21 == 0)) {print $0}}' | cut -f 1-10 | sort | uniq | wc –l 
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b. Peaks present A but not in B or C: 
> intersectBed -wao -a <A.narrowPeak> -b <B.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21 == 0) || 
($21 == 0)) {print $0}}' | cut -f 1-10 | sort | uniq | 
intersectBed -wao -a stdin -b <C.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21 == 0) || 
($21 == 0)) {print $0}}' | cut -f 1-10 | sort | uniq | wc –l 
c. Peaks present in A, B and C 
> intersectBed -wo -a <A.narrowPeak> -b <B.narrowPeak> | awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21/s1 >= 0.5) 
|| ($21/s2>= 0.5)) {print $0}}' | cut -f 1-10 | sort | uniq 
|intersectBed -wo -a stdin -b <C.narrowPeak> |awk 
'BEGIN{FS="\t";OFS="\t"}{s1=$3-$2; s2=$13-$12; if (($21/s1 >= 0.5) 
|| ($21/s2 >= 0.5)) {print $0}}' | cut -f 1-10 |sort | wc –l 
d. Peaks present in gene location 
> intersectBed -u -a <input.narrowPeak> -b <genomic_location.bed >  
<output.bed>  
Finally, the motifs present in then different peak were identified using Homer: 
> findMotifsGenome.pl <narrowPeak> <genome.fa> <outout/> -size given 
To calculate the coverage in the different peaks to analyse the enhancer 
dynamic, bedtools coverage was used: 
> bedtools coverage -a <narrowPeak> -b <replicate.bed > <output.bed> 
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3.1. Rationale 
The main purpose of this chapter was to identify epigenetic elements 
relevant for Xenopus neural crest formation, i.e. for neural crest specification 
and/or differentiation. This has been subdivided in the following objectives. 
The first objective was the identification of epigenetic modifiers involved 
in Xenopus NC formation. To do this, we propose to carry out a chemical screen 
using a library of small molecules that are known inhibitors of DNA and histone 
modifiers. This type of technique is a simple first approach to selecting 
candidate genes, as it requires no prior knowledge. Moreover, the Xenopus 
model organism is ideal for this approach as the different phenotypes are easy 
to visualize (Tomlinson et al. 2009; Kälin et al. 2009).  
The second objective was the identification of cis-regulatory elements 
relevant for NC formation in Xenopus. As it has been pointed out, there is little 
conservation of CREs, excepting a small number of highly conserved non-
coding regions, and there are few studies aiming to identify neural crest 
regulatory elements in Xenopus, most of them being performed in chick or 
mouse embryos (for instance see Betancur et al. 2010; Milewski et al. 2004). 
Moreover, most of the studies have been performed analysing potential 
regulatory regions next to candidate genes rather than carrying out a whole 
genome analysis (Simões-Costa et al. 2012; Vadasz et al. 2013; see section 
1.2.2.2 for more examples). The main reason behind this is that the neural crest 
cell population represents a small percentage of the total embryo and most of 
the whole genome techniques require 3-5 orders of magnitude more material 
(Buenrostro et al, 2013). The development of new techniques based on the 
transposase Tn5 enzyme such as ATAC-sequencing and ChIPmentation, which 
allow whole genome analysis with a small amount of starting material, will 
enable cell type analysis. According to Buenrostro et al. 2013, DNase-
sequencing requires 3-5 orders of magnitude more cells than ATAC-
sequencing, generating similar results. Therefore, it is of interest to perform a 
whole genome analysis of neural crest cells to identify enhancers involved in 
this cell type formation. In order to obtain information specifically about NC 
cells, ATAC-sequencing is going to be performed not only in NC-induced animal 
caps but also in neuroectoderm and ectoderm-induced animal caps. The 
following bioinformatics analysis will reveal putative NC-specific enhancers and 
their putative upstream transcription factors.  
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3.2. Epigenetic modifiers involved in neural crest formation 
3.2.1.Chemical screen using a library of epigenetic inhibitors in X. tropicalis 
Chemical screens are assays that utilize small molecules to alter the 
function of specific gene products and infer the role of such a gene in development, 
based on the obtained phenotype. These are easy-to-perform, cheap and can be 
used to inhibit a gene product at specific time points. Moreover, they can be used to 
discover new drugs and test their toxicity levels. The use of Xenopus is 
advantageous because hundreds of eggs are obtained frequently, they can take 
compounds from the media and the phenotypes are easy-to-score (Tomlinson et al. 
2009; Schmitt et al. 2014). 
A library of 66 inhibitors of epigenetic modifiers (Table 2) was used in a 
chemical screen performed in X. tropicalis embryos. Those compounds include, 
among others, inhibitors for HAT, DMTS, HMT families, the importance of which has 
been previously mentioned in relation to NC formation. In order to see the 
phenotype after the treatment with the inhibitors, embryos at stage 15 were 
incubated with the compounds for three days at 26°C until they reached stage 38-
40, when the phenotype was scored (Figure 16A). The phenotypic categories were 
assigned according to the main defect the embryo presented, designating one 
phenotype for each compound. The phenotypes (Figure 16B) were distributed into 
the following categories: (1) normal development, when the treated embryo looked 
similar to the control, treated with the appropriate amount of solvent; (2) general 
development, when the embryos showed general body shape alteration or the 
development was pronouncedly delayed compared with the control; (3) edema 
formation, when the embryo presented an increase of fluid around the heart cavity; 
(4) melanocyte morphology, when pigment cells did not present the dendritic shape 
characteristic to this cell type; (5) melanocyte migration, when pigment cells 
presented an abnormal pattern, usually located in stripes along the dorsal spine; (6) 
pigmentation defects, when embryos did not show any pigmentation or it was very 
reduced; (7) craniofacial defects, when embryos had obvious defects in the 
craniofacial structures; and (8) eye morphology defects, when the eye structures 
were not present or had an abnormal morphology. Compounds were first added at a 
final concentration of 50µM. If after the screen, embryos did not show any 
phenotype the concentration of the drugs was increased to 100µM; in contrast, if 
embryos were dead or very damaged the concentration was reduced to 25µM and 
10µM. The screen was replicated twice to ensure the phenotypes were due to the 
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presence of the drug in the media. Out of the 66 compounds, 28 were associated to 
normal development; 18 to general development; 4 to edema formation; 3 to 
melanocyte morphology; 2 to melanocyte migration; 6 to pigmentation defects; 3 to 
craniofacial defects and 2 to eye morphology defects (Figure 16C).  
 
Figure 16: Results of the screening using epigenetic inhibitors. (A) Strategy followed for 
the experiments, embryos were incubated with the drug dissolved in the media from stage 
15 to stage 38-40. (B) Phenotypic categories in which embryos are distributed with an 
example of the phenotype. White square shows a closer look to the melanocytes. Arrows 
show the main defect. (C) Distribution of the drugs into the different phenotypic categories.  
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3.2.2. Analysis of compounds associated with pigment loss  
It was noticed that all the compounds associated with pigment loss were 
related to changes in histone acetylation, either histone acetyltransferases (HAT) or 
histone deacetylases (HDAC). Therefore, further characterization of these families 
of inhibitors was carried out to determine the optimal concentration and affects on 
NC formation (Figure 17 and Figure 18).  
Regarding HDACs (Figure 17A), SAHA, also called Vorinostat, is a general 
inhibitor of HDAC that when applied at 40µM showed complete loss of pigmentation 
(Richon et al. 1998). At increasing concentration toxic defects such as bent spine 
and reduced size are observed. HDACs are mainly divided in four families 
depending on sequence homology: class I (HDAC 1-3, 8), class II (HDAC 4-7, 9-
10), class III (SIRT1-7) and class IV (HDAC11) (Dawson & Kouzarides 2012). 
Burkholdac B is a compound that targets exclusively HDAC class I (Benelkebir et al. 
2011). At 50µM it also showed pigment and developmental defects similar to SAHA, 
suggesting that SAHA and Burkholdac B might be inhibiting the same enzymes. 
The other compounds that inhibit HDAC mainly affect general development. 
Regarding HATs (Figure 17B), there are many available compounds 
targeting several members of this family. PU139 (Gajer et al. 2015) is a general 
HAT inhibitor, which showed the most severe loss-of-pigmentation phenotype even 
in the eyes. The nuclear HATs are divided into three families: GNAT (containing 
KAT2A/B members), MYST (containing Tip60 member) and CPB/p300 (Dawson & 
Kouzarides 2012). CPTH2 (Chimenti et al. 2009) inhibits KAT2B a member of 
GNAT family producing at high doses a partial loss of pigmentation coupled with 
melanocyte morphology defects. Tip60 is inhibited by the compound NU9056 
(Coffey et al. 2012) and barely affected pigmentation. PU141 (Gajer et al. 2015) 
inhibits the p300/CBP family and also reduced embryo pigmentation. L002 
compound inhibits p300 whereas CTPB enhances p300 (Yang et al. 2014; 
Balasubramanyam et al. 2003). The treatment with CTPB at 100µM did not show 
any pigmentation defect while the treatment with L002 at 12µM clearly reduced the 
pigmentation of the embryo. C646 (Bowers et al. 2010) is another p300/CBP 
inhibitor but its inhibition mainly affected the development of the embryo.  
To address if the defects on pigmentation were caused by an alteration of 
early neural crest formation, embryos at stage 8-9 were treated with the optimum 
concentration previously determined and allowed to develop until stage 15. Then a 
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whole mount in situ hybridization (WISH) using probes against a neural plate border 
gene, zic1 and a neural crest specifier, foxd3, was carried out (Figure 18). None of 
the embryos did show defects in either zic1 or foxd3 expression suggesting that 
theses enzymes are affecting neural crest cells at later stages or they are affecting 
the production of melanin, melanogenesis (Figure 18).  
 
Figure 17: Phenotypes observed after HDAC and HAT inhibitors screen. (A) HDAC 
inhibitors. (B) HAT inhibitors. 
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Figure 18: Screening of a selection of HAT and HDAC inhibitors followed by WISH. (A) 
Strategy followed, embryos were treated with drugs from stage 9 to stage 15 and then 
performed a WISH using foxd3 and zic1 markers. (B) Expression of zic1 and foxd3 after 
treatment with a selection of HDAC and HAT inhibitors. 7 embryos were used per condition. 
3.2.3. Discussion 
After the treatment with the library of 66 epigenetic inhibitors, 28 small 
molecule inhibitors did not cause any obvious phenotype in embryos; 18 were 
associated with developmental defects; 6 with pigment defects; 4 with edema 
formation; 3 with melanocytes morphology; 3 with craniofacial defects; 2 with 
melanocytes migration and lastly, 2 with eye morphology. 
The categories overrepresented were mainly normal development and 
developmental defects. The abundance of first category has many explanations, 
which are also considerations to take into account when performing chemical 
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screens: (1) the drug, dissolved into the media, might not be taken up by the 
embryos; (2) the compounds, tested in human cells, might not recognize the 
Xenopus form of the target enzymes or might have more affinity for another 
enzyme; (3) there might be a compensation mechanism that does not allow the 
visualization of any obvious phenotype; (4) the drugs are added in a certain 
windows of time the target might not be having a crucial role in; and finally, (5) the 
concentration to inhibit certain enzymes might be higher than 150µM that is the 
maximum concentration above which the phenotypic effects can be due to the 
solvent. It was experimentally determined that toxic effects were observed when 
1.5% of DMSO was added to the media. In order to prevent the phenotypic effects 
of the solvent, the amount of solvent was always smaller than 1.5% therefore the 
maximum concentration of drug screened was 150µM. 
The second overrepresented category was defects in normal development, 
which reflect the importance and broad role that epigenetic modifiers have in 
development. It has been previously mentioned the importance of p300, as one of 
the co-factors that correlates with active enhancers, in general development. As 
expected, the inhibition of p300 through the compound C646, showed major defects 
in development at low concentration.  
The third represented category is pigment reduction or absence. This is 
because scoring for pigment changes is relatively easy in this type of assays. As the 
pigment cells derive form the NC cells and our study focuses on NC formation, a 
further analysis was carried out with these compounds, which were all associated 
with changes in acetylation. The first thing to notice is the range of optimal 
concentrations varies from 10µM to 150µM. The amount of compound needed to 
inhibit the target depends on the amount of compound that is effectively absorbed 
by the embryo, the amount target enzyme present in the organism and the different 
affinity of the compound for its target.  
The zic1 and foxd3 WISH after compound treatment did not show any 
affects on NC specification. It has to be mentioned that the initial screening was 
performed from stage 15 to stage 38-40, where the specification of NC cells has 
already occurred. Therefore it does make sense that the pigment reduction is not 
due to defects in early NC formation, but rather to the differentiation of melanocytes 
or melanogenesis. To determine if melanocytes are properly formed, it would be 
required to perform mitf or tyrosinase WISH, which are markers for pigment cell 
projenitors. 
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The general inhibitor of HDAC (SAHA) produces a similar phenotype to the 
HDAC class I inhibitor (BurkholdacB), suggesting than the phenotype produced by 
SAHA is caused by inhibition of class I HDACs (HDAC 1-3, 8). The lack of 
pigmentation in these organisms is consistent with the results published by Ignatius 
et al. (2008), where the function of hdac1 in zebrafish melanocytes is characterized. 
Ignatius and collegues (2008) showed that the inhibition of hdac1 produces a 
reduction on the number of melanocytes. Hdac1 prevents Foxd3 from blocking mitf 
expression therefore allowing melanogenesis; when this is disrupted by HDAC 
inhibition, Foxd3 represses pigment formation.  
Regarding HATs, the results are not as easy to interpret. First, both C646 
and L002 claim to inhibit specifically p300 although the phenotypes were quite 
different: whereas C646 affected general development, L002 affected mainly 
pigment cells. Second, there are members of both GNAT family (KAT2B) and 
p300/CBP family (P300), which show a loss-of-pigmentation phenotype. Although it 
is clear that histone acetyltransferases are relevant for melanocyte formation or 
melanogenesis, it remains unclear which specific subfamily is responsible for these 
effects. Another possibility is that there is no specificity and the inhibition of HATs 
does not allow the transcription of certain genes related with this cell type. As 
mentioned before, acetylation of histones is associated with active transcription due 
to repulsion between negatively charged DNA and acetylated histone residues 
which are also negatively charged allowing a relaxed nucleosome conformation 
making the DNA accessible to transcription related proteins.  
There are a few studies reporting the importance of HATs for NC 
development. Two studies show that Kat6a (a member of the MYST subfamily) is 
relevant for proper craniofacial formation (Miller et al. 2004; Kong et al. 2014) . The 
MYST member inhibited in our screening, Tip60, did not show any major 
craniofacial defect, suggesting that Kat6a is specifically involved in head formation, 
at least in zebrafish.  
The strategy followed did not produce the desired results, which were to 
identify small molecules affecting NC specification. No specific early NC affects 
were detected. This could be in part due to the time of incubation with the drug: the 
drugs should have been added at an earlier stage, such as stage 8-9, the embryos 
grown until stage 38-40 to check for defects in pigment cells or craniofacial 
structures. However, compounds were affecting melanocyte formation and/or 
melanogenesis, neural crest migration and craniofacial structure formation were 
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identified. This could be followed up by further characterizing the phenotypes with 
techniques such as Alcian blue staining, which stains cartilage and can reveal 
craniofacial malformations or WISH with melanocytes markers to investigate the 
pigment phenotypes. It would also be interesting to deeply characterize the 
phenotypes caused by an alteration on the histone acetylation in the context of 
gene expression. For that, ChIP-sequencing targeting RNAPII or specific histone 
acetylation modifications such as H3K27ac would be required. 
We were not able to detect any specificity in epigenetic modifiers driving NC 
formation using this selection of small molecules. We then decided to determine if 
there was any specificity in CREs and motifs presents in those regulatory regions 
associated with NC formation. 
 
3.3. Transcriptome analysis of X. laevis neural crest cells 
3.3.1. NC-induced animal cap samples 
In order to dissect the regulatory landscape of NC cells it was first necessary 
to analyse the transcriptome of this cell population. RNA-sequencing of different 
stages of NC formation, stage 9, stage 13 and stage 18 has been performed. The 
comparison between stage 9 and 13 would allow us to identify transcriptional 
changes required for NC specification whereas the comparison between stage 13 
and 18 would reveal transcriptional changes involved in NC differentiation. 
The neural crest cell population represents a very small percentage of the 
total number of cells present in the embryo; therefore to undergo genomic analysis 
specific for this cell population it is crucial to obtain an enriched population of NC 
cells. For that, the animal cap assay is a particularly good approach in Xenopus. 
Animal cap assay is a useful technique in Xenopus as it can be induced to become 
several tissue types, depending on the inducing signals provided (Smith 1995). To 
perform an animal cap assay, embryos are injected at 2-cell stage with the inducing 
signals, at stage 9 the animal pole of the embryo is dissected and allowed to 
develop until sibling non-dissected embryos reach the appropriate developmental 
stage; in our case stage 9, 13 and 18. Figure 14 shows a diagram of the animal cap 
assay. To obtain a NC population, embryos need to be injected with mRNA 
encoding a Wnt ligand, Wnt1, and a BMP antagonist; in our case noggin was used 
as a BMP antagonist (Garcia-Morales et al. 2009). The concentration of Wnt1 and 
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noggin sufficient to induce neural crest cell fate was found to be 100pg of Wnt and 
500pg of noggin. In addition, embryos were also injected with 200pg of gfp to check 
the caps were properly injected. 
The samples were analysed to ensure the expression of NC (foxd3, snai2, 
id3, cmyc) as well as neural (sox2), ectodermal (keratin) and mesodermal (myoD, 
xbra) markers was appropriate. For that, at the appropriate stage, RNA extraction 
followed by cDNA synthesis was performed in animal caps. In all the cases, the 
expression of myoD, Xbra, was very low, suggesting that there was no 
contamination with the underlying mesodermal tissue during the animal cap 
dissection (Figure 19A). This was also confirmed as mesodermal-contaminated 
caps display an elongated shape in comparison with rounded non-contaminated 
caps. The expression of keratin was also almost null indicating that the embryos 
were properly injected to induce NC. sox2 is a early neural marker expressed in 
neural plate and later necessary for peripheral nervous system formation, which 
partly derive from NC cells. Moreover, the injection of noggin on its own is sufficient 
enough to induce neuroectoderm. This explains the presence of sox2 in the NC 
samples. The expression of NC markers clearly confirms that the samples are 
enriched in NC cells (Figure 19A).  
The RNA samples were sent for sequencing to the Earlham Institute. The 
requirements were 4 µg of material and 260/280 and 260/230 rations over 2 
indicating no protein or phenol contamination of the samples (Figure 19B). RNA 
from 40-50 caps was extracted and 1ug of that was used to synthetize cDNA and 
test the samples for the correct gene expression by qPCR (Figure 19A). RNA 
samples were sequenced in a HiSeq2500 platform with a 125bp paired-end metric.  
The analysis of the RNA samples was performed using Kallisto, for mapping 
the reads. About 80% of the reads were aligned against the XL_9.1_v1.8.3.2 
available transcriptome (Figure 20A). EdgeR was used to perform differential 
expression analysis. In order to check the similarities between replicates and 
conditions, principle component analysis (PCA) was carried out (Figure 20B). We 
can observe that the three replicates cluster together. Also, that there are more 
differences between stage 9 and stage 13 rather than stage 13 and 18. This will be 
later reflected in the number of genes differentially expressed between those 
samples. There is one sample at stage 18, marked with *, that is separated form the 
other replicates in the PCA plot. This sample has been discarded for the further 
analysis. 
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Figure 19: Animal cap samples used for RNA-sequencing experiment. (A) qPCR results 
showing the expression of NC markers (foxd3, id3, cmyc, snai2), neuroectoderm marker 
(sox2), ectodermal marker (keratin) and mesodermal markers (xbra, myoD) in animal caps 
at stage 9 and induced to become neural crest at stages 13 and 18. n=3 represent 
mean+SD. Samples were normalized against odc in non-induced caps. (B) Characteristics 
of the samples sent for sequencing. 
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Figure 20: Analysis of RNA-sequencing samples. (A) Percentage of aligned reads using 
kallisto (B) PCA plot of the RNA samples. * indicates sample that was discarded for further 
analysis. 
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3.3.2. Comparison between stage 9 and stage 13 neural crest samples 
Comparison between stage 9 and stage 13 was first carried out to identify 
required changes to specify NC cells. With a p-value <0.05, 7595 genes do not 
change between the two stages, 7597 genes were upregulated at stage 13 and 
7171 genes were upregulated at stage 9 (Figure 21). To follow the analysis, genes 
were ranked according to the p-value and the top 100 genes were selected and 
separated in two lists, those upregulated at stage 9 and those upregulated at 
stage13 (Hierarchical cluster shown in Figure 22A). From the total 100 top genes, 
38 were upregulated at stage 9 and after removing those without homology to any 
described gene and S and L duplications, 24 genes were selected. On the other 
side, 62 were upregulated at stage 13 and after discarding the duplicated 
homologues and the genes for which no homology was found to any annotated 
gene, 41 genes were selected. The total 65 genes were split into categories 
according their function and/or where they are expressed (Figure 22B, C). It was not 
possible to carry out GO term analysis because the Xenopus genes are poorly 
annotated and most of the genes appear unclassified; it was decided to manually 
annotate and classify the genes into categories according to their function and/or 
where they are express. These categories are broken down into a list of individual 
genes comprising them in Table 5 and Table 6.  
 
Figure 21: Gene comparison between NC stage 9 and stage 13 samples. Red dots mark 
differentially expressed genes. Black dots represent equally expressed genes and yellow 
line indicates no change blue lines indicate 10 fold change. 
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Figure 22: Genes differentially expressed between stage 9 and stage 13 NC caps. (A) 
Heatmap of the top 100 genes most differentially expressed between caps at stage 9 and 
NC caps stage 13. Hierarchical clustering performed using the complete lineage method. (B) 
Pie chart showing the categories of genes upregulated at stage 9 caps. (B) Pie chart 
showing the categories of genes upregulated at stage 13 neural crest caps. The number of 
genes in each category is annotated in the legend. 
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The genes upregulated in the stage 9 cap (Figure 22B, Table 5) samples are 
related mainly with: (1) proliferation; (2) cytoskeleton; (3) transcription and 
translation regulation and (4) stemness. The main category of upregulated genes is 
proliferation that together with stemness is consistent with the multipotency identity 
of the animal pole of the blastula embryo. At stage 8-9, the mid-blastula transition 
occurs, where zygotic gene transcription is activated. This could explain the 
upregulation of genes involved in transcription and translation regulation such as 
h2ab. Finally, just after stage 9, gastrulation starts, from stage 10 to stage 14, in 
which a complex process of cell rearrangements takes place. This can be the 
reason why a large set of cytoskeleton related genes such as rapgef3, involved in 
actin rearrangements, and arhgap, involved in regulating actin dynamics, are highly 
expressed at stage 9 compared with stage 13 when the gastrulation has already 
occurred.  
The genes upregulated at stage 13 neural crest caps (Figure 22C, Table 6) 
are mainly involved in: (1) neural crest formation; (2) neural formation; (3) 
anteroposterior patterning; (4) proliferation; (5) cement gland and (6) transcription 
and translation regulation. As expected, neural plate borders associated genes such 
as pax3, meis3 and gbx2 are upregulated when comparing stage 9 versus stage 13 
neural crest caps. There are also some brain markers upregulated such as pinhead, 
dmbx1 or irx3. This might be due to the fact that Wnt3 and noggin are also used to 
induce hindbrain (Dibner et al. 2001) and that noggin alone also induce 
neuroectodermal tissue. There are also genes involved in AP patterning of the 
neural plate and cement gland, which marks the most anterior part of the embryo 
such as gli3, vill and ag1.  
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Table 5: Top genes differentially expressed in stage 9 caps when compared with 
stage 13 NC-induced caps. Transcription factors relevant for ATAC-sequencing are 
highlighted in bold. 
Categories Gene name Description p-value 
Proliferation cyclin A1 Cell cycle regulator 1.36E-121 
 
cyclin B1 Cell cycle regulator 7.47E-84 
 
cyclin B5 Cell cycle regulator 1.42E-83 
 
cell division cycle 
associated 7 like 
Positive regulation of cell 
proliferation 
2.90E-74 
 
f-box protein 43 E3 ubiquitin ligase, 
mediates degradation of 
cyclins 
9.18E-70 
 
NDC80 kinetochore 
complex component 
Centromere-associated 
protein 
4.50E-69 
 
BTG family member 3 Anti-proliferation factor 9.08E-69 
proline rich 14-like 
 
Tethers heterochromatin to 
the nuclear laminar 
1.90E-61 
 
Stemness pou5f3.3 Oct60 homolog 1.93E-108 
dand5 Involved in pluripotency 
maintenance 
2.13E-90 
 
Transcription 
and 
Translation  
Regulation 
cytoplasmic 
polyadenylation element 
binding protein 1 
Regulates cytoplasmic 
polyadenylation 
2.21E-103 
 
foxi2 Transcription activator  1.95E-96 
 
h2ab Variant histone of 
conventional H2A 
3.06E-80 
 
zinc finger protein 36, 
C3H type-like 2, gene 1 
Promotes poly(A) tail 
removal 
7.12E-78 
 
h1foo 
 
H1 histone variant oocyte 
specific 
3.64E-66 
 
protein associated with 
topoisomerase II homolog 
Translational repressor 9.69E-62 
 
Cytoskeleton  rap guanine nucleotide 
exchange factor 3  
 
Required for the actin 
rearrangement 
6.14E-74 
 
rho GTPase activating 
protein  
Regulates intracellular actin 
dynamics 
8.47E-65 
 
microtubule associated 
protein 1 light chain 3 
gamma 
Involved in autophagy and 
membrane trafficking 
8.52E-65 
 
exportin 6 Mediates the nuclear export 
of actin 
1.29E-64 
 
FH2 domain containing 1 Contributes to the 
coordination of 
microtubules with actin 
fibers 
3.45E-64 
 
Wiskott-Aldrich syndrome 
like 
Regulates actin 
polymerization 
4.68E-61 
 
Biosynthesis UDP-N-
acetylglucosamine 
pyrophosphorylase 1 
Nucleotide-sugar 
biosynthesis 
7.23E-65 
 
Endocytosis sH3-domain kinase 
binding protein 1  
Involved in endocytosis 1.10E-64 
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Table 6: Top genes differentially expressed in stage 13 neural crest caps when 
compared with stage 9 caps. Transcription factors relevant for ATAC-sequencing analysis 
are highlighted in bold. 
Category Gene name Description p-value 
Neural crest 
related 
laminin subunit beta 1 Involved in migration 1.30E-108 
 
pax3 NC specifier 2.35E-100 
 
zeb2b Found in tissues 
differentiated from the 
neural crest 
7.66E-100 
 
mmp14 Involved in migration 2.86E-80 
 
meis3 NC specifier 3.73E-80 
gbx2 NC specifier 1.35E-79 
 
axin2 Upregulated in neural crest 
precursors 
1.92E-72 
 
complement component 3  Involved in migration 1.84E-71 
sp5 Early regulator of neural 
crest 
2.41E-64 
 
osterix Required for cranial neural 
crest-derived 
2.20E-65 
 
mn1 
 
Required for palate 
development 
2.97E-88 
 
Proliferation cyclin B3 
 
Cell cycle regulator 3.49E-75 
 
thymine DNA glycosylase 
 
Base excision repair 
enzyme 
2.40E-62 
 
retinoblastoma-like 1 Tumor suppressor 6.17E-88 
 
topoisomerase II beta Manages DNA tangles and 
supercoils 
6.88E-88 
 
Transcription  
and Translation 
regulation 
heterogeneous nuclear 
ribonucleoprotein R 
 
Processes mRNA 
precursors  
2.42E-79 
 
eukaryotic translation 
initiation factor 4 gamma, 
3 
 
Aids the assembly of the 
ribosome onto the mRNA 
8.03E-65 
 
eukaryotic translation 
elongation factor 1-alpha 
Facilitates translational 
elongation 
5.79E-64 
 
Neural related pinhead 
 
When inhibited causes 
microcephaly 
5.91E-99 
 
diencephalon/ 
mesencephalon 
homeobox 1 
Involved in brain and 
sensory organ 
development. 
5.81E-86 
 
olfactomedin 4 Involved in nerve tissue 
formation 
1.39E-80 
 
spalt-like transcription 
factor 2 
Plays a role in 
neurogenesis, neuronal 
differentiation and eye 
development 
7.24E-73 
 
iroquois homeobox 3 Involved in neural 
patterning 
1.71E-72 
 
eukaryotic translation 
initiation factor 4A2 
Involved in neural 
patterning 
1.81E-66 
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zygotic DNA replication 
licensing factor mcm3 
Associated with stem cell 
pluripotency retinal cells 
 
1.64E-64 
 
tubulin beta class I Involved in brain 
development 
2.13E-64 
 
retinal pigment 
epithelium-specific protein 
65kDa 
 2.91E-62 
 
cadherin EGF LAG 
seven-pass G-type 
receptor 1 
 
Involved in neural tissue 4.98E-60 
 
Anteroposterior 
patterning 
nuclear receptor 
subfamily 6 group A 
member 1 
 
Required for 
anteroposterior patterning 
1.66E-87 
 
forkhead box B1  
 
Early anteroposterior 
patterning of the 
neuroectoderm 
2.61E-63 
 
transcriptional enhancer 
factor TEF-1-like 
Localized anterior region of 
the neural plate 
6.74E-62 
 
gli3 Involved in neuroectoderm 
patterning 
1.07E-59 
 
rax 
 
Involved in anterior neural 
plate 
4.03E-62 
 
Cement gland anterior gradient 1  
 
Expressed in cement gland 5.96E-70 
 
arfGAP with dual PH 
domains 1  
 
Expressed in cement gland 1.12E-68 
 
vill Expressed in cement gland 1.84E-68 
 
Stemness msi1 Neural stem cell regulatory 
gene 
7.83E-63 
 
Retinoic acid  retinoic acid receptor 
gamma  
 
 4.21E-80 
 
Cytoskeleton epiplakin 1 
 
Involved in cytoskeletal 
architecture organization  
1.80E-79 
 
EMT GLI pathogenesis-related 
2 
Positive regulation of 
epithelial to mesenchymal 
transition 
2.94E-66 
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3.3.3. Comparison between stage 13 and stage 18 neural crest samples 
The differential expression of stage 13 compared with stage 18 neural crest 
animal cap was carried out. With a p-value <0.05, there are 16075 genes equally 
expressed, 2052 genes upregulated at stage 13 and 2928 genes upregulated at 
stage 18 (Figure 23). To follow the analysis, genes were ranked according to the p-
value and the top 100 genes were selected and separated in two lists, those 
upregulated at stage 13 and those upregulated at stage18 (Hierarchical cluster 
shown in Figure 24A). Out of the 100 top genes differentially expressed, 24 were 
upregulated at stage 13. After removing the genes with no homology to any 
described gene and duplicated homologous genes, only 15 genes were selected. 
On the other side, 76 genes were upregulated in stage 18 neural crest caps. From 
those, 44 were selected after removing duplicated homologous genes and genes 
with no homology found to any described gene (Figure 24A). The selected genes 
were manually split into categories according to their function and/or expression 
pattern (Figure 24A, B).  
 
Figure 23: Gene comparison between NC stage 13 and stage 18 samples. Red dots 
mark differentially expressed genes; black dots represent equally expressed genes, yellow 
line indicates no change blue lines indicate 10 fold change. 
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Figure 24: Genes differentially expressed between stage 13 and stage 18 NC caps. (A) 
Heatmap of the top 100 genes most differentially expressed between NC caps stage 13 and 
stage 18. Hierarchical clustering performed using the complete lineage method. (B) Pie 
chart showing the categories of genes upregulated at stage 13 neural crest caps. (B) Pie 
chart showing the categories of genes upregulated at stage 18 neural crest caps. The 
number of genes in each category is annotated in the legend. 
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The genes upregulated at stage 13, when compared to stage 18 (Figure 
24B, Table 7), are mainly related to: (1) neural formation; (2) anteroposterior 
patterning; (3) dorsoventral patterning and (4) metabolism. At later stages the 
patterning of the different tissues has already been established which explains the 
presence of genes such as foxb1 and foxd4l1.1 involved in patterning establishment 
upregulated at stage 13. It might be surprising not to find genes involved with NC 
specification but it should be considered that there might be a change in expression, 
but not significant enough to appear in the top 100 genes or NC genes remain on in 
stage 13 and 18 animal caps. The only NC related gene is ventx2, more related with 
maintaining pluripotency in NC specified cells.  
Alternatively, the genes upregulated at stage 18 (Figure 24C, Table 8), 
mainly correspond to the following categories: (1) neural crest related; (2) neural 
related; (3) epidermal related; (4) cement gland and (5) metabolism (Figure 23C, 
Table 7). Not surprisingly, several NC markers such as sox9, sox8, foxd3 and snai2 
are found significantly upregulated at stage18 when compared with stage 13. There 
are also some neural genes such as en2 and epidermal genes such as krt. This can 
reflect the heterogeneity of cells within the neural crest animal caps. There is also 
an upregulation in genes expressed in the cement gland such as gale or xa-1. 
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Table 7: Top genes differentially expressed at stage 13 neural crest animal caps when 
compared with stage 18 caps. Transcription factors relevant for ATAC-sequencing analysis 
are highlighted in bold. 
Category Gene name Description p-value 
Stemness pou5f3.2 Oct25 homolog 1.10E-34 
 
Neural related tdgf1.3 Downregulation causes 
forebrain defects. 
9.73E-45 
 
pinhead Downregulation cause 
microcephaly 
6.55E-37 
 
geminin Induces neural progenitor 
formation 
7.27E-29 
 
Neural crest 
related 
ventx2 Maintains NC multipotency 2.71E-23 
 
Anteroposterior 
patterning 
sp5l Involved in neuroectoderm 
patterning 
4.48E-35 
 
forkhead box B1  
 
Early anteroposterior 
patterning of the 
neuroectoderm 
4.25E-21 
 
Dorsoventral 
patterning 
forkhead box D4 like 1, 
gene 1  
 
Transcriptional repressor 
with a role in dorsal axis 
formation 
1.01E-23 
 
admp Anti-dorsalizing morphogenic 
protein 
5.86E-21 
 
Metabolism histidine ammonia-lyase Converts histidine into 
ammonia 
7.54E-42 
 
htxA Oxidoreductase enzymes 7.77E-40 
 
monocarboxylate 
transporter 4-like 
Carries lactate and pyruvate, 
across biological 
membranes. 
1.08E-27 
 
slc16a3 Carries lactate and pyruvate, 
across biological 
membranes 
4.10E-27 
 
insulin Regulates the metabolism of 
carbohydrates, fats and 
protein 
8.57E-23 
 
Heart related LIM domain 7 protein Involved in heart 
development  
1.28E-24 
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Table 8: Top genes differentially expressed at stage 18 neural crest animal caps when 
compared with stage 13 caps. Transcription factors relevant for ATAC-sequencing analysis 
are highlighted in bold. 
Category Gene name Description p-value 
Neural crest 
related 
sox8 Induces neural crest 
progenitors 
9.94E-57 
 
tp63 Expressed in branchial 
arches  
2.22E-36 
 
sox9 Induces neural crest 
progenitors 
6.50E-35 
 
snai2 NC marker 4.01E-33 
 
bmp1 Expressed in premigratory 
NC 
6.74E-33 
 
tbx3 Expressed in NCC 1.11E-28 
 
pdgfra Involved in NCC migration 1.72E-28 
 
plakophilin 3 
 
Involved in NCC migration 1.67E-25 
 
tfap2b  NC specifier 8.64E-25 
 
kremen1 Required for neural crest 
induction 
2.64E-24 
 
foxd3 NC specifier 5.26E-24 
 
ezr Expressed in neural plate 
cell 
1.15E-23 
 
capn8 Involved in NCC migration 4.05E-22 
 
castor zinc finger 1 Expressed in 
neuroblastoma cell lines 
9.22E-22 
 
pcdh8 Involved in cephalic NC 
migration 
1.16E-21 
 
protogenin Prevents premature 
apoptosis of cephalic 
neural crest cells 
8.45E-21 
 
gata2 Sympathetic neuron 
development 
2.10E-20 
 
Neural related engrailed homeobox 2  
 
Involved in midbrain 
formation 
2.95E-38 
 
huntingtin-associated 
protein 1 
 
Involved in vesicular 
trafficking 
1.81E-22 
 
cmahp Involved in brain growth 3.44E-22 
 
diacylglycerol kinase, eta Associated with bipolar 
disorder 
4.46E-20 
 
camk2g Involved in neuronal 
plasticity 
1.79E-28 
 
nr2f5 Expressed in hindbrain 1.73E-30 
 
fam171B Expressed in brain 5.94E-20 
 
Epidermal 
related 
keratin, type I cytoskeletal 
47 kDa 
Epidermal fibrous structural 
proteins 
1.67E-47 
 
x-epilectin Posterior epidermal marker 7.43E-36 
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sciellin Epidermis terminal 
differentiation marker 
1.42E-23 
 
ahnak Localized in the cell 
surface of human 
epidermis 
4.81E-23 
 
periplakin Localized in the epidermal 
cornfield envelope 
1.48E-22 
 
krt5.7 Epidermal fibrous structural 
proteins 
1.60E-22 
 
krt Epidermal fibrous structural 
proteins 
6.11E-22 
 
otogelin Expressed in goblet cells 8.30E-60 
 
Cement gland nkx3-1 Expressed in cement gland 3.52E-31 
 
xa-1 Expressed in cement gland 1.91E-30 
 
fam3D Expressed in cement gland 7.43E-25 
 
hatching enzyme Expressed in cement gland 3.67E-24 
 
gale Expressed in cement gland 3.65E-20 
 
anterior gradient 2 Involved in cement gland 
differentiation 
2.77E-20 
 
Metabolism phosphodiesterase 4C 
 
Hydrolyzes, cAMP 7.77E-22 
 
galnt6.2 Involved in glycosylation 2.58E-24 
 
a-kinase anchoring protein 
9 
Interact with signal 
transduction pathways 
3.31E-22 
 
s100 calcium binding 
protein A1 
Involved in several cellular 
processes 
8.02E-29 
 
Cytoskeleton filamin a  
 
Stress fiber component 1.19E-22 
 
calpain 2, gene2 
 
Modulates convergent 
extension movements 
6.80E-20 
 
Blood etv6 Regulates embryonic 
hematopoiesis 
5.19E-22 
 
gata2 Involved in globulin 
production 
2.10E-20 
 
Bones  transmembrane protein 
119 
Promotes the differentiation 
of myoblasts into 
osteoblasts 
1.72E-20 
 
acid phosphatase 5, 
tartrate resistant 
Involved in osteoclast 
migration 
4.25E-20 
 
Dorsoventral 
patterning 
sizzled When overexpressed can  
dorsalize embryos 
3.29E-20 
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3.3.4. Time of expression of neural crest genes 
The expression of neural crest genes across the different stages of neural 
crest development has been addressed by analysing the changes in expression, 
i.e., transcript per million (tpm), in the different stages of Xenopus NC formation. 
The aim of this is to determine which genes behave in the same way and try to 
correlate time-related expression patterns with the function of these genes.  
The expression of neural plate border genes (Figure 25) i.e. dlx5, dlx6, id3, 
meis3, msx1, pax3, tfap2a, zic1 and zic 5 was analysed. For all of them, there is a 
common massive increase in expression at stage 13 compared with stage 9 and 
after that the expression is either maintained, increased or decreased. The most 
dramatic change in expression corresponds to pax3 and msx1.L whose expression 
increase by 200 tpm. The change in expression of other genes such as zic5, dlx5, 
dlx6 is not as drastic but all of them increase their expression at stage 13. 
Following that, the expression of neural crest specifiers was also analysed 
(Figure 26). For genes such as foxd3, cmyc, nmyc, msx2, pax7, snai2, sox5, sox8, 
sox9, sox10 and twist there is almost no expression or some expression at stage 9 
and 13 but a massive increase of expression at stage 18. Genes such as snai2 and 
sox10 raise their expression from 0 to 360 and 97 tmp, respectively whereas genes 
like sox5, pax7 and nmyc are barely expressed.  
Another thing to notice is that for most of the genes, both X. laevis L and S 
homologues behave the same way. This might reflect that both homologous genes 
are functionally equivalent. However there are a few cases for which the expression 
varies. snai2 and sox9 have an homologue that shows very little expression across 
the different stages i.e. snai2.S and sox9.L. 
Moreover, the pluripotency factors have been analysed as it has been 
suggested that specified neural crest cells at stage 13 share the expression of some 
pluripotency factors from blastula cells (Figure 27). In Buitrago-Delgado et al. (2015) 
they conclude that NC stage at 13 and stage 9 blastula both express pluripotency 
factors such as Pou5f1 xenopus homologs (pou5f3.1, pou5f3.2 and pou5f3.3), Sox2 
Xenopus homologs (sox2 and sox3), Nanog homolog (ventx1.2). Both stages also 
express neural crest markers such as id3, sox5, tfap2a, foxd3 and snai1. In order to 
confirm if our RNA-sequencing results support that hypothesis, the expression of 
these genes has been analysed. The least expressed genes in stage 9 and stage 
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13 are sox5, ventx1.2 and foxd3. Most of the genes are expressed in all the stages, 
stage 9, 13 and 18. However, the level of expression of those genes at stage 13 is 
more similar to stage 18 than to stage 9. From the pluripotency factors, the Oct4 
Xenopus forms show an interesting pattern: whereas pou5f3.2 and pou5f3.3 are 
highly expressed at stage 9 and their expression is reduced across the time, 
pou5f3.1 has a peak of expression at stage 13 (Figure 27). 
 
 
Figure 25: Expression profile of neural plate border genes. The mean of the transcripts 
per million (tpm) of each gene and homologues is plot across the three different stages: 
stage 9 (left), stage 13 (middle) and stage 18 (right). Solid line indicates L and dash line 
indicates S homologues.  
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Figure 26: Expression profile of neural crest specifiers genes. The mean of the 
transcripts per million (tpm) of each gene and homologues is plot across the three different 
stages: stage 9 (left), stage 13 (middle) and stage 18 (right). Solid line indicates L and dash 
line indicates S homologues. 
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Figure 27: Heatmap showing the expression of pluripotency and NC factors. The log10 
of the mean of transcripts per million has been plotted. Selection of genes has been made 
according to the genes described in Buitrago-Delgado et al. (2015). 
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3.3.5. Discussion  
The aim of the RNA-sequencing was to validate a method to obtain a cell 
population enriched in neural crest cells, the neural crest-induced animal caps. This 
would allow us to study the NC population in detail without needing to use whole 
embryos, where the NC regulation would be masked by whole embryo regulation. 
The study of the transcriptional changes across the different stages of neural crest 
formation is going to be later integrated with the epigenomic data to have a better 
understanding of the NC regulome (see section 3.4).  
The injection of 500pg of noggin and 100pg of Wnt1 is sufficient to induce a 
neural crest population. The results demonstrate that the NC population obtained 
across the different stages behaves the same way as the neural crest cells in the 
embryo. The neural plate border markers have a peak of expression at stage 13 
(Figure 25), when they regulate each other to define the neural plate border domain 
and together with the initial signaling pathways, Wnt, BMP and FGF, allow the 
expression of NC specifiers. NC specifiers, on the other hand, have a peak of 
expression at stage 18 (Figure 26), and these drive the expression of genes 
involved in EMT, delamination, migration and, differentiation into the several NC 
derivatives.  
The analysis of the top genes most differentially expressed also shows that 
NPB genes such as pax3, gbx2 and meis3 are significantly upregulated when 
compared with stage 9 samples, where there is mainly an upregulation of genes 
such as cyclins and pou5f3.3 involved in proliferation and stemness. When 
comparing stage 18 with stage 13, there is also significant increase in NC specifier 
genes such as sox9, snai2 and foxd3. This confirms that the neural crest-induced 
animal cap is a valid method to obtain NC cells and so can be used to obtain 
information about the regulatory regions involved in neural crest formation.  
However, there are also neural and epidermal markers found to be 
expressed in these samples. This can be explained, as animal cap is an organoid 
model to obtain neural crest population based on RNA injection, and there might be 
a heterogenic population where some cells are not fully committed to be NC or are 
committed down alternative routes. The injection of noggin alone is used to induce 
neural tissue whereas the non-injection controls form ectodermal tissue. For that, it 
would be interesting to perform single cell sequencing of the animal caps to 
determine the percentage of fully NC cells compared with the other cell types that 
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might be present on the animal cap and to have a better idea of how cells are being 
committed and specified to become neural crest cells.  
The comparison between samples shown in the PCA plot (Figure 20) shows 
that there are more similarities between stage 13 and 18 rather that between stage 
9 and stage 13. This could be due to the fact that stage 9 caps have not been 
injected with noggin and Wnt1. It would be of interest to compare not-injected caps 
and NC-induced caps at stage 9 to really answer the hypothesis raised by Buitrago-
Delgado et al. (2015) that claims NC cells retain multipotent properties rather than 
differentiate into this cell type. Our data confirm that stage 9 and stage 13 neural 
crest share expression of pluripotency and neural crest genes although the level of 
expression is not comparable.  
This transcriptome data can also be interpreted in the context of Xenopus 
laevis genome evolution, where whole genome duplication has led to an 
allotetraploid genome and so two copies of each gene, designated L and S. 
Although the developmental genes have mostly been retained, some changes in 
spatiotemporal pattern of expression suggesting subfunctionalization have been 
identified (Session et al. 2016). In the majority of NC genes, both homologous 
genes are expressed and show a similar patter of expression. However, sox9 and 
snai2 show differences of expression: only the snai2.L and the sox9.S homologues 
are expressed. This indicates a possible subfunctionaliztion of the two homologues, 
which could be further analysed by designing WISH probes and specific primers for 
each homologue. On the other hand, Xenopus has three copies of Oct4, which 
show a possible subfunctionalization: whereas pou5f3.2 and pou5f3.3 have a peak 
of expression at stage 9, pou5f3.1 has its peak of expression at stage 13. This is 
especially interesting in this context as Session et al. (2016) suggest that this 
subfunctionalization is due to changes in the epigenetic regulation of the different 
homologous genes.  
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3.4. ATAC-sequencing to identify cis-regulatory elements 
3.4.1. ATAC-sequencing protocol optimization 
Section 3.3 has confirmed that the neural crest-induced animal cap is a 
good method to obtain an enriched population of neural crest cells. The main goal 
of this study was to identify regulatory regions specific for NC formation and, if 
possible, identify differences between CRE activated at stage 13 (specification) and 
stage 18 (differentiation). Because of the small amount of required material, the new 
method of ATAC-sequencing was chosen over the different techniques that identify 
enhancers such as ChIP-sequencing and DNase-sequencing (Shlyueva et al. 
2014).  
The first step was to optimize the protocol first published by Buenrostro and 
collegues (2015). The main modifications in the protocol are listed below. (1) To 
dissociate the tissue with a collagenase/trypsin solution and pass it through a cell 
strainer to obtain a single cell population. This way the cells are easier to lyse and 
therefore the enzyme can better reach the nuclei. (2) To increase the NP40 amount 
to 0.2% rather than 0.1% in the lysis buffer. NP40 is a non-denaturing detergent; 
therefore it increases cell permeability without disrupting protein complexes. The 
increase in NP40 facilitates the access to the nuclei. (3) To count the number of 
nuclei that will be incubated with the enzyme and add a maximum of 50,000 cells. 
On average, a cap stage 18 contains 100,000 cells whereas a cap stage 13 
contains approximately 50,000 cells. It was decided to do ATAC-sequencing on 
single animal caps and not to pool several caps as that could reduce the 
background. (4) To reduce the volume of transposase reaction to 20µl instead of 
50µl. (5) To inactivate the enzyme through two methods: firstly, incubating the 
reaction 30min at 55°C, temperature at which the enzyme is inactivated and 
secondly, adding EDTA which sequesters magnesium ions, that act as a cofactor 
for the Tn5 enzyme (Picelli et al. 2014; Buenrostro, et al. 2015). After the incubation 
at 55°C with EDTA, the same amount of MgCl2 needs to be added as it is required 
for the following PCR reaction. That way the enzyme is inactivated after 30 minutes 
incubation at 37°C and overtagmentation is prevented. (6) To purify the libraries 
generated with AMPure Beads SRI 1X, to eliminate small fragments present in the 
library.  
During the optimization experiments, several profiles of tagmentation were 
obtained (Figure 28). Not-tagmented samples are defined as having no clear peak 
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whereas overtagmented samples contain a peak around 200bp. In the later, taking 
into account that the primers used to generate the library are 50bp long, the 
amplified region is not informative. In properly tagmented samples a peak around 
300bp is obtained and occasionally a nucleosome pattern can be seen, which is 
characterized by a periodicity of 200bp (Figure 28C). This peak corresponds to the 
size of a regulatory region. 
 
Figure 28: Examples of tagmentation profiles obtained with bioanalyser. (A) Not 
tagmented sample, there is no clear peak. (B) Overtagmented sample, there is a peak 
around 200bp. (C) Properly tagmented sample with a peak around 300bp and a nucleosome 
profile. 
3.4.2. ATAC-sequencing samples 
As mentioned previously, the aim of this study was to obtain regulatory 
regions specific for neural crest formation. As controls, animal caps injected with 
noggin to give neuroectoderm and non-injected animal caps were also processed. 
The comparison between CREs in the three samples would allow the identification 
of NC specific enhancers. 
Neural crest-induced animal caps were obtained by injection of 500pg of 
noggin and 100pg of Wnt1 at stage 2 and dissection of the animal pole at stage 9. 
Neuroectodermal caps were obtained by injection of 500pg of noggin and 
ectodermal caps were obtained without injecting any inducing agent. All of them, 
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however, were injected with 200pg of gfp to ensure the embryos were properly 
injected in case of neural crest and neuroectoderm, and in the case of ectoderm as 
a control of the injection process.  
In each experiment, a subset of sibling caps was collected to check that the 
expression profile of the samples was appropriate as determined by RNA 
extraction, cDNA synthesis and qPCR. The expression of NC markers (foxD3 for 
early stages and snai2 for later stages), neuroectodermal markers (sox2), 
ectodermal marker (keratin) and mesodermal markers (myoD) was evaluated 
(Figure 29). None of the samples contained myoD indicating that there was no 
mesodermal contamination during the dissection process. Ectodermal caps just 
expressed keratin (Figure 29A, B). Neuroectodermal caps showed mainly sox2 
expression (Figure 29C, D). Finally neural crest caps expressed foxD3 and snai2 
confirming that they were NC-induced. Note they also expressed sox2 which is both 
a neural marker and a marker for stemness (Figure 29E, F) (Zhang & Cui 2014). 
For each condition three replicates were obtained. The bioanalyser analysis 
and the sequencing using a MiSeq was performed in collaboration with the Sauka-
Spengler Lab at the University of Oxford, obtaining approximately 15M reads per 
sample. All the samples were properly tagmented, as a peak at 300bp, 
approximately was obtained, except the neuroectoderm stage 18 replicate 3 that 
later will be discarded for being overtagmented (Figure 30 and Figure 31).  
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Figure 29: Expression prolife of samples used in ATAC-sequencing. (A) Ectodermal 
caps stage 13. (B) Ectodermal caps stage 18. (C) Neuroectodermal caps stage 13. (D) 
Neuroectodermal caps stage. (E) Neural crest caps stage 13. (F) Neural crest caps stage 
18. The expression of NC markers (foxd3 and snai2), neuroectoderm markers (sox2), 
ectoderm markers (keratin) and mesoderm marker (myoD) was evaluated by qPCR. NC and 
neuroectoderm samples were normalized against the odc in non-injected samples and 
ectoderm samples were normalized against odc expression. Mean+SD is represented. 
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Figure 30: Bioanalyser profile of the stage 13 ATAC-sequencing samples. 
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Figure 31: Bioanalyser profile of the stage 18 ATAC-sequencing samples.
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After checking the quality of the samples using FastQC, the data analysis 
was performed. Reads were aligned to the X. laevis genome version 9.1 using 
Bowtie1 and just those pair-reads with a unique mapping site were kept. According 
to Encode an alignment rate of 80% is acceptable. The percentage of properly 
aligned reads was between 41-72%. This could be due to the fact that reads 
mapping in more than one place were discarded. The X. laevis genome is still not 
optimally assembled and the genome is duplicated thus favoring the multiple 
mapping of the reads.  
The insert size distribution of the samples was analysed to check the 
number of reads that map on the nucleosome free (NF) region and on the mono-
nucleosome (MN) fraction (Figure 32-34). The NF fraction is smaller than 100bp 
and, as it is free of nucleosome, is more accessible to transcription factors. The MN 
fraction comprises DNA fragments between 180 to 250bp and it is protected with 
nucleosomes. Enhancers contain a central region with no nucleosomes or highly 
remodeled nucleosomes flanked with mononucleosomes with highly modified 
histone tails (Hoffman et al. 2013).  
Most of the samples display a similar metric and also similar to the one 
reported in Buenrostro et al. (2013). There is an increase at 50bp and then a 
decrease in the distribution of reads and a more subtle increase in the MR region. 
The metrics also show a periodicity of approximately 10.5bp, which is equal to the 
helical pitch of DNA. The ratio between NF and MN is close to 2, suggesting that 
the samples are enriched in the nucleosome free fraction and therefore in cis-
regulatory elements, similar to the one reported in Buenrostro et al. (2013). The 
peaks were then called in the whole sample using MACS2. 
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Figure 32: Metrics of neural crest samples. The plot represents the normalized reads in 
function of the different insert size. Red rectangle marks nucleosome free (NF) region and 
black rectangle mark mononucleosome (MN) region. The ratio between NF and MN is 
shown.  
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Figure 33: Metrics of neuroectoderm (NE) samples. The plot represents the normalized 
reads in function of the different insert size. Red rectangle marks nucleosome free (NF) 
region and black rectangle mark mononucleosome (MN) region. The ratio between NF and 
MN is shown. 
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Figure 34: Metrics of ectodermal samples. The plot represents the normalized reads in 
function of the different insert size. Red rectangle marks nucleosome free (NF) region and 
black rectangle mark mononucleosome (MN) region. The ratio between NF and MN is 
shown. 
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3.4.3. Comparison between ATAC-sequencing samples 
In order to compare the different samples, first, the three replicates were 
combined; only those peaks overlapping 50% in all the samples were selected for 
the following analysis, as recommended in the Encode guidelines version 7 
(Encode 2017). Using this, at stage 13 there are 17,997 peaks present in the NC 
sample, 20,274 peaks in the neuroectoderm sample and 12,245 in the ectoderm 
sample. The number of peaks common in the different samples was then analysed. 
There are 5,592 peaks common in the three samples, 1,116 peaks common 
between NC and ectoderm samples, 1,816 peaks common between neuroectoderm 
and ectoderm samples and lastly, 5,264 peaks are common between NC and 
neuroectoderm samples. Finally, there are 6,025 peaks specific for NC, 7,602 
peaks for neuroectoderm and 3,721 for ectoderm (Figure 35A).  
The same analysis was carried out for the stage 18 samples. 11,705 are 
present in the NC sample, 46,515 peaks in the neuroectodermal sample and 23,923 
peaks in the ectodermal sample (Figure 35B). There are 7,541 peaks common for 
the three samples, 2,618 peaks common between NC and neuroectoderm samples, 
9,176 peaks common between neuroectoderm and ectoderm samples and 334 
peaks common between NC and ectoderm samples. Finally, there are 1,212 peaks 
specific for NC samples, 27,181 peaks specific for neuroectoderm samples and 
6,872 peaks are specific for ectoderm samples. There are a lot of peaks exclusive 
for neuroectoderm sample and this could be due to the fact that there are only two 
replicates in this sample. 
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Figure 35: Venn diagrams comparing peaks of open regions present in the different 
samples. Peaks overlapping 50% were considered the same. (A) Comparison of NC, 
neuroectoderm and ectoderm at stage 13. (B) Comparison of NC, neuroectoderm and 
ectoderm at stage 18.  
 
3.4.4. Analysis of the ectodermal cis-regulatory elements  
The ectoderm samples were analysed with the aim of ensuring the 
experiment was well designed and the expected results were obtained (Figure 36). 
The behavior of the ectoderm marker keratin across the different samples was 
studied to make sure the promoter of this gene showed a significant increase of 
reads on the ectodermal samples, suggesting activation (Figure 36A). Compared 
with the neural crest and neuroectoderm samples, the ectodermal samples show an 
increase of reads across the gene and in the promoter. This confirms that the 
ectodermal samples behave as expected.  
The specific peaks present in the ectoderm samples were then compared 
between the two stages. Out of the 3,721 specific peaks present at stage 13 and 
6,872 peaks present at stage 18, there are 523 peaks common to the two samples, 
3,198 peaks only present at stage 13 and 6,349 peaks only present at stage 18 
(Figure 36B).  
Peaks present in the different samples were located in several genome 
locations. In order to identify which peaks correspond to enhancers, the genomic 
location of each peak was determined. Those selected correspond to intergenic 
regions as this relates to possible cis-regulatory elements. Several chromatin marks 
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and a high degree of conservation have been found in the first intron of genes, 
indicating that the presence of enhancers in the first intron (Park et al. 2014). 
However the X. laevis annotation does not allow the distinction between exons and 
introns and therefore these potential enhancers were not considered. The genome 
was divided into four different locations: (1) genes, including exon and intron 
regions, (2) promoter regions defined as TSS + /– 200bp, (3) proximal enhancer 
regions that were defined as peaks in a range of 2kb upstream the TSS and finally, 
(4) distal enhancers which are peaks further than 2kb from the TSS and not present 
inside a gene. The analysis of the ectodermal samples reveals that 54% of the 
stage 18 peaks correspond to intergenic regions, in particular 41.9% to distal 
enhancers and 13.1% to proximal enhancers, 11.2% correspond to promoters and 
33.8% to genic regions. On the other side, 59.3% of the stage 13 ectoderm peaks 
correspond to intergenic regions, in particular, 48.6% to distal enhancers and 10.7% 
to proximal enhancers, 8.5% correspond to promoters whereas 32.2% are inside 
gene coordinates (Figure 36C).  
The intergenic regions, 2,556 and 4,697 for stage 13 and stage 18, 
respectively, were selected to continue with the analysis, as they could be potential 
enhancers. The motifs present in the stage 18 intergenic regions were analysed 
using Homer in order to detect which transcription factors are bound to the peaks 
and could drive expression of genes involved in the formation of non-neural 
ectoderm. The most relevant transcription factors are gata2, gata3 and six1 (Figure 
36D). The complete list of motifs found in the ectodermal stage 18 intergenic 
regions is displayed in Appendix 1 Table iii. The transcription factors gata2 and 
gata3 are involved in the anteroposterior segmentation of the non-neural ectoderm. 
In Xenopus and Zebrafish gata2 and gata3 are expressed anteriorly in the 
prospective head region, gata2 is expressed in the middle region and none is 
expressed in the posterior region that will become the tail (Read et al. 1998). Later 
on during development, gata2 is involved in the formation of erythropoiesis 
progenitors whereas gata3 is required for luminal epithelial cells differentiation in 
mammary glands (Dalgin et al. 2007; Chou et al. 2010). The motifs for both 
transcription factors are found in stage 18 ectoderm peaks; 14.36% of the peaks 
contain gata2 motifs whereas 24.24% contain gata3. Also, 4.5% of the peaks 
contain six1 motif. This transcription factor is crucial for the pre-placodal ectoderm 
formation, together with its co-activator eya1, which give rise to the cranial sensory 
organs and ganglia. A transcriptome analysis of the pre-placodal region determined 
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that six1 acts upstream of other transcription factors involved in sensory neurons 
differentiation such as atoh1 and neurog1 (Riddiford & Schlosser 2016).  
 
Figure 36: Analysis of ectoderm cis-regulatory elements. (A) Genomic location of an 
ectodermal marker, keratin, showing a representative track for each condition, neural crest 
caps stage 13 (NC st13), neural crest caps stage 18 (NC st18), neuroectoderm caps stage 
13 (NE st13), neuroectoderm caps stage 18 (NE st18), ectodermal caps stage 13 (ECT 
st13) and ectodermal caps stage 18 (ECT st18). Grey rectangle marks the promoter of the 
gene. (B) Venn diagram showing the distribution of ectodermal specific peaks in the two 
stages analysed, stage 13 and stage 18. (C) Distribution of the ectoderm specific peaks into 
four different genomic locations, gene, promoter defined as TSS+/- 200bp, proximal 
enhancer, defined as 2kb upstream the TSS, and distal enhancer. (D) Significant ectoderm 
motifs present in the stage 18 intergenic ectoderm peaks.  
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3.4.5. Analysis of the neuroectoderm cis-regulatory elements  
In a similar way to the ectodermal samples, the neuroectoderm samples 
were also analysed to check if expected results were obtained (Figure 37). The 
analysis of the krox20 loci, also known as egr2, revealed that there was an 
enrichment of reads in the promoter. Although the neural crest and ectoderm 
samples also showed some reads in the promoter region, they were not as 
abundant as the neuroectodermal samples (Figure 37A).  
The analysis of the specific peaks revealed that among the 7,602 stage 13 
peaks and the 27,181 stage 18 peaks, there are 4,792 exclusive for the 
neuroectoderm stage 13, 24,371 exclusive for stage 18 and 2,810 are common 
between the two stages (Figure 37B). The analysis of the peak location revealed 
that both stage 13 and stage 18 have a similar proportion of peaks in each location. 
The 54% of both samples correspond to intergenic regions, in particular, 41% to 
distal enhancers and 13% to proximal enhancers, 10% correspond to promoters 
and 34% to gene locations (Figure 37C). 
The intergenic regions for stage 13 and stage 18, 5,246 and 19,147, 
respectively were identified as a potential enhancers involved in the formation of the 
neural tissue. Analysis of the motifs present in stage 18 cis-regulatory elements 
revealed that nkx6.1, otx2 and sox3 are statistically significant present on those 
peaks  (Figure 37D). The complete list of motifs found in the neuroectoderm stage 
18 intergenic regions is displayed in Appendix 1 Table iv. The transcription factor 
nkx6.1, which is present in 57.45% of the peaks, is required for mid-hindbrain 
boundary. This gene acts upstream of en2 and Wnt1 which are both necessary for 
the mid-hindbrain boundary (Ma et al. 2013). 21.44% of the peaks contain otx2-
binding sites. otx2 is required to establish the presumptive forebrain, where the eye 
field is specified, and midbrain (Gammill & Sive 2001; Zuber et al. 2003). Finally, 
sox3 is found in 46.89% of the intergenic stage 18 peaks. This gene is expressed in 
the presumptive central nervous system (Penzel et al. 1997).  
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Figure 37: Analysis of neuroectoderm cis-regulatory elements. (A) Genomic location of 
an neuroectodermal marker, krox20 also known as egr2, showing a representative track for 
each condition, neural crest caps stage 13 (NC st13), neural crest caps stage 18 (NC st18), 
neuroectoderm caps stage 13 (NE st13), neuroectoderm caps stage 18 (NE st18), 
ectodermal caps stage 13 (ECT st13) and ectodermal caps stage 18 (ECT st18). Grey 
rectangle marks the promoter of the gene. (B) Venn diagram showing the distribution of 
neuroectodermal specific peaks in the two stages analysed, stage 13 and stage 18. (C) 
Distribution of the neuroectoderm specific peaks into four different genomic locations, gene, 
promoter defined as TSS+/- 200bp, proximal enhancer, defined as 2kb upstream the TSS, 
and distal enhancer. (D) Significant neuroectoderm motifs present in the stage 18 intergenic 
neuroectoderm peaks. The p-value, percentage of target sequences with the motif and a 
bibliographic reference relating the transcription factor to the formation of neuroectoderm are 
shown.  
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3.4.6. Analysis of the neural crest cis-regulatory elements  
The analysis of the snai2 locus reveals that only in the neural crest samples 
there is a significant enrichment of reads in the promoter region compared with the 
neuroectoderm and ectoderm samples. This observation, together with the keratin 
and krox20 loci, gives more confidence in the generated data (Figure 38A).  
The comparison between stages showed that 85 peaks are common 
between the two stages whereas 5,940 peaks are exclusive for stage 13 and 1,127 
exclusive for stage 18 (Figure 38B). Furthermore, the study of the peak location of 
the NC samples revealed that at stage 13 there are 46.3% of peaks located in 
intergenic regions, with 23% in distal enhancers and 23.3% in proximal enhancers, 
21.5% correspond to promoters and 32.2% to genes. At stage 18, 62% of the peaks 
correspond to intergenic regions, 53.4% to distal enhancers and 8.7% to proximal 
enhancers, 7.2% correspond to promoters and 30.7% to genic regions (Figure 
38C). To continue with the analysis, the intergenic peaks, 852 at stage 13 and 
4,528 at stage 18, were used. 
3.4.7. Neural crest enhancer dynamic 
The ATAC-sequencing analysis allows the identification of different 
enhancer dynamics among the NC specific peaks (Figure 39). The most frequent 
enhancer dynamics found are CRE present exclusively at stage13, 2,460 peaks, 
and at stage 18, 715 peaks (Figure 39B and C). From the peaks present at both 
stages, the coverage in each peak was determined to identify those peaks 
differentially enriched in either one stage or the other (Figure 39D-F). Out of the 41 
common intergenic peaks, most of them, 39 peaks, show a similar coverage in both 
stages. Just one peak is significantly more expressed at stage 13, the closest gene 
of which is pcdh8.2.L at 28kb. On the other side, a peak located at 300bp of 
slc40a.S shows a significant increase in the coverage at stage 18 compared with 
stage 13 (Figure 39 D and E). However, according to the RNA-sequencing data 
generated, none of those genes are expressed in NC-induced caps. 
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Figure 38: Analysis of neural crest cis-regulatory elements. (A) Genomic location of an 
neural crest marker, snai2, showing a representative track for each condition, neural crest 
caps stage 13 (NC st13), neural crest caps stage 18 (NC st18), neuroectoderm caps stage 
13 (NE st13), neuroectoderm caps stage 18 (NE st18), ectodermal caps stage 13 (ECT 
st13) and ectodermal caps stage 18 (ECT st18). Grey rectangle marks the promoter of the 
gene. (B) Venn diagram showing the distribution of neural crest specific peaks in the two 
stages analysed, stage 13 and stage 18. (C) Distribution of the neural crest specific peaks 
into four different genomic locations, gene, promoter defined as TSS+/- 200bp, proximal 
enhancer, defined as 2kb upstream the TSS, and distal enhancer. 
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Figure 39: Enhancer dynamics. (A) Pie chart showing the distribution of the different 
enhancer dynamics in the intergenic NC peaks. The number of peaks in each category is 
annotated in the legend. (B) Example of a peak only present at stage 13. (C) Example of a 
peak only present at stage 18. (D) Example of a peak present at stage 13 and 18 with the 
coverage higher at stage 13, close to pcdh8.2. (E) Example of a peak present at stage 13 
and 18 with the coverage higher at stage 18, close to slc40a. (F) Example of a peak present 
at stage 13 and 18 with the coverage equal in both stages. 
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3.4.8. Analysis of neural crest transcription factor motifs present in intergenic 
neural crest open regions 
The presence of neural crest-related motifs in the intergenic NC peaks was 
evaluated using Homer (Heinz et al. 2010). The complete list of motifs found in the 
stage 13 and 18 intergenic regions are displayed in Appendix 1 Tables i and ii. This 
data reveals NC specific transcription factors involved in activating other NC genes, 
through binding to their enhancers. The RNA-sequencing data was used to support 
this data as it confirmed if specific transcription factors were being expressed at 
these stages. 
Figure 40 shows that a zic motif is present in 18.39% of the intergenic open 
regions at stage 13 and 17.46% at stage 18 with a p-value smaller than 10-10. The 
presence of zic bound to NC enhancers is likely to happen as zic1 is expressed in 
both stages at high levels, according to the RNA-sequencing. pax3 and meis show 
similar results. A pax3 motif is present in 4.88% of the intergenic peaks at stage 13, 
and in 4.37% of the peaks at stage 18, in both cases with a p-value smaller than 10-
2. meis motif is present in 28.91% and 26.19% of the stage 13 and stage 18 
intergenic peaks, respectively, also with a p-value smaller than 10-2. Both pax3 and 
meis3 are expressed at the two stages, pax3 with more than 200 tpm and meis3 
between 100-200 tpm in both stages. A different case is pax7, this motif appears in 
a low percentage of NC peaks and moreover this gene shows almost no expression 
across the different stages. The sox10 motif is present in 26.23% and 28.04% of 
peaks with a significant p-value at stage 13 and 18, respectively. However, while 
sox10 is highly expressed at stage 18, it is almost not detected at stage 13 
suggesting that sox10 plays an important role in NC enhancer activation at stage 
18. sox9 motif is present in 12.04% of the stage 13 peaks and 15.34% of the stage 
18 peaks, in both cases with a p-value between 10-10 and 10-2. sox9 is expressed at 
both stages. nmyc is expressed at stage 18, with differences between the S and the 
L form. The nmyc motif is only present significantly in 9.48% of the inergenic NC 
regions at stage 13. cmyc also shows a similar pattern, although cmyc is highly 
expressed in both stages, its motif is only significantly present in 7.32% of the stage 
13 intergenic regions. tfap2a motif is only significantly present in 8.60% of the stage 
18 peaks where both homologous genes are highly expressed.  
In conclusion, based on the ATAC-sequencing combined wih the RNA-
sequencing data, the NC genes relevant for the stage 13 enhancer activation are 
zic1, pax3, meis3 and cmyc. At stage 18, zic1, pax3 meis3, sox10, sox9 and tfap2a 
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seem to be the most relevant transcription factors for the activation of stage 18 
enhancer.  
 
 
Figure 40: Analysis of neural crest motifs present in NC enhancers. The diameter of the 
circles represents arbitrary the significance of motifs found in the intergenic peaks using 
Homer (Heinz et al. 2010). Small circles represent p-value greater then 10-2, mid-size circles 
represent p-value between 10-2 and 10-10 and big circles represent p-values small than 10-10. 
Next to the circle the percentage of the motif in the peaks selection is shown. The level of 
expression of each gene is shown by the color of the circle: yellow marks no expression, 
less than 1 transcript per million (tpm) and log10tpm <0, orange marks low expression, 
between 1 and 10 tpm and log10tpm between 0 and 1, dark orange marks moderate 
expression, between 10 and 100 tpm, and log10tpm between 1-2 and brown marks high 
expression, more than 100 tpm, and log10tpm grater than 2. The left half of the circle 
represents the S homologous of the genes and the right half of the circle the L homologous 
of the gene.  
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3.4.9. Analysis of pluripotency transcription factor motifs present in intergenic 
neural crest open regions 
Using a similar strategy and the same peak selection used in section 3.4.8, 
the importance of pluripotency factors in neural crest formation has been evaluated. 
The presence of oct4, sox2 and nanog motifs was studied in the context of their 
homologs expression during NC formation (Figure 41). 
The oct4 motif is present in 11.70% of the stage 13 NC and in 4.89% of the 
stage 18 NC intergenic peaks, both significantly. The oct4 Xenopus homologs, 
pou5f3.2 and pou5f3.3 are all highly expressed at stage 9. At stage 13 pou5f3.1 is 
highly expressed whereas pou5f3.2 and pou5f3.3 have moderate and low 
expression. At stage 18, pou5f3.1 is moderately expressed and pou5f3.2 and 
pou5f3.3 are low expressed. The sox2 motif is present in 16.31% of the stage 13 
peaks and 19.05% of the stage18 peaks. There are two Xenopus homologs, sox2 
and sox3. The expression of the sox2.S form is moderate-high across all stages 
whereas the L form has not been annotated yet if shown to be present. sox3 shows 
a similar pattern to sox2, sox3 is expressed also moderate-high across all stages 
and its motif is present in 28.55% and 31.35% of the stage 13 and stage 18 neural 
crest intergenic peaks, respectively. Finally, the nanog motif is significantly present 
in 56.15% of the stage 13 peaks but not at all at stage 18. However, the expression 
of the nanog homolog, ventx1, is low across all the stages. 
To sum up, the pluripotency motifs are present in the specific NC peaks 
across the different stages of this cell type formation and the Xenopus homologs 
are relatively highly expressed also across the different stages. Although they are 
expressed and the motifs are present across the different stages, they seem more 
relevant at stage 13 than at stage 18. 
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Figure 41: Analysis of pluripotency motifs present in NC enhancers. The size of the 
circles represents the significance of motifs found in the intergenic peaks using Homer 
(Heinz et al. 2010). Small circles represent p-value greater then 10-2, mid-size circles 
represent p-value between 10-2 and 10-10 and big circles represent p-values small than 10-10. 
Next to the circle the percentage of the motif in the peaks is shown. The level of expression 
of each gene is shown by the color of the circle: yellow marks no expression, less than 1 
transcript per million (tpm) and log10tpm<0, orange marks low expression, between 1 and 
10 tpm and log10tpm between 0 and 1, dark orange marks moderate expression, between 
10 and 100 tpm and log10 between 1-2 and brown marks high expression, more than 100 
tpm and log10tpm grater than 2. The left half of the circle represents the S homologue of the 
genes and the right half of the circle the L homologue of the gene. 
 
3.4.10. Analysis of the cmyc as a key neural crest transcription factor in cis-
regulatory elements  
Recent work in the lab (see Appendix 2) suggested that the neural crest 
specifier cmyc is poised at early stages of NC formation (Figure 42). The RNA 
polymerase II is recruited in the promoter region of cmyc, upstream of the TSS, 
where it is bound by the pause factors, DRB-sensitivity inducing factor (DSIF), 
negative elongation factor (NELF) and Gdown1. In order to start cmyc transcription, 
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the transcription elongator factor (P-TEFb), mainly composed of cyclin dependent 
kinase 9 (CDK9) and CYCLINT1, needs to be recruited. The P-TEFb complex then 
phosphorylates the pause factors and the RNA polymerase II thus releasing the 
pause stage and allowing transcriptional elongation. This work showed that the loss 
of the P-TEFb components, CDK9 and CYCLINT1, leads to the loss of cmyc and 
therefore to the expression of the NC specifiers such as sox10 (Hatch et al. 2016).  
                
Figure 42: Model displaying the mechanism by which cmyc is paused in neural crest 
cells. On the left cmyc is shown in a paused state with Pol ll bound to NELF, DSIF and 
Gdown1. We have shown that a knockdown of the P-TEFb components cdk9 and cyclinT1 
leads to a loss of cmyc expression and a subsequent loss of sox10 expression and incorrect 
development of neural crest derivatives (bottom scenario). This suggests that in a wild type 
neural crest cell, P-TEFb is promoting transcriptional elongation of cmyc. P-TEFb in its 
active form bounds to the SEC will phosphorylate DSIF, NELF, Gdown1 and serine2 of the 
C terminal of RNAP ll. This promotes pause release on the cmyc gene and allows the 
subsequent expression of sox10 leading to correct synchronous development of neural crest 
derivatives (top scenario). S2=Serine2, S5=Serine5, P=phosphorylation mark, 
NELF=Negative elongation factor, DSIF=DRB sensitivity inducing factor, Pol ll=RNA 
polymerase II, CDK9=Cyclin dependent kinase 9, SEC=Super elongation complex. Figure 
extracted from Hatch et al. (2016). 
In order to confirm that cmyc is a paused gene and that after the lost of 
function of the PTEF-b components, the pausing stage is not released; ChIP-
sequencing of RNA polymerase II on control and CDK9 morpholino (MO) injected 
embryos was performed. X. tropicalis embryos were injected at 2-cell stage with 
100ng of CDK9 morpholino or control morpholino and fixed for ChIP-sequencing. 
This experiment was carried out at Radboud University under the supervision of Dr. 
Saartje Hontelez and the experiments were analysed with help from Dr. Saartje 
Hontelez, Dr. Simon van Heeringen and Prof. Gert Jan C. Veenstra. This work was 
published in Hatch et al. (2016), see Appendix 2. 
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The results of the RNA polymerase II ChiP-qPCR showed that after the cdk9 
inhibition, there is an increase in the amount of reads in both the cmyc promoter 
and the gene body compared with the control (Figure 43A). In the control situation, 
almost all the regions are below 10 fold change occupancy compared with a gene 
desert region whereas in the CDK9 morpholino, all the regions are above 10 fold 
change occupancy compared with the input sample even some promoter regions 
are enriched over 20 times. This is also confirmed by the visualization of the ChIP 
data on the genome browser (Figure 43B). The overall effect of cdk9 inhibition was 
also analysed by plotting the rpkm (reads per kilobase of transcript per million of 
mapped reads) on the gene body vs the promoter region, defined as TSS +/- 150bp. 
When comparing control and cdk9 MO plots, there is a shift in the y-axis indicating 
that there is an accumulation of reads in the promoter region. The cmyc gene is one 
of the genes more sensitive to the transcription pausing release, while the rpkm on 
its gene body is increased from 5 to 10, the rpkm on its TSS goes from 11 to 50 
(Figure 43C). The pausing index values for all annotated genes were determined by 
calculating rpkm TSS +/-150bp divided by the rpkm on the gene body. The 
histogram shows that there is an overall increase in the pausing index mainly due to 
the increase in promoter occupancy (Figure 43D). 
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Figure 43: cmyc is a paused gene and Cdk9 morpholino causes cmyc to become 
more paused during development. (A) RNAPII ChIP-qPCR results showing fold change of 
accupancy compared with a negative primer design in a gene desert in the input sample. 
Solid blue bars show enrichment in promoter region and stripped blue bars show enrichment 
in the gene body. (B) RNAPII profile of the cmyc gene at stage 16 from embryos injected 
with control or Cdk9s morpholino visualized in the UCSC genome browser. C) ChIP-
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sequencing scatter plots of rpkm on the gene body versus the transcriptional start site (TSS) 
in Control (left panel) and Cdk9 morpholino-injected embryos (right panel). The cmyc gene 
is shown by the blue spot. (D) Histogram plots showing the distribution of the Pausing Index 
values (rpkm TSS +/-150 bp divided by the rpkm on the gene body) in log2 for control (grey) 
and Cdk9 morpholino-injected embryos (orange). 
 
Although the previous results indicate that cmyc is a poised gene in 
Xenopus, the experiments were performed in whole embryo due to the starting 
material limitation. The ATAC-sequencing data combined with the RNA-sequencing 
data on animal caps allow the visualization of the poised stage (Figure 44A). Initially 
there is a high accessibility in the promoter region, reflected by ATAC-sequencing 
peak at the promoter. Active promoters and are characterized by being accessible 
and occupied by RNAPII. Although the promoter is active, the transcription is not 
effective, as reflect the RNA-sequencing data. After releasing the pausing stage, 
there is an increase in the transcript production coupled with a decrease in the 
promoter accessibility, as the transcription machinery is being processive and not 
recruited in the promoter. The analysis of cmyc.S shows that there is an increase in 
the transcription level at stage 18 compared with stage 13, there are 20 tpm at 
stage 13 but 74 tpm at stage 18. Conversely, there is a decrease in the promoter 
accessibility; the number of reads decreases from 11 to 6 rpkm. However, the L 
homologue does not show similar results suggesting different functionalization of 
the L and S homologue. This confirms that the poised stage observed in whole 
embryo in part occurs in NC-induced animal cap cells (Figure 44A).  
The presence of cmyc-binding sites in intergenic enhancers was also 
evaluated (Figure 44B). cmyc binding-sites are significantly present in 7.32% of the 
NC enhancers at stage 13 but not in neuroectoderm and ectoderm enhancers. 
However, at stage 18 cmyc-binding sites are not present at neural crest enhancers 
but they are in neuroectoderm and ectoderm enhancers. This serves as a 
mechanism by which cmyc activates NC specifiers such as sox10. cmyc-binding 
sites are not present in stage 13 or stage 18 promoters. As demonstrated in Hatch 
et al. (2016) the loss of cmyc, through inhibiting cdk9, leads to defects in NC 
specifiers expression such as sox10 and foxd3. Moreover, a potencial enhancer of 
sox10 contains cmyc-binding sites (Figure 44C). This provides a link between 
transcriptional elongation of cmyc and expression of NC derivatives to allow correct 
formation of NC structures. 
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Figure 44: ATAC-sequencing data provides a link between transcriptional elongation 
of cmyc and expression of NC derivatives. (A) Transcription expression on cmyc.S and L 
and accessibility in cmyc.S and L promoter at stage 9, 13 and 18. Solid line indicate L form 
dashed line indicate S form. Tpm= transcripts per million, rpkm=reads per kilobase transcript 
per million of mapped reads. (B) Table comparing cmyc-binding sites across different stages 
and samples. The p-value and percentage of sequences with cmyc motif is reported. (C) 
Visualization of ATAC-sequencing data at stage 13 and 18 in the UCSC genome browser at 
sox10 location. The orange rectangle shows a potential active enhancer in which cmyc 
binding motif is present. 
 
3.4.11. Selection of neural crest enhancers  
A detailed analysis of five enhancers was carried out because of their 
potential role in activating expression of crucial NC genes i.e. cmyc, snai2, foxd3, 
id3 and sox10. This selection was done taking into account that those enhancers 
were NC exclusive, close to a neural crest related gene and that the motifs present 
on those peaks were other NC genes whose interaction has been previously 
described.  
A potential cmyc cis-regulatory element (Figure 45) is found 1880bp 
downstream the cmyc.L gene transcription terminal site. It is 2Kb long containing 
two potential enhancers. It contains motifs for cmyc, zic, ets1, tfap2a, nmyc, tcf and 
smad. The relationship of some of these transcription factors with cmyc has been 
reported. As a NC specifier, it is downstream of the Wnt and BMP signaling 
pathways, this could be through the Wnt effector Tcf and the BMP effector Smad 
motifs, both present in this enhancer (Simões-Costa & Bronner 2015). zic1, together 
with pax3, are involved in activating NC specifiers such as snail2, foxd3, twist1. 
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Although the direct regulation of cmyc via zic1 has not been established yet, this 
would not be surprising. ets1 and nmyc have also been related to NC formation. 
However, their regulation of cmyc has not been demonstrated (Wang et al. 2015; 
Wakamatsu et al. 1997). The appearance of a cmyc-binding motif suggests that 
cmyc could autoregulate itself. Finally, tfap2a has been suggested as a key element 
for NC enhancer activation (Rada-Iglesias et al. 2012). Moreover, in the motif 
analysis performed on human NC enhancers, motifs such as Ets, Zic, Tcf3, Smad4, 
Ebox (cMyc) appeared significantly upregulated (Rada-Iglesias et al. 2012). There 
is not much known about the genes upstream of cmyc. However, all this evidences 
suggest that this cmyc enhancer located 1880bp downstream of the cmyc.L 
transcription terminal site could be involved in regulating cmyc expression in neural 
crest cells. A potential enhancer is found intronically. However, it does not contain 
any NC-transcription factor motif, suggesting it is not involved in the NC expression 
of cmyc. 
 
Figure 45: Potential cmyc enhancer. Genomic location and motifs present in the cmyc.L 
enhancer are shown. A second potential enhancer is framed in orange. 
The second enhancer is the snai2.L enhancer located 7kb downstream of 
the TSS and 900bp long. It contains tfap2a, sox10, foxd3, cmyb and smad4 binding 
motifs and this region is mainly open in NC cell type at both stages and ectoderm 
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stage 18 (Figure 46). The transcription factors, whose motifs are found in the 
enhancers, have been previously related with snai2. The presence of tfap2a in this 
potential CRE reinforces the potentially important role of this enhancer in NC cells 
(Rada-Iglesias et al. 2012). The expression of snai2 is regulated by sox10 (Honoré 
et al. 2003). foxd3 and snai2 have largely overlapping expression pattern. However 
overexpression of foxd3 induces ectopic expression of snai2 indicating that foxd3 
regulates snai2 expression (Sasai et al. 2001). In neuroblastoma cells, a tumor 
derived from neural crest cells, cmyb activates snai2 expression (Tanno et al. 
2010). Finally, snai2 is induced by BMP stimulation (Larman et al. 2012). This all 
supports the potential role of this enhancer in snai2.L expression therefore allowing 
correct formation of NC derivatives.  
 
Figure 46: Potential snai2 enhancer. Genomic location and motifs present in the snai2.L 
enhancer are shown. 
A potential foxd3 enhancer is located 1kb upstream of foxd3.S and it is 
960bp long. This enhancer contains sox5, foxd3, pax7, six1, smad4 and meis 
binding sites, which have all been reported as foxd3 regulators (Figure 47). Both 
six1 and sox5 genes inhibit foxd3 expression; the inhibition of sox5 and six1 expand 
the expression domain of foxd3 (Perez-Alcala et al. 2004; Brugmann et al. 2004). 
Contrary, this expression of foxd3 is highly reduced when meis3 is inhibited 
(Gutkovich et al. 2010). pax3/7 directly regulates foxd3 expression through binding 
to two regulatory regions that drive expression in chick cranial and trunk NC cells 
(Simões-Costa et al. 2012). Finally, it has been suggested that foxd3 negatively 
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auto-regulates itself as its expression is reduced after exogenous protein injection in 
Xenopus embryos. Also, the early expression of foxd3 is activated by BMP signaling 
pathway (Pohl & Knöchel 2001). The appearance of these motif binding sites 
support the hypothesis that this potential foxd3.S enhancer could be involved in NC 
formation. Upstream of the TSS there is another potential enhancer only present at 
stage 13 (Figure 47). However, the motif analysis does not reveal any NC-
transcription factor binding sites. 
 
Figure 47: Potential foxd3 enhancer. Genomic location and motifs present in the foxd3.S 
enhancer are shown. A second potential enhancer is framed in orange. 
The potential id3 enhancer is found in chromosome 2S, 1.9kb upstream the 
id3 TSS (Figure 48). This CRE is 980bp and contains binding sites for the two major 
id3 regulator, cmyc and BMP signaling. BMPs induce Id proteins thus inhibiting 
neural differentiation (Ying et al. 2003). Also, id3 is a cmyc effector and its inhibition 
affects the formation of NC cells (Light et al. 2005). The appearance of these two 
motifs supports the potential involvement of this enhancer in id3 expression. 
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Figure 48: Potential id3 enhancer. Genomic location and motifs present in the id3.S 
enhancer are shown. 
Finally, a potential sox10 CRE is located 9.6kb upstream the sox10.L TSS 
(Figure 49). It is 5,176bp long and it contains three potential enhancers. This 
regulatory region contains, among others transcription factors-binding sites, pax7, 
sox5, sox10, tfap2a, smad, tcf and sox9, all of them previously described as sox10 
regulators. During mouse embryogenesis, a sox10 enhancer contains transcription 
factor binding sites for sox, tcf, pax and tfap2a (Werner et al. 2007). Also, tfap2a is 
found in human NC enhancers as a key factor for NC enhancer activation (Rada-
Iglesias et al. 2012). sox9 activates sox10 expression through a cranial enhancer 
Sox10E2 in chick embryos (Betancur et al. 2010b). BMP and Wnt maintain sox10 
expression in cells, in the absence of both, these cells die or dedifferentiate (Kléber 
et al. 2005). The appearance of these motifs that relates NC genes with the 
potential enhancer reinforces the potential role of this CRE in sox10 regulation. The 
epigenetic profile upstream the sox10 TSS suggest that there might be a super-
enhancer. There are several enhancers concatenated within 12.5Kb and there are 
transcription factor-binding sites for Oct4, Sox2 and Nanog, both characteristics of 
super-enhancers (Pott & Lieb 2014). The presence of mediator, Med1, cannot be 
detected through Homer motif analysis. It would be required to perform ChIP-qPCR 
to detect if this potential super-enhancer contains mediator-binding sites. 
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Figure 49: Potential sox10 enhancer. Genomic location and motifs present in the sox10.L 
enhancer are shown. 
3.4.12. Discussion 
The aim of the study was to characterize the epigenome during the NC 
formation, comparing stage 13, where this cell type is specified, and stage 18, 
where the differentiation of NC cells occurs. For that, NC-specific enhancers at both 
stages and the potential transcription factors involved in NC enhancer activation 
have been identified. Also enhancers, which could drive expression of key NC 
genes, have been described.  
The main problems encountered were related with the protocol and its 
analysis. The most important point to take into account when performing ATAC-
sequencing is the number of cells used in the reaction, a large number of cells can 
inhibit the enzyme, the optimum being between 10-50,000 cells. Because ATAC-
sequencing is a quite recent technique there is no clear protocol and consensus 
about the data analysis. However, Encode constantly updates the recommended 
pipeline to follow (Encode 2017).  
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Looking at the results, the ATAC-sequencing samples are quite variable; an 
average of 20% of the peaks of a sample (minimum of 7% and maximum of 32%) 
are common between the three replicates and taken into account for the analysis. 
This is due to the technique per se and the analysis. Because Tn5 is an enzyme 
that cuts unprotected regions of the genome and this is quite dynamic, the peaks 
are not in a fixed position and when adopting the premise that 50% of the peak 
should overlap, a lot of them are discarded. Actually, the neuroectoderm stage 18 
sample, which consist of 2 replicates, contains twice more peaks than the rest of the 
samples, which consist of three replicates. This suggests that the increase of 
replicates reduces dramatically the number of common peaks and therefore it is 
necessary to analyse several replicates to draw conclusions about the ATAC-
sequencing data. The distribution of peaks at stage 18 will likely vary if another 
replicate is incorporated at the neuroectoderm sample. 
At stage 13, about 30% of the open regions are common between the three 
cell types (NC, neuroectoderm and ectoderm) and could be regulating 
housekeeping genes whereas 30% are cell type-specific (Figure 35). Not 
surprisingly, neural crest and neuroectoderm share more than 50% of the regulatory 
elements in both stages revealing the great similarities between these two cell types 
or a mixed population inside the animal cap. This could be due to the fact that both 
cell types are induced with the same amount of noggin and the neural crest cap 
could contain some neuroectodermal cells or that, being generated in the same 
environment, the transcriptome and epigenome at early stages are similar. It would 
be necessary then to perform single cell analysis to analyse the NC-induced animal 
cap. Contrary to this, the ectoderm sample does not share as many regulatory 
elements with the NC or neuroectoderm samples.  
The analysis of the neuroectoderm and ectoderm peaks confirms that the 
experiment was well performed and gives more confidence when drawing 
conclusions about the NC data. The neuroectoderm peaks contain motifs for 
transcription factors such as nkx6.1, otx2 and sox3, all involved in anterior nervous 
system formation (Ma et al. 2013; Gammill & Sive 2001; Penzel et al. 1997). The 
ectodermal peaks, in contrast, contain gata2/3, six1 binding sites all involved in the 
formation of ectodermal derivatives (Read et al. 1998; Riddiford & Schlosser 2016). 
It was noticed that at stage 18, there are not many NC specific open regions 
when compared with stage 13 (i.e.1,212 vs 6,025). Also the comparison of NC open 
regions between the two stages reveals that there are only 85 common regions. 
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Looking at the distribution of peaks in the stage 18 sample, there is a small 
percentage that relates with open or active promoters. All this suggests that the 
chromatin becomes progressively more closed as differentiation proceeds. This is 
also reflected by the great proportion of pluripotency transcription factors motifs 
found at stage 13 but not as present at stage 18. 
When analysing the enhancer dynamics of the NC enhancers, most of them 
are present in either one stage or in both stages. Not many enhancers being 
activated or closed are observed. As mentioned before, these two stages, 
specification and differentiation are quite different at epigenetic level, as shown by 
ATAC-sequencing. However, specification and differentiation are not similar at 
transcription level, as revealed by the RNA-sequencing. In order to distinguish the 
transition between the two stages, ATAC-sequencing at intermediate stages should 
be performed.  
The open regions in the different samples were distributed according to their 
genomic location in a gene, including exons and introns; a promoter, defined as 
TSS +/- 200bp; a proximal enhancer, arbitrarily defined as peaks located 2kb 
upstream; and distal enhancers located farther than 2kb from the TSS and not 
inside the gene coordinates. About 25% of the open regions are located inside the 
genes. The X. laevis genome annotation does not allow the distinction between 
exons and introns, therefore potential enhancers located in the first intron are not 
considered, thus underestimating the number of enhancers. Also, reads across the 
gene body are observed which could be related to active transcription taking place 
in the gene. Although the distinction of proximal and distal enhancer is made, both 
of them are taken into account for the motif analysis. However, whereas the target 
of the distal enhancers is not easy to predict, proximal enhancers are quite likely to 
interact with the closest promoter. On average, 50% of the specific peaks are 
potential enhancers. However, not all open regions are enhancers, they can also be 
insulators or silencers (Kolovos et al. 2012). It is then advisable to complement 
ATAC-sequencing data with other epigenetic marks such as p300 or H3K27ac, to 
confirm which peaks are truly active enhancers.  
To determine which genes are involved in activating those enhancers and 
therefore add information to the gene regulatory network established for the 
Xenopus neural crest, it is required to analyse the motifs overrepresented in the 
active enhancers. The motifs present at stage 13 and stage 18 are mainly NC 
related genes. At stage 13, the most relevant transcription factors according to the 
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expression level, the abundance of motifs and the p-value are Meis (p-value=10-16) 
and Zic (p-value=10-29); at stage 18 Zic (p-value=10-13), Meis (p-value=10-7) and 
Sox10 (p-value=10-13). Zic and Meis proteins therefore seem important for activating 
NC enhancers during the different stages of NC formation whereas Sox10 is more 
relevant for activating late stages of NC formation. Although it is not possible to 
determine which Zic and Meis proteins are involved in NC formation, based on the 
literature zic1 and meis3 are the more plausible option (Plouhinec et al. 2014; 
Gutkovich et al. 2010). It would be of interest to perform ChIP-sequencing for these 
transcription factors to determine which enhancers those genes are activating and if 
there is a core of transcription factors involved in activating NC enhancers. 
A similar study performed in human derived NC cells suggested Tfap2a and 
Nr2f1/2 as the key elements in the NC enhancer activation (Rada-Iglesias et al. 
2012). Moreover, it was found that the inhibition of nr2f1 in Xenopus triggers 
craniofacial defects. Surprisingly, the Nrf2/1 motif is not found on the NC enhancers 
that have been identified and moreover, nr2f1 expression is very low in the NC-
induced animal caps according the RNA-sequencing data generated. On the other 
hand, in that study 10% of the active enhancers contain Tfap2a motifs; this 
percentage being similar to the 8.6% that found in our data at stage 18. However, it 
was surprising not to find the tfap2a motif present at stage 13. Perhaps, tfap2a is 
more relevant for late stages of NC cells formation and/or cranial NC cells. For that 
it would be required to perform a similar study but at later stages on NC 
development. 
Our results support the hypothesis that multipotent cells at the blastula stage 
remain multipotent to become NC cells (Buitrago-Delgado et al. 2015). The 
presence of motifs for pluripotency factors such as Oct4, Sox2 and Nanog 
homologs in NC enhancers, both at transcript and motif level, is quite significant at 
stage 13. Oct4 and Nanog homologs do not seem as relevant during the 
differentiation of NC cells indicating that there is a decrease on the multipotency 
abilities as differentiation occurs. Sox2 homologs, however, are maintained at stage 
18 potentially because the function of this gene is required later on during brain 
formation (Zhang & Cui 2014).  
The combination of ChIP-sequencing and ATAC-sequencing revealed that 
the poised stage release of cmyc allows the processive transcription of this gene, 
which in turn can activate downstream genes through binding to their enhancers. 
However, cmyc is not the pioneer factor for NC genes as it can only bind to open 
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chromatin that contains active histone modifications (Iwafuchi-Doi & Zaret 2014). 
cMyc cannot bind to the NC promoters, as they do not contain cmyc binding sites. 
In order to confirm this hypothesis and identify the cmyc downstream targets, it will 
be necessary to carry out ChIP-sequencing using a cmyc antibody. cmyc motif 
analysis indicates that it is required during NC specification but it is not necessary 
later during differentiation. However, at stage 18, cmyc is present in neuroectoderm 
enhancers as it is necessary for proliferation and self-renewal of neural stem cells 
(Kerosuo et al. 2008).   
Another objective of the project was to identify enhancers that drive the 
expression of key NC genes, conferring tissue specificity to the linked genes. For 
this purpose enhancers close to NC genes, i.e cmyc, foxd3, snai2, id3 and sox10, 
which are mainly open in NC samples and containing NC related motifs, were 
selected. Most regulatory regions are not evolutionarily constrained (Bulger & 
Groudine 2010). The conservation in the Tibetean frog, zebrafish, chick and mice of 
the candidate enhancers has been analysed using UCSC liftOver. The selection of 
enhancers is only partially conserved in frogs, both X. tropicalis and the Tibetean 
frog Nanorana parkeri, suggesting they are conserved only on the Anura order. 
Among the genes selected, only a chick sox10 and foxD3 enhancers have been 
previously described (Simões-Costa et al. 2012; Betancur et al. 2010b). The sox10 
and foxd3 characterized enhancers are not conserved in Xenopus although they 
contain respectively sox9 and pax7 binding sites. The fact that the binding sites are 
conserved but it is not the broader DNA sequencing that contains them, is a known 
fact in evolutionary studies (Heintzman et al. 2007; Bogdanović et al. 2012; Neph et 
al. 2012). It would then be interesting to check if those enhancers can drive not only 
expression in Xenopus embryos but in distally related organisms such as zebrafish 
and chick.  
The validation of the enhancer activity needs to be tested, for that I-SceI 
meganuclease method is going to be carried out in X. laevis (Ogino et al. 2006). 
Briefly, a construct with the enhancer to test, a minimal promoter and a reporter 
gene such as gfp flanked by I-SceI sites needs to be generated. The construct is 
digested and injected at 1-cell stage X. laevis embryo. The embryo is grown until 
the appropriate stage and the fluorescence is checked under the microscope. The 
method has been optimized using a gata2 enhancer and a pax3 promoter provided 
by the Grainger lab. An efficiency of 10% of full transgenic embryos is obtained, 
similar to the reported by Ogino et al. (2006). 
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Also, the contribution of the transcription factors whose motifs are found in 
the enhancers should be validated. To answer that, first, the different transcription 
factors should be inhibited, by morpholino injection, and the level of transcription of 
the target gene should be analysed. Second, a construct with the enhancer 
containing a mutation in a specific binding site should be injected and tested for the 
ability to drive gfp expression.  
To sum up, this study has allowed the characterization of Xenopus NC 
enhancers and the identification of enhancers that could drive expression of snai2, 
foxD3, id3, sox10 and cmyc.  
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CHAPTER IV: 
EPIGENOMIC REGULATION OF THE ANTEROPOSTERIOR 
REGENERATION IN PLANARIANS 
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4.1. Rationale 
Regeneration and tissue renewal are essential processes of adult animals 
that must be tightly controlled, since its dysfunction leads to common illnesses as 
cancer. The study of regeneration is also important to understand and deliver 
treatments to regenerate organs injured or damaged due to heart attacks, liver 
damage or nerve injury. During regeneration the proper amount of new cells must 
be produced and their fate is to be properly re-specified and they are to be 
integrated into an already developed body plan. The aim of this chapter was to 
study the genomic regulation of the regeneration of anterior and posterior poles of 
planarians, which define head vs tail identity. For this, data obtained from high 
throughput genomic technologies such as ATAC and ChIP-sequencing have been 
performed. This project has been carried out in collaboration with Emili Saló’s lab in 
the UB (Spain) and José Luis Gómez-Skarmeta’s lab in the CABD (Spain). 
The first objective was to set up the ATAC-sequencing technique in 
planarians, as the identification of CRE in S. mediterranea is a new field. For that, 
ATAC-sequencing in 0h and 48h regenerating (0hR and 48hR) blastemas was 
carried out to check the feasibility of the project, through the identification of specific 
transcription factors motifs in open regions known to be required for anterior or 
posterior specification. The current planarian genome contains 15,046 scaffolds and 
an average scaffold length of 77,506bp and thus the mappability of the reads could 
have been difficult. Also, as a distantly related organism, how successful the 
prediction of motifs present in the enhancers would be unclear.  
The second objective, once the technique was validated, was to identify 
anterior and posterior specific active enhancers at 12 hours of regeneration (12hR) 
and analyse the motifs present in those. For this aim, ATAC-sequencing of anterior 
and posterior 12hR blastemas has been carried out. To select only open regions 
related with polarity ATAC-sequencing on 12hR anterior blastemas of notum RNAi 
organism, which forms a tail instead of a head, and 12hR posterior blastema of 
wnt1 RNAi organism, which forms a head instead of a tail, has been carried out. To 
narrow the relevant active regulatory elements in such regions, H3K27ac ChIP-
sequencing on 12hR blastemas has also been performed. Potential transcription 
factors that bind to the active enhancers will be identified as well as preliminary 
attempts to link them with their target genes. With this approach, we aim to bring to 
light more elements to reconstruct the GRN underlying the anterior and posterior 
regeneration. 
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4.2. Analysis of the cis-regulatory elements at 0hR and 48hR 
As the ATAC-sequencing protocol was previously optimised (see section 
3.4.1), the same protocol was followed but changing the initial cell dissociation 
procedure, according to a specific protocol for planarians. For that, organisms were 
first cut in the postpharyngeal region. For the 0 hour regeneration (0hR) sample, 20 
anterior and posterior regions were pooled. For the 48 hours regeneration (48hR) 
samples, organisms were left for 48h and then 20 anterior and 20 posterior 
blastemas were dissected. Figure 50 illustrates the dissections carried out. The 
bioanalyser profiles of the three samples showed a peak around 300bp confirming 
the samples were good for sequencing (Figure 50B). 
 
Figure 50: ATAC-sequencing samples at 0hR and 48hR. (A) Schematic representation of 
the samples. Ph=pharynx. (B) Bioanalyser profile of the samples. The peak at approximately 
300bp is indicated by an arrow. 
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The samples were analysed in a similar way to the Xenopus samples, but in 
this case there was just one replicate per sample, as it was just a first attempt to 
check if the bioinformatics analysis afterwards gave relevant results. Despite the 
planarian genome not being well-assembled -containing 15,046 scaffolds and an 
average scaffold length of 77,506bp- the reads aligned properly. Between 59% and 
67% of the reads aligned to the genome. This is low compared to the 80% 
threshold, which is the percentage of mapped reads advised by Encode. However, 
this threshold has been established taking into account well annotated genomes 
such as human or Drosophila. Although the reads reached only 67%, and because 
of the specificities of the planarian genome, it was decided to continue with the 
analysis. 
The comparison between samples reveals that 20% of 0hR peaks, 15% of 
the anterior 48hR and 5% of the posterior 48hR are specific for each sample (Figure 
51A). Most of the peaks are common between the three samples. The anterior and 
posterior 48hR share just a few open regions, indicating that the change of fate has 
already occurred. When analysing the location of the open regions, more than 70% 
are potential proximal or distal enhancers (Figure 51B). However, because the 
genome is not completely assembled, these values might be overrepresented.  
Because in planarians there is currently no possibility to generate transgenic 
organisms to test enhancers, the most interesting thing to look at is the transcription 
factors that activate those enhancers. For that, motif analysis on the different 
intergenic regions was carried out (Figure 51C-E). The complete list of top motifs, 
ranked according to the p-value and percentage of open regions with each motifs 
are displayed in Appendix 1 Tables v-vii. At 0hR the intergenic open regions are 
enriched in gata4, hnf4 and foxA, all transcription factors associated with the 
digestive system of the planarians (Figure 51C). Considering the location of the 
cuts, these all make sense. gata4 is expressed in the digestive track of planarians 
and it is required for the homeostasis and differentiation of the intestinal structures 
(Flores et al. 2016). The hepatocyte nuclear factor 4, hnf4, is an intestine 
associated gene and it is required for the gut differentiation (Scimone et al. 2014). 
Finally, foxA is expressed in the pharynx and surrounding tissue and it is necessary 
for the pharynx regrowth (Adler et al. 2014). The motifs present at anterior 48hR 
intergenic regions are involved in nervous system regeneration, i.e. prep, neuroD-1 
and lhx2 (Figure 51D). Moreover, these transcription factors are upregulated at 
48hR after anterior amputation (Scimone et al. 2014). prep is required to 
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differentiate and pattern anterior structures as its inhibition produces defects in the 
regeneration of brain and eyes (Felix & Aboobaker 2010). neuroD-1 and lhx2 are 
nervous system genes involved in neural specification (Cowles et al. 2013; Scimone 
et al. 2014). The posterior 48hR intergenic regions are enriched in islet, hoxD and 
egr-1 motifs (Figure 51E). islet is one of the key genes that determines posterior 
identity as its inhibition causes a ‘tail-less’ phenotype. In the posterior blastema islet 
maintains wnt1 expression (Hayashi et al. 2011). hoxD is the only posterior hox 
gene found in planarians and it is expressed in the posterior blastema of 
regenerating planarians (Iglesias et al. 2008). Finally, egr-1 is a marker of zeta-
neoblasta which gives rise to the epidermal derivatives (Van Wolfswinkel et al. 
2014).  
The results demonstrate that despite the incompleteness of the genome, it is 
possible to obtain relevant information performing ATAC-sequencing in planarians 
and analysing the motifs present in the potential enhancers. However, these motifs 
are involved with late stages of regeneration, once the polarity is established. In 
order to analyse how the polarity is determined, it is required to perform a similar 
study but at earlier stages of the planarian regeneration, at 12hR, the time point 
previous to the establishment of the anterior and posterior poles.  
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Figure 51: Analysis of the 0hR and 48hR ATAC-sequencing samples. (A) Venn diagram 
showing the distribution of peaks in the three samples. (B) Bar plot showing the location of 
the exclusive peaks. The categories are genes, promoters defined as TSS+/- 200bp, 
proximal enhancer located 2Kb upstream the promoter and distal enhancers. (C) Motifs 
overrepresented in the 0hR exclusive intergenic peaks. (D) Motifs overrepresented in the 
anterior 48hR exclusive intergenic peaks. (E) Motifs overrepresented in the anterior 48hR 
exclusive intergenic peaks. The motifs, transcription factor associated, p-value, %of peaks 
with the motifs, and a bibliographic reference for the transcription factors are shown. 
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4.3. Preliminary analysis of the cis-regulatory elements at 12hR 
To identify the enhancers and transcription factors involved in the formation 
of the anterior and posterior poles, ATAC-sequencing at 12hR has been performed 
(Figure 52). Posterior and anterior blastemas at 12hR were collected for ATAC-
sequencing. To select only regulatory elements involved in the polarity, anterior 
blastemas of notum RNAi animals (which regenerate a tail instead of a head) and 
posterior blastemas of wnt1 RNAi planarians (which regenerate a head instead of a 
tail) were also collected for ATAC-sequencing. Three replicates per sample were 
done. All the samples showed a peak around 300bp when analysing the fragment 
length profile using a bioanalyser (Figure 53). 
The comparison between anterior and posterior blastemas, as well as with 
the corresponding RNAi sample, will allow the identification of cis-regulatory 
elements specifically involved in posterior and anterior regeneration. In order to 
obtain RNAi organisms, planarians are injected for three days with double stranded 
RNA specific for the gene, then cut pre and postpharyngeal, and after three days 
the injection procedure is repeated. The synthesis of the double stranded RNA and 
injections were carried out by Eudald Carreras at the University of Barcelona.  
In order to identify, out of the open regions, the active enhancers, ChIP-
sequencing with H3K27ac of wild-type blastemas at 12hR has been carried out. 
This technique requires around 2,000 blastemas at 12hR, those were collected by 
Eudald Carreras and the experiment has been performed at the Centro Andaluz de 
Biologia del Desarollo, Spain. Two replicates of anterior and posterior 12hR 
blastemas were obtained. The ChIP-qPCR validation carried out is not conclusive 
enough (Figure 54). The anterior samples show enrichment in the notum promoter 
compared with a gene dessert (Figure 54A). However, the posterior samples did not 
show enrichment for any wnt1, follistatin and notum promoter. It was expected to 
obtain wnt1 or follistatin enrichment in the posterior samples (Figure 54B). This 
could be because the follistatin and wnt1 primers have been designed upstream the 
TSS and might not be in the promoter regions, as they are not clearly defined. Also, 
the negative primer could be an open region specific for the posterior sample. It 
might have been useful to design two or three more negative primers. Despite this, 
because the anterior samples look good and there is no prior information about the 
enhancers and promoters activated during regeneration, it was decided to 
sequence the four samples.  
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All the ATAC-sequencing samples and ChIP-sequencing samples are 
currently being sequenced in the BGI Hong Kong.  
!
Figure 52: Schematic representation of the ATAC-sequencing samples at 12h 
regeneration. Posterior 12hR, anterior 12hR, notum 12hR and wnt1 12hR. !!!!!!!
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Figure 53: Bioanalyser profile of the ATAC-sequencing 12hR samples. 
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Figure 54: ChIP-qPCR validation. Enrichment of H3K27ac in wnt1, follistatin and notum 
promoter compared with a gene dessert location. (A) Anterior samples. (B) Posterior 
samples. 
 
4.4. Discussion 
The aim of this study was firstly to determine the potential of the ATAC-
sequencing technique in planarians and secondly to study the genomic regulation of 
the anterior and posterior poles, since they define head vs tail identity, through 
integrating ATAC-sequencing and ChIP-sequencing methodology. 
The ATAC-sequencing study carried out at 0hR revealed transcription factor 
binding sites for genes related with digestive system. This is consistent with the 
dissected area in which ATAC-sequencing was performed. On the other side, 
ATAC-sequencing carried out on anterior and posterior blastemas at 48hR revealed 
motifs for nervous system and posterior regeneration, respectively. This confirms 
that despite the not well-assembled genome and the motif data being from distantly 
related organisms, it is possible to identify enhancers and potential transcription 
factors that can bind to them. This opens a window of high-throughput 
methodologies to answer relevant questions in the regenerative field in planarians. 
Knowing the potential of this technique, it was decided to study the genomic 
regulation of the anterior and posterior poles. The study at 48hR revealed late 
effectors of the anterior and posterior regeneration. To discover the regulatory 
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elements involved in the specification of the poles, it was required to perform a 
similar study at an early time point, i.e. 12hR. The anterior pole is currently defined 
by the expression of notum (a Wnt inhibitor), and the posterior pole is defined by the 
expression of wnt1. To narrow the number of potential enhancers to those 
exclusively related with pole identity, ATAC-sequencing on notum and wnt1 RNAi 
organisms was also performed. Furthermore, as the functional validation of the 
enhancers in the planarian animal model is not possible, ChIP-sequencing with 
H3K27ac, which reveals active enhancers, has also been performed. The 
integration of both data will provide a list of cis-regulatory elements (promoters and 
enhancers), and potential transcription factors bound to those elements, specifically 
involved in the anterior and posterior specification. The full list of candidate 
elements will be categorized according to genomic position, signalling pathway and 
biological process. Special attention will be paid to the elements found to be related 
with the Wnt signalling pathway.  
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CHAPTER V: 
GENERAL DISCUSSION 
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5.1. About ATAC-sequencing 
Cis-regulatory elements in the genome are known to control animal 
development. These elements contain multiple target sites for transcription factors 
and collectively control the expression of developmental gene regulatory networks. 
Therefore, CRE analysis provides a method to study transcription factors 
interactions.  
ATAC-sequencing is a relatively new high throughput technique that thanks 
to the Tn5 transposase reveals open regions in the genome. The advantages of this 
technique are: (1) the low amount of starting material required, (2) the low 
complexity of the protocol, and (3) the no need for any antibody steps, enabling it to 
be performed in any organism. Disadvantages of the method include (1) the high 
variability in the samples, (2) the rudimentary bioinformatics analysis and (3) the 
necessity to test the enhancer functionality to determine if they are active enhancers 
or to combine the ATAC-sequencing data with p300 or H3K27ac ChIP-sequencing 
data, which specifically identify active enhancers. Despite its draw backs, since the 
protocol was published in 2013, the number of papers containing ATAC-
sequencing, according to Pubmed, has been rising dramatically (Figure 55A). The 
method has been used to identify active enhancers in for example, Drosophila 
dorsoventral patterning, mouse rod photoreceptors or human myeloid differentiation 
and many other tissues and cells, examples shown in Figure 5B. 
In this study, ATAC-sequencing has been carried out in order to identify cis-
regulatory elements in the genome to answer two biological questions: (1) how 
neural crest genes are regulated in Xenopus embryos and (2) how the 
anteroposterior polarity of planarians is re-established during regeneration. 
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Figure 55: Impact of ATAC-sequencing in the literature. (A) Pubmed trendline of the 
ATAC-sequencing citation. (B) Main publications that carries out ATAC-sequencing to 
identify enhancers. !
5.2. About Xenopus neural crest formation 
 Chapter III focused on the investigation of the regulatory elements involved 
in NC formation. For this, several approaches were tested. Firstly, a chemical 
screen with specific epigenetic inhibitors was carried out on Xenopus embryos. Out 
of the 66 tested compounds, distinct phenotypes were identified such as 
developmental defects, edema formation or pigment defects. Among these, the 
pigmentation phenotype was of more interest, as the pigment cells derive from the 
neural crest. All the compounds associated with pigment cell phenotypes were 
histone acetyltransferases and histone deacetylases, suggesting that histone 
acetylation plays a role in pigmentation. However, when testing the expression of 
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neural crest markers (i.e. zic1 and foxd3) by WISH no alteration was detected; this 
suggested that the HAT and HDAC compounds rather than affecting NC 
specification affected later stages such as melanocyte formation or melanogenesis. 
Several hypotheses have been given for the fact of not finding compounds affecting 
NC specification, the main one being that the drugs should have been added 
earlier. Thus, in order to test this hypothesis, it would be needed to repeat the 
chemical screen adding the drugs during gastrulation (i.e. between stages 9 and 
13). Also, in order to determine if the reason for the lack of pigmentation was the 
melanocyte formation or the melagonesesis process, it would be required to 
visualise if the melanocytes are properly formed through for example WISH of mitf 
or tyrosinase, markers for melanocyte cells.  
As an alternative approach, it was decided to identify regulatory elements on 
the DNA and transcription factors associated, responsible for activating NC genes. 
To address this, ATAC-sequencing was carried out on NC-induced animal caps. 
Firstly, transcriptome analyses were performed on different stages (i.e. stage 9, 13 
and 18) of organoid-like NC-induced animal caps in order to check that these caps 
resembled NC cells present in the embryo. This transcriptome analysis showed that 
the expression of NC markers followed the expected temporal pattern of expression 
according to the literature (Betancur et al. 2010a). With this study, it could be 
possible to not only look at already described genes but also look for potential new 
NC genes. As the model was proven to work, it was then possible to study another 
level of genomic regulation analysing the cis-regulatory elements of such animal 
caps. However, as it may not be like the in vivo situation, it would be necessary to 
confirm the obtained results at whole embryo level.  
ATAC-sequencing as described by Buenrostro et al. (2013) was first carried 
out on numerous animal caps, but the fragment length profile analysed by 
bioanalyser did not show an enrichment in the regulatory region fraction (i.e. 300 
bp); thus indicating that proper tagmentation was not occurring. A number of 
optimization steps were introduced in the protocol the main ones being: (1) the 
tissue was dissociated with trypsin/collagenase, and (2) cells were counted to not 
exceed a maximum number of 50,000 cells (i.e. to not overload the Tn5 
transposase enzyme).  
In order to make sure that specific NC open regions were identified via 
ATAC-sequencing, neuroectoderm and ectoderm-induced animal caps were also 
used. For each cell type two stages were sampled (i.e. stage 13 and stage 18), 
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which were particularly interesting for the study as this is when NC specification is 
originated and differentiation is starting. Three replicates were obtained for each 
stage and cell type. When doing the bioinformatics analysis three restrictions were 
applied to constrain, as much as possible, the potential NC enhancers. That is: (1) 
due to the genome dynamics and the activity of the transposase generating 
variability among the replicates, for each of the cell type and stage, only those open 
regions which were present in the three replicates were considered for further 
bioinformatics analyses; (2) as the open regions revealed by the transposase may 
relate not only to enhancers but also to promoters and gene locations, only peaks in 
the intergenic regions, which is the main location for enhancers, were taken into 
account and (3) the peaks in the intergenic regions of each of the cell types were 
compared and only those present in NC were considered potential enhancers. 
Thus, the analysis of the samples allowed us to identify 4528 NC potential specific 
enhancers at stage 13 and 852 at stage 18 (Figure 38).  
When comparing the potential enhancers at the two different stages, it was 
noticed: (1) that not many of them were present in both, and (2) that not many 
enhancer transitions, from more to less active or accessible or vice versa, were 
detected. With this in mind, it would seem appropriate to carry out the same ATAC-
sequencing protocol at intermediate stages.  
The transcription factor motifs present in the selected potential enhancers 
were identified using Homer (Heinz et al. 2010). This analysis revealed: (1) most of 
the enhancers contained potential transcription factors binding sites which have 
been shown to be specific for NC genes, supporting that the NC regulatory network 
is complex; (2) Zic and Meis motifs are particularly enriched in both stages and 
Sox10 only at stage 18. Also, at stage 13, motifs for pluripotency factors are found, 
which support the hypothesis by Buitrago-Delgado et al. (2015) that indicates that 
NC cells at stage 13 retain the pluripotency capabilities.  
Finally, by combining Homer observations and visualizing the ATAC-
sequencing tracks in the UCSC genome browser, five candidate enhancers were 
identified, based on (1) their proximity to key NC genes, (2) the enhancer specificity, 
and (3) their NC transcription factors binding sites. These enhancers could 
potentially drive expression of cmyc, snai2, foxd3, id3 and sox10. These enhancers 
are only conserved in X. tropicaIis and Nanorana parkeri indicating that these are 
anura-specific. In order to further confirm the functionality of these enhancers,      I-
SceI meganuclease transgenesis needs to be carried out.  
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Our work suggests that this type of study allows the obtainment of large 
amounts of information about the epigenome of a single cell type and the regulation 
of specific genes in a cell specific context, which is especially interesting in 
organisms such as Xenopus, which do not have a great level of conservation with 
other organisms. 
5.3. About planarian anteroposterior polarity 
Chapter IV focused on the investigation of the regulatory elements involved 
in the formation of the planarian anterior and posterior poles, which define head vs 
tail identity. For this, the ATAC-sequencing approach was carried out. It was first 
required to test how successful this technique would be in planarians taking into 
account (1) that the published genome is not well-assembled, -currently it is formed 
by 15,046 scaffolds, with an average scaffold length of 77,506bp-, and (2) that it 
was uncertain if the transcription factor motifs identified in higher organisms would 
be conserved in planarians.  
Thus, in order to test the feasibility of the ATAC-sequencing in planarians, a 
first attempt was carried out with three types of regenerating blastemas: at 0hR, 
anterior 48hR and posterior 48hR, and only one replicate of each. These time points 
were chosen according to published literature, as they have been widely studied. 
The bioinformatics analysis of these samples was done with the same methodology 
as developed for the Xenopus analysis, that is: only the exclusive intergenic peaks 
were selected. With this, potential transcription factor binding sites were obtained. 
No further analysis (i.e. selection of candidate enhancers) was done, as their 
functional validation in planarians is not possible. Results of this preliminary study 
showed that the 0hR blastemas contain motifs for digestive system related genes 
whereas the anterior and posterior 48hR blastemas contain motifs for nervous 
system and posterior patterning related genes, respectively. This observation, which 
is in line with all the published literature, proved that the ATAC-sequencing protocol 
and informatics analysis, as followed, could be successfully used in planarians.  
ATAC-sequencing was then applied to planarians in order to unravel 
specification of anterior and posterior poles. For this, an earlier regeneration time 
point was required (i.e. 12hR). Moreover, to select only potential enhancers 
involved in anterior and posterior identity, ATAC-sequencing of notum RNAi 
organisms, which form a tail instead of a head, and wnt1 RNAi, which forms a head 
instead of a tail, was also incorporated in the analysis. As established previously, 
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three replicates per condition were obtained. The combination of the anterior and 
posterior samples taking into account the notum and wnt1 RNAi, will generate a list 
of potential enhancers involved in pole identity. To select from those only the active 
enhancers, the data will be combined with ChIP-sequencing results for a marker of 
active enhancer, H3K27ac, performed on anterior and posterior 12hR blastemas. All 
the ATAC-sequencing and ChIP-sequencing samples have been obtained and they 
are currently being sequenced. As a result of the analysis, a list of potential 
transcription factors involved in the anterior vs posterior polarity will be obtained. 
The transcription factors will be validated through RNAi methodology and 
characterization of the phenotype.  
5.4. Future work  
This research has allowed us to firstly standardize a protocol (both 
experimental and bioinformatic) for ATAC-sequencing, which has been applied to 
two different species (Xenopus laevis and Schmidtea mediterranea), and secondly 
to identify potential enhancers and/or their associated transcription factors in 
Xenopus and planarians. However, these results are only the first step in the 
characterisation of the genome regulatory regions in the context of Xenopus NC 
and planarian regeneration. Thus, in order to fully understand these processes 
more research needs to be done.  
For instance, in order to complete the Xenopus study it is required to test the 
functionality of the enhancers through I-SceI meganuclease transgenesis. For those 
positive hits, the contribution to the transcription factors whose motifs are found in 
the enhancers should be validated. To test that (1) the different transcription factors 
should be inhibited, by morpholino injection, and the level of transcription of the 
target gene should be analysed and (2) a construct with the enhancer containing a 
mutation in a specific binding site, should be introduced either by DNA injection or 
transgenesis and tested the ability to drive gfp expression. Ultimately, a transgenic 
line for a specific NC enhancer could be generated which would facilitate the study 
of NC cells. For example, cell sorting based techniques to isolate specific 
populations of cells possibly for single cell sequencing or chemical screen testing 
the fluorescence after compounds treatment could be carried out. The data 
generated can be also used to analyse any gene of interest to identify potential 
enhancers, not only NC but also neuroectoderm and ectoderm genes. Finally, the 
relevance of the NC transcription factors motifs found in most of the enhancers, i.e, 
Zic and Meis, as a key element for NC enhancer activation should be tested. For 
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that, these transcription factors alone or in combination could be used to induce NC 
in animal caps and the comparison of the epigenetic landscape with the obtained 
with noggin and Wnt1 induction would reveal the percentage of enhancers activated 
due to the action of Zic and Meis, and their potential role as a pioneer factors. 
With respect to the planarian project, the ATAC-sequencing and ChIP-
sequencing data needs to be processed and the list of potential transcription factors 
involved in specification of anterior and posterior polarity needs to be generated. 
Those transcription factors can be validated by RNAi methodology and analysing 
the phenotype in the regeneration context. Furthermore, it would be of interest to 
perform a similar analysis at different time points to understand how the 
specification of the planarian poles occurs.  
5.5. Where this research sits in a wider scientific context 
This research has been designed in order to bring light into the broad 
genomic fields of the Xenopus NC formation and the planarian regeneration, and for 
that, the novel ATAC-sequencing methodology has been implemented. It is worth 
noticing that traditionally, gene studies both in Xenopus and planarian are based on 
placing a gene of interest inside a gene regulatory network, which only suggests 
indirect regulatory interactions. Instead, the strength of the high throughput methods 
such as ATAC or ChIP-sequencing, resides on the fact that the technique enables 
us to directly reveal interactions between enhancers and promoters, transcription 
factors and genes; thus giving a global picture of genomic interactions. Moreover, 
this study has also considered single cell populations to be used with the high 
throughput techniques. The advantage that we see in performing ATAC or ChIP-
sequencing with cell populations (i.e. animal caps or dissected blastemas) is that 
the direct interactions revealed are less prone to background noise, allowing us to 
draw more robust conclusions which can be further tested. 
In the neural crest field it is known that organisms such as mice, chicken, 
zebrafish or humans have enhancers, which are not conserved in Xenopus. For 
instance, our five candidate Xenopus NC enhancers have not been found in any of 
these organisms. We think that, from an evolutionary point of view, it would be of 
interest to perform similar high throughput studies in the aforementioned organisms 
and to analyse the evolution of the NC regulatory regions. NC development has 
been extensively studied in Xenopus. Our results will be shared with the community 
and used to further understand the dynamics of NC development. 
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Lastly, regarding the planarian field, our research is one of the first studies to 
apply high throughput techniques for approaching the regeneration process. Only 
Duncan et al. (2015) have performed ChIP-sequencing in whole organisms 
planarians with the aim of identifying targets of two H3K4 methyltransferases. 
Hence, our research, which sets up a standardized protocol, could be a precedent 
for other studies aiming to use the same methodology. This is also the first time that 
planarian regeneration is approached with such a technique. Thus, these results, 
which take into account new elements (i.e, promoters and enhancers), would 
generate a lot of information about how the anteroposterior identity is defined. Also, 
as ATAC-sequencing has not been so much used in any other regenerative 
organisms, the identification of transcription factors and enhancers associated to 
regeneration, could be relevant not only for the planarian but for the regenerative 
field. For example, in Kang et al. (2016) a zebrafish regeneration enhancer can 
drive the expression of genes in injured mammalian tissue.  
To sum up, the application of ATAC-sequencing is a relatively novel 
technique, which can generate robust information to build up better gene regulatory 
networks.  
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Appendix 1: Tables of top motifs presents in the potential enhancers of 
the analyzed samples 
Table i: Top motifs found in the specific NC intergenic open regions stage 13 using 
Homer. * Indicates the Xenopus homolog. The transcription factors mentioned in the 
Chapter 3 are highlighted. The TPM data is extracted form the RNA-sequencing data. Motifs 
shown have a p-value <0.01 and are sorted by the % of target sequences with motifs. 
Tpm=transcripts per million. L and S refer to the long and short version of the gene. 
Motif Name P-value 
% of Target 
with Motif 
TPM st13 NC (L/S) 
Nanog(Homeobox) 1.00E-06 56.18% none/none 
Tgif2(Homeobox) 1.00E-06 46.10% 40.36/124.49 
PHA-4(Forkhead) 1.00E-05 45.58% *foxa4 2.52/0.95 
Tgif1(Homeobox) 1.00E-07 44.82% 28.24/12.50 
Tbx5(T-box) 1.00E-04 43.02% 0.12/0.04 
Nkx6.1(Homeobox) 1.00E-07 39.98% 0.23/0.10 
Smad3(MAD) 1.00E-03 36.43% 0.30/0.14 
KLF14(Zf) 1.00E-112 36.39% none/none 
Ptf1a(bHLH) 1.00E-02 33.55% 0.04/ 
Lhx3(Homeobox) 1.00E-32 32.39% 0.42/0.12 
Isl1(Homeobox) 1.00E-07 30.51% 17.88/14.87 
Eomes(T-box) 1.00E-09 29.67% 0.15/0.07 
Meis1(Homeobox) 1.00E-16 28.91% 4.10/0.47 
Sox3(HMG) 1.00E-18 28.55% 175.23/461.03 
NFY(CCAAT) 1.00E-54 26.47% *nfya 211.62/48.27 
Sox10(HMG) 1.00E-15 26.23% 0.23/0.16 
Sox6(HMG) 1.00E-13 26.03% 0.30/0.11 
Znf263(Zf) 1.00E-03 25.95% none/none 
PABPC1(?) 1.00E-02 24.23% 5044.78/1382.64 
KLF5(Zf) 1.00E-74 23.67% 27.23/11.38 
Maz(Zf) 1.00E-16 23.43% 6.41/18.71 
Foxo1(Forkhead) 1.00E-02 23.15% 0.82/0.48 
IBL1(bHLH) 1.00E-02 22.03% *Thy1 0.01/ 
Smad4(MAD) 1.00E-03 21.47% 
*smad4.1 
75.81/274.89 
*smad4.2 3.80/6.81 
Lhx2(Homeobox) 1.00E-23 21.15% 5.21/3.79 
Ascl1(bHLH) 1.00E-03 20.55% 0.30/0.21 
Lhx1(Homeobox) 1.00E-15 20.39% 0.10/0.21 
E2A(bHLH) 1.00E-03 20.27% *tcf3 60.36/222.10 
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ERG(ETS) 1.00E-03 19.83% 0.02/0 
ETV1(ETS) 1.00E-04 18.83% 26.36/24.64 
Ap4(bHLH) 1.00E-07 18.59% *ap4e1 0.71/2.73 
FOXA1(Forkhead) 1.00E-10 18.47% 0.00/0.42 
Zic(Zf) 1.00E-29 18.39% *zic1 181.82/366.90 
SPCH(bHLH) 1.00E-09 17.59% *foxp2 0.11/0.06 
Fli1(ETS) 1.00E-05 17.39% 0.39/0.00 
Sox15(HMG) 1.00E-12 17.23% 515/ 
MyoG(bHLH) 1.00E-09 17.07% none/none 
Tcf12(bHLH) 1.00E-08 16.99% 37.55/23.91 
Sox2(HMG) 1.00E-18 16.31% /276.76 
GSC(Homeobox) 1.00E-04 16.19% 3.52/1.52 
PU.1-IRF(ETS:IRF) 1.00E-07 15.79% *spi1 0.14/0.22 
Rbpj1(?) 1.00E-04 15.75% 4.91/7.16 
MITF(bHLH) 1.00E-09 15.67% 0.03/0.10 
HIF-1b(HLH) 1.00E-02 15.59% *arnt 5.01/10.43 
NPAS2(bHLH) 1.00E-05 15.39% 0.24/ 
MyoD(bHLH) 1.00E-10 15.35% *myod1  0.14/0.94 
FOXM1(Forkhead) 1.00E-07 15.19% 2.69/19.89 
ZNF467(Zf) 1.00E-11 14.71% none/none 
ETS1(ETS) 1.00E-04 14.67% 1.22/1.50 
Tcf21(bHLH) 1.00E-06 14.63% 0.19/0.88 
GABPA(ETS) 1.00E-04 14.27% 28.23/56.36 
Atf1(bZIP) 1.00E-07 13.91% 53.64/41.32 
LIN-39(Homeobox) 1.00E-02 13.87% none/none 
HOXD13(Homeobox) 1.00E-02 13.71% 0.01/0.10 
Pdx1(Homeobox) 1.00E-04 13.39% none/none 
Etv2(ETS) 1.00E-03 12.99% 0.94/0.08 
Pit1(Homeobox) 1.00E-02 12.95% *pou1f1 none/ 
Myf5(bHLH) 1.00E-08 12.79% 1.63/0.84 
TEAD4(TEA) 1.00E-10 12.75% none/none 
FoxL2(Forkhead) 1.00E-07 12.75% 0.12/0.06 
Foxa2(Forkhead) 1.00E-05 12.51% 0.40/0.15 
Sox9(HMG) 1.00E-04 12.04% 3.78/7.13 
Sox4(HMG) 1.00E-05 11.92% 0.92/4.32 
Oct4(POU,Homeobox) 1.00E-31 11.76% 
*pou5f3.1 
435.03/150.06 
*pou5f3.2 39.68/59.31 
*pou5f3.3 2.45/1.61 
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Klf9(Zf) 1.00E-59 11.04% 2.42/0.20 
Otx2(Homeobox) 1.00E-02 11.04% 144.69/65.24 
Oct6(POU,Homeobox) 1.00E-27 10.72% *pou3f1 8.14/3.96 
Elk1(ETS) 1.00E-03 10.72% 6.97/0.97 
KLF10(Zf) 1.00E-21 10.68% 14.55/50.38 
Elk4(ETS) 1.00E-04 10.56% 2.20/15.76 
Egr1(Zf) 1.00E-13 10.32% 1.41/1.76 
Atf7(bZIP) 1.00E-04 10.32% 3.06/4.12 
ELF5(ETS) 1.00E-02 10.28% 0.11/0.11 
ZNF189(Zf) 1.00E-02 10.16% none/none 
EBF1(EBF) 1.00E-02 10.12% *ebf1-like /0.20 
CLOCK(bHLH) 1.00E-07 10.08% 3.18/11.53 
Max(bHLH) 1.00E-06 10.04% 71.81/ 
DPL-1(E2F) 1.00E-05 9.92% none/none 
Cdx2(Homeobox) 1.00E-03 9.92% 4.03/4.40 
n-Myc(bHLH) 1.00E-04 9.48% 0.66/0.57 
HOXA9(Homeobox) 1.00E-02 9.44% 0.14/0.09 
Foxh1(Forkhead) 1.00E-02 9.16% 1.64/0.41 
USF1(bHLH) 1.00E-06 8.80% 5.51/15.65 
Brn1(POU,Homeobox) 1.00E-25 8.48% none/none 
Klf4(Zf) 1.00E-33 7.96% 0.10/0.50 
Usf2(bHLH) 1.00E-12 7.84% 102.20/ 
Atf2(bZIP) 1.00E-02 7.84% 0.37/0.18 
E2F4(E2F) 1.00E-04 7.76% 27.38/42.68 
Hoxc9(Homeobox) 1.00E-04 7.76% 0.24/0.23 
c-Jun-CRE(bZIP) 1.00E-02 7.40% 0.87/0.65 
c-Myc(bHLH) 1.00E-09 7.32% 13.03/19.81 !!
Table ii: Top motifs found in the specific NC intergenic open regions stage 18 using 
Homer. * Indicates the Xenopus homolog. The transcription factors mentioned in the 
Chapter 3 are highlighted. The TPM data is extracted form the RNA-sequencing data. Motifs 
shown have a p-value <0.01 and are sorted by the % of target sequences with motifs. 
Tpm=transcripts per million. L and S refer to the long and short version of the gene. 
Motif Name P-value 
% of Target 
with Motif 
TPM st18 NC (L/S) 
Tgif2(Homeobox) 1.00E-03 42.99% 34.21/63.13 
Tgif1(Homeobox) 1.00E-02 40.74% 30.44/14.50 
Sox3(HMG) 1.00E-17 31.35% 63.89/168.25 
Sox10(HMG) 1.00E-13 28.04% 64.49/54.13 
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Sox6(HMG) 1.00E-11 27.38% 0.11/0.41 
Meis3(Homeobox) 1.00E-07 26.19% 75.46/76.55 
Lhx3(Homeobox) 1.00E-05 25.66% 0.22/0.04 
Pdx1(Homeobox) 1.00E-22 23.02% 0/0 
LIN-39(Homeobox) 1.00E-13 21.43% none/none 
Sox15(HMG) 1.00E-12 19.97% 129.92/- 
Sox2(HMG) 1.00E-17 19.05% /92.7 
Zic(Zf) 1.00E-13 17.46% zic1* 48.84/57.57 
Lhx1(Homeobox) 1.00E-02 15.74% 0.18/0.31 
Sox9(HMG) 1.00E-09 15.34% 9.34/93.33 
KLF14(Zf) 1.00E-03 14.95% 3.42/0.50 
Lhx2(Homeobox) 1.00E-02 14.95% 18.85/9.01 
Sox4(HMG) 1.00E-07 14.02% 3.24/4.47 
HOXA9(Homeobox) 1.00E-08 13.89% 0.41/0.35 
FOXA1(Forkhead) 1.00E-02 13.10% 5.87/2.29 
Hoxc9(Homeobox) 1.00E-10 11.51% 0.28/0.43 
HNF6(Homeobox) 1.00E-04 10.71% none/none 
AP-2gamma(AP2) 1.00E-02 10.32% 148.37/193.11 
AP-2alpha(AP2) 1.00E-05 8.60% 92.49/42.20 
HOXA2(Homeobox) 1.00E-33 7.67% 2.97/4.73 
Tcf4(HMG) 1.00E-08 7.28% none/none 
BATF(bZIP) 1.00E-02 6.88% 0/0.13 
Hoxb4(Homeobox) 1.00E-11 6.35% 0.76/0.20 
Egr1(Zf) 1.00E-02 5.82% 1.03/1.14 
Pbx3(Homeobox) 1.00E-05 5.56% 0.28/1.78 
Pknox1(Homeobox) 1.00E-05 5.42% 21.77/17.04 
PAX3(Homeobox) 1.00E-04 4.37% 148.75/153.01 
Tbx20(T-box) 1.00E-04 3.84% 1.41/ 
Tcf3(HMG) 1.00E-03 3.84% 77.99/214.77 
OCT4(POU) 1.00E-02 3.31% 
*pou5f3.1 47.03/11.87 
*pou5f3.2 0.89/2.67 
*pou5f3.3 2.14/1.44 
VDR(NR) 1.00E-02 3.17% 3.60/13.85 
Nur77(NR) 1.00E-03 3.04% none/none 
PBX1(Homeobox) 1.00E-03 2.25% 49.07/26.91 
Pax7(Homeobox) 1.00E-03 2.12% 0.42/1.47 
TR4(NR) 1.00E-03 1.85% none/none !!
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Table iii: Top motifs found in the specific ectoderm intergenic open regions stage 18 
using Homer. The transcription factors mentioned in the Chapter 3 are highlighted. Motifs 
shown have a p-value<0.01 and are sorted by the % of target sequences with motifs.  
Motif Name P-value 
% of Target  
with Motif 
Nkx6.1(Homeobox) 1.00E-13 40.82% 
Isl1(Homeobox) 1.00E-05 27.95% 
Lhx3(Homeobox) 1.00E-18 27.90% 
GATA3(Zf) 1.00E-21 24.24% 
Eomes(T-box) 1.00E-03 23.84% 
AP-2gamma(AP2) 1.00E-180 22.82% 
Sox3(HMG) 1.00E-03 20.61% 
Foxo1(Forkhead) 1.00E-02 20.45% 
KLF14(Zf) 1.00E-47 19.75% 
Sox6(HMG) 1.00E-02 19.70% 
Lhx2(Homeobox) 1.00E-21 19.67% 
Meis1(Homeobox) 1.00E-02 19.22% 
Sox10(HMG) 1.00E-03 19.06% 
AP-2alpha(AP2) 1.00E-180 18.77% 
Lhx1(Homeobox) 1.00E-11 18.71% 
Gata4(Zf) 1.00E-34 18.42% 
FOXA1(Forkhead) 1.00E-07 17.43% 
Smad4(MAD) 1.00E-03 16.74% 
KLF5(Zf) 1.00E-79 16.55% 
TEAD4(TEA) 1.00E-78 16.15% 
GRHL2(CP2) 1.00E-217 15.40% 
NFY(CCAAT) 1.00E-05 14.63% 
Maz(Zf) 1.00E-05 14.44% 
Gata2(Zf) 1.00E-39 14.36% 
FOXM1(Forkhead) 1.00E-04 13.96% 
Rbpj1 1.00E-05 13.85% 
Gata1(Zf) 1.00E-39 13.45% 
Sox15(HMG) 1.00E-03 13.19% 
Tbet(T-box) 1.00E-04 12.44% 
ZNF416(Zf) 1.00E-04 12.36% 
FoxL2(Forkhead) 1.00E-02 11.64% 
Foxa2(Forkhead) 1.00E-04 11.40% 
TEAD2(TEA) 1.00E-72 11.19% 
EBF1(EBF) 1.00E-21 10.86% 
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Sox2(HMG) 1.00E-02 10.62% 
Bcl6(Zf) 1.00E-02 10.01% 
Sox4(HMG) 1.00E-02 9.42% 
NFAT(RHD) 1.00E-03 9.21% 
CEBP(bZIP) 1.00E-02 8.76% 
STAT4(Stat) 1.00E-02 8.68% 
Oct4(POU,Homeobox) 1.00E-14 8.44% 
Oct6(POU,Homeobox) 1.00E-20 8.38% 
AP-1(bZIP) 1.00E-03 7.34% 
KLF10(Zf) 1.00E-22 7.21% 
Zelda(Zf) 1.00E-05 7.15% 
FOXP1(Forkhead) 1.00E-08 6.67% 
Atf3(bZIP) 1.00E-02 6.67% 
BATF(bZIP) 1.00E-05 6.27% 
Brn1(POU,Homeobox) 1.00E-16 6.25% 
Stat3+il21(Stat) 1.00E-03 6.22% 
Rfx5(HTH) 1.00E-11 6.14% 
Egr1(Zf) 1.00E-06 5.74% 
Fra1(bZIP) 1.00E-03 5.58% 
Klf9(Zf) 1.00E-27 5.34% 
Klf4(Zf) 1.00E-33 5.29% 
Oct2(POU,Homeobox) 1.00E-05 4.86% 
Phox2a(Homeobox) 1.00E-02 4.59% 
Six1(Homeobox) 1.00E-05 4.54% 
Stat3(Stat) 1.00E-07 4.51% 
Tcf4(HMG) 1.00E-05 4.51% 
p63(p53) 1.00E-05 4.35% 
Pbx3(Homeobox) 1.00E-04 3.36% 
E-box 1.00E-03 3.26% 
Fosl2(bZIP) 1.00E-08 3.23% 
Pknox1(Homeobox) 1.00E-04 3.18% 
c-Myc(bHLH) 1.00E-02 3.04% 
Chop(bZIP) 1.00E-02 3.02% 
Hoxb4(Homeobox) 1.00E-02 2.88% 
STAT1(Stat) 1.00E-04 2.70% 
STAT5(Stat) 1.00E-04 2.62% 
Sp1(Zf) 1.00E-17 2.59% 
Pho2(bHLH) 1.00E-02 2.43% 
PAX5(Homeobox) 1.00E-15 2.24% 
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Rfx1(HTH) 1.00E-03 2.19% 
Jun-AP1(bZIP) 1.00E-07 2.16% 
Tcf3(HMG) 1.00E-02 2.16% 
CTCF(Zf) 1.00E-03 2.08% 
JunD(bZIP) 1.00E-02 2.03% 
GATA3(Zf),DR4 1.00E-10 1.92% 
Egr2(Zf) 1.00E-09 1.74% 
p53(p53) 1.00E-06 1.60% 
Rfx2(HTH) 1.00E-05 1.39% 
Brn2(POU,Homeobox) 1.00E-02 1.39% 
GATA3(Zf),DR8 1.00E-02 1.07% 
FOXA1 (Forkhead,NR) 1.00E-03 0.93% 
Pax7(Homeobox) 1.00E-08 0.69% 
E2F7(E2F) 1.00E-02 0.69% !!
Table iv: Top motifs found in the specific neuroectoderm intergenic open regions 
stage 18 using Homer. Highlighted the transcription factors mentioned in the Chapter 3. 
Motifs shown have a p-value <0.01 and are sorted by the % of target sequences with motifs.!
Motif Name P-value 
% of Target 
with Motif 
Nanog(Homeobox) 1.00E-06 67.13% 
Nkx6.1(Homeobox) 1.00E-68 57.45% 
Lhx3(Homeobox) 1.00E-243 47.40% 
Sox3(HMG) 1.00E-491 46.89% 
Isl1(Homeobox) 1.00E-137 46.61% 
Sox6(HMG) 1.00E-366 43.34% 
Sox10(HMG) 1.00E-439 43.26% 
CRX(Homeobox) 1.00E-31 43.08% 
Trl(Zf) 1.00E-08 39.24% 
Lhx2(Homeobox) 1.00E-414 38.36% 
Lhx1(Homeobox) 1.00E-320 37.87% 
Eomes(T-box) 1.00E-06 36.01% 
EGL-5(Homeobox) 1.00E-34 35.04% 
Sox15(HMG) 1.00E-475 33.76% 
Sox2(HMG) 1.00E-662 32.64% 
Foxo1(Forkhead) 1.00E-09 29.37% 
Meis1(Homeobox) 1.00E-10 29.23% 
GSC(Homeobox) 1.00E-126 28.39% 
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GATA3(Zf) 1.00E-03 27.35% 
Sox4(HMG) 1.00E-346 25.47% 
NFY(CCAAT) 1.00E-50 24.77% 
Smad4(MAD) 1.00E-09 24.49% 
Maz(Zf) 1.00E-44 24.42% 
Sox9(HMG) 1.00E-218 23.69% 
HOXD13(Homeobox) 1.00E-08 23.16% 
Otx2(Homeobox) 1.00E-140 21.44% 
Pdx1(Homeobox) 1.00E-21 21.10% 
Rbpj1 1.00E-03 19.99% 
PU.1-IRF(ETS:IRF) 1.00E-19 19.47% 
FOXA1(Forkhead) 1.00E-02 19.32% 
Ap4(bHLH) 1.00E-02 19.20% 
FOXM1(Forkhead) 1.00E-03 19.02% 
Gata4(Zf) 1.00E-05 18.84% 
Tbet(T-box) 1.00E-03 17.43% 
RXR(NR),DR1 1.00E-16 16.74% 
Zic(Zf) 1.00E-42 16.70% 
KLF5(Zf) 1.00E-50 16.52% 
HOXA9(Homeobox) 1.00E-09 14.70% 
NFAT(RHD) 1.00E-07 14.68% 
CEBP(bZIP) 1.00E-05 13.98% 
Gfi1b(Zf) 1.00E-06 13.80% 
CES-1(Homeobox) 1.00E-34 13.77% 
HNF6(Homeobox) 1.00E-15 13.29% 
Phox2a(Homeobox) 1.00E-137 12.90% 
Foxh1(Forkhead) 1.00E-08 12.89% 
TEAD(TEA) 1.00E-26 12.59% 
MafA(bZIP) 1.00E-04 12.50% 
Oct6(Homeobox) 1.00E-54 11.76% 
Hoxc9(Homeobox) 1.00E-05 10.95% 
AP-1(bZIP) 1.00E-06 10.88% 
PRDM1(Zf) 1.00E-20 10.60% 
Atf3(bZIP) 1.00E-09 10.39% 
BATF(bZIP) 1.00E-17 9.37% 
FOXP1(Forkhead) 1.00E-13 8.93% 
Max(bHLH) 1.00E-03 8.87% 
Brn1(POU,Homeobox) 1.00E-49 8.85% 
KLF10(Zf) 1.00E-41 8.82% 
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Egr1(Zf) 1.00E-16 8.78% 
n-Myc(bHLH) 1.00E-03 8.59% 
Fra1(bZIP) 1.00E-10 8.47% 
Esrrb(NR) 1.00E-06 8.34% 
Tcf4(HMG) 1.00E-31 8.22% 
NFkB-p65(RHD) 1.00E-02 7.77% 
STAT6(Stat) 1.00E-02 7.46% 
Klf9(Zf) 1.00E-104 7.30% 
ELT-3(Gata) 1.00E-02 7.28% 
IRF4(IRF) 1.00E-03 7.27% 
Oct2(POU,Homeobox) 1.00E-11 7.21% 
Rfx5(HTH) 1.00E-04 6.59% 
HNF4a(NR) 1.00E-02 6.19% 
FXR(NR) 1.00E-05 6.08% 
Pbx3(Homeobox) 1.00E-29 5.87% 
DMRT1(DM) 1.00E-03 5.71% 
E2F6(E2F) 1.00E-12 5.70% 
PAX5(Paired,Homeobox) 1.00E-16 5.58% 
Hoxb4(Homeobox) 1.00E-31 5.49% 
PAX3(Homeobox) 1.00E-25 5.42% 
Pknox1(Homeobox) 1.00E-20 5.34% 
Klf4(Zf) 1.00E-32 5.20% 
MafF(bZIP) 1.00E-04 5.04% 
E-box 1.00E-06 4.99% 
Oct4(Homeobox) 1.00E-58 4.92% 
c-Myc(bHLH) 1.00E-05 4.81% 
DMRT6(DM) 1.00E-03 4.77% 
Nur77(NR) 1.00E-39 4.67% 
PGR(NR) 1.00E-02 4.35% 
Tcf3(HMG) 1.00E-11 4.35% 
GRE(NR),IR3 1.00E-02 3.87% 
Pax8(Paired,Homeobox) 1.00E-08 3.84% 
Pho2(bHLH) 1.00E-04 3.80% 
Fosl2(bZIP) 1.00E-07 3.72% 
VDR(NR),DR3 1.00E-03 3.70% 
ARE(NR) 1.00E-04 3.60% 
Rfx1(HTH) 1.00E-21 3.60% 
Sp1(Zf) 1.00E-43 3.56% 
Tbx20(T-box) 1.00E-07 3.37% 
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PAX6(Homeobox) 1.00E-93 3.32% 
PU.1:IRF8(ETS:IRF) 1.00E-03 3.02% 
FHY3(FAR1) 1.00E-06 2.90% 
BORIS(Zf) 1.00E-02 2.86% 
EKLF(Zf) 1.00E-07 2.80% 
CTCF(Zf) 1.00E-09 2.73% 
ABF1 1.00E-04 2.61% 
Jun-AP1(bZIP) 1.00E-09 2.61% 
TR4(NR),DR1 1.00E-52 2.56% 
Hnf1(Homeobox) 1.00E-03 2.37% 
Rfx2(HTH) 1.00E-40 2.26% 
RFX(HTH) 1.00E-53 2.13% 
Brn2(POU,Homeobox) 1.00E-06 2.05% 
Egr2(Zf) 1.00E-18 2.00% 
HOXA2(Homeobox) 1.00E-08 1.99% 
PBX1(Homeobox) 1.00E-11 1.98% 
RORgt(NR) 1.00E-06 1.97% 
Pax7(Homeobox) 1.00E-76 1.66% 
GLI3(Zf) 1.00E-02 1.28% 
TCFL2(HMG) 1.00E-06 1.26% 
ZNF519(Zf) 1.00E-03 1.23% 
E2F7(E2F) 1.00E-04 1.16% 
ZNF41(Zf) 1.00E-06 0.61% 
EBNA1(EBV-virus) 1.00E-06 0.31% 
REST-NRSF(Zf) 1.00E-07 0.29% 
ZBTB33(Zf) 1.00E-05 0.29% 
p53(p53) 1.00E-02 0.23% !!
Table v: Top motifs found in the specific 0hR intergenic open regions using Homer. 
The transcription factors mentioned in the Chapter 4are highlighted. Motifs shown have a p-
value<0.01 and are sorted by the % of target sequences with motifs. 
Motif Name P-value 
% of Target 
with Motif 
Isl1(Homeobox) 1.00E-17 20.56% 
EGL-5(Homeobox) 1.00E-03 20.54% 
LIN-39(Homeobox) 1.00E-02 19.04% 
Nkx2.1(Homeobox) 1.00E-16 16.83% 
Bapx1(Homeobox) 1.00E-43 15.76% 
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GATA3(Zf) 1.00E-17 15.67% 
KANADI1(Myb) 1.00E-03 15.65% 
Eomes(T-box) 1.00E-07 15.19% 
Nkx2.5(Homeobox) 1.00E-44 14.60% 
AR-halfsite(NR) 1.00E-16 14.04% 
Nkx3.1(Homeobox) 1.00E-14 13.68% 
Nkx2.2(Homeobox) 1.00E-45 12.32% 
Sox3(HMG) 1.00E-02 11.83% 
LHY(Myb) 1.00E-02 11.69% 
FoxL2(Forkhead) 1.00E-17 10.87% 
Foxo1(Forkhead) 1.00E-03 10.25% 
FOXA1(Forkhead) 1.00E-07 10.13% 
Gata4(Zf) 1.00E-13 10.04% 
NFY(CCAAT) 1.00E-03 9.04% 
Trl(Zf) 1.00E-05 8.80% 
Mef2b(MADS) 1.00E-03 7.53% 
Sox15(HMG) 1.00E-08 7.53% 
Hoxc9(Homeobox) 1.00E-07 6.91% 
Erra(NR) 1.00E-06 6.86% 
Foxa2(Forkhead) 1.00E-06 6.59% 
ZNF264(Zf) 1.00E-86 6.26% 
EHF(ETS) 1.00E-07 6.23% 
ETV1(ETS) 1.00E-02 5.84% 
Gata2(Zf) 1.00E-13 5.79% 
Rfx5(HTH) 1.00E-92 5.74% 
Smad2(MAD) 1.00E-02 5.66% 
ERG(ETS) 1.00E-06 5.64% 
Sox2(HMG) 1.00E-05 5.44% 
E2A(bHLH),near_PU.1 1.00E-15 5.13% 
Gata1(Zf) 1.00E-06 4.71% 
Sox4(HMG) 1.00E-03 4.49% 
PQM-1(?) 1.00E-03 4.47% 
SPDEF(ETS) 1.00E-04 4.44% 
FOXP1(Forkhead) 1.00E-14 3.95% 
PRDM1(Zf) 1.00E-43 3.89% 
ELF5(ETS) 1.00E-09 3.76% 
ABF1 1.00E-02 3.56% 
Gfi1b(Zf) 1.00E-07 3.48% 
ZFX(Zf) 1.00E-09 3.30% 
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FHY3(FAR1) 1.00E-75 3.28% 
Etv2(ETS) 1.00E-08 3.27% 
Esrrb(NR) 1.00E-05 3.02% 
Egr1(Zf) 1.00E-58 2.97% 
KLF14(Zf) 1.00E-02 2.65% 
ZBTB12(Zf) 1.00E-44 2.43% 
Nr5a2(NR) 1.00E-02 2.12% 
GEI-11(Myb?) 1.00E-76 2.06% 
Egr2(Zf) 1.00E-85 1.97% 
IRF1(IRF) 1.00E-50 1.64% 
HNF4a(NR),DR1 1.00E-11 1.59% 
Oct4(POU,Homeobox) 1.00E-06 1.50% 
IRF2(IRF) 1.00E-43 1.44% 
Rfx1(HTH) 1.00E-30 1.40% 
Rfx2(HTH) 1.00E-23 1.35% 
SpiB(ETS) 1.00E-11 1.23% 
ISRE(IRF) 1.00E-61 1.17% 
PAX5(Homeobox), 1.00E-32 1.08% 
FXR(NR),IR1 1.00E-05 1.07% 
HOXA2(Homeobox) 1.00E-02 1.05% 
HRE(HSF) 1.00E-02 0.98% 
Dorsal(RHD) 1.00E-02 0.95% 
Jun-AP1(bZIP) 1.00E-05 0.79% 
Ets1-distal(ETS) 1.00E-03 0.78% 
MafK(bZIP) 1.00E-10 0.69% 
ZNF136(Zf) 1.00E-02 0.69% 
ZNF675(Zf) 1.00E-06 0.62% 
Bach1(bZIP) 1.00E-07 0.36% 
NF-E2(bZIP) 1.00E-16 0.36% 
GLI3(Zf) 1.00E-07 0.35% 
Nrf2(bZIP) 1.00E-12 0.28% 
TR4(NR),DR1 1.00E-04 0.23% 
ZNF382(Zf) 1.00E-02 0.11% !!!
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Table vi: Top motifs found in the specific anterior 48hR intergenic open regions using 
Homer. Highlighted the transcription factors mentioned in the Chapter 4. Motifs shown have 
a p-value<0.01 and are sorted by the % of target sequences with motifs. * Indicates the 
planarian homolog 
Motif Name P-value 
% of Target 
with Motif 
Nkx6.1(Homeobox) 1.00E-12 51.13% 
Nanog(Homeobox) 1.00E-44 50.78% 
PHA-4(Forkhead) 1.00E-63 42.68% 
Lhx3(Homeobox) 1.00E-106 39.29% 
Tgif2(Homeobox) 1.00E-22 31.90% 
Tgif1(Homeobox) 1.00E-21 31.01% 
LIN-39(Homeobox) 1.00E-15 30.12% 
Lhx1(Homeobox) 1.00E-67 27.08% 
EGL-5(Homeobox) 1.00E-09 26.92% 
Isl1(Homeobox) 1.00E-45 26.84% 
Lhx2(Homeobox) 1.00E-59 24.88% 
CRX(Homeobox) 1.00E-05 22.99% 
MYB(HTH) 1.00E-14 21.41% 
Pdx1(Homeobox) 1.00E-24 20.12% 
Pit1(Homeobox) 1.00E-15 19.98% 
HNF6(Homeobox) 1.00E-32 19.70% 
CES-1(Homeobox) 1.00E-39 19.53% 
SCL(bHLH) 1.00E-06 19.15% 
Eomes(T-box) 1.00E-02 19.01% 
SUT1? 1.00E-02 18.30% 
GATA3(Zf) 1.00E-02 18.06% 
NFY(CCAAT) 1.00E-239 17.60% 
BMYB(HTH) 1.00E-06 16.78% 
RBFox2(?) 1.00E-41 16.20% 
Bapx1(Homeobox) 1.00E-20 15.83% 
Tbx5(T-box) 1.00E-03 15.46% 
AMYB(HTH) 1.00E-11 15.06% 
Foxo1(Forkhead) 1.00E-26 14.89% 
FOXA1(Forkhead) 1.00E-13 14.88% 
Smad3(MAD) 1.00E-17 14.54% 
Phox2a(Homeobox) 1.00E-45 14.46% 
FoxL2(Forkhead) 1.00E-07 14.14% 
GSC(Homeobox) 1.00E-05 13.87% 
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FOXM1(Forkhead) 1.00E-10 13.41% 
Gata4(Zf) 1.00E-05 11.49% 
HOXA9(Homeobox) 1.00E-03 11.42% 
BMAL1(bHLH) 1.00E-12 11.09% 
Meis1/*prep (Homeobox) 1.00E-23 10.87% 
Ptf1a(bHLH) 1.00E-16 10.53% 
Hoxc9(Homeobox) 1.00E-05 10.40% 
Olig2(bHLH) 1.00E-05 10.31% 
Foxa2(Forkhead) 1.00E-13 10.00% 
HIF-1b(HLH) 1.00E-04 9.79% 
Trl(Zf) 1.00E-34 9.59% 
Foxh1(Forkhead) 1.00E-13 9.37% 
AP-1(bZIP) 1.00E-118 9.03% 
SPCH(bHLH) 1.00E-19 8.83% 
Atf3(bZIP) 1.00E-122 8.80% 
IBL1(bHLH) 1.00E-13 8.64% 
BATF(bZIP) 1.00E-117 8.59% 
Fra1(bZIP) 1.00E-134 8.56% 
NFAT(RHD) 1.00E-03 8.40% 
Atf1(bZIP) 1.00E-03 8.07% 
Tal1 1.00E-02 7.33% 
Smad4(MAD) 1.00E-07 6.81% 
PIF4(bHLH) 1.00E-08 6.71% 
HEB(bHLH) 1.00E-19 6.69% 
Fli1(ETS) 1.00E-02 6.41% 
Oct4(POU,Homeobox) 1.00E-02 6.37% 
EHF(ETS) 1.00E-07 6.23% 
Smad2(MAD) 1.00E-02 6.23% 
Gata2(Zf) 1.00E-03 6.22% 
PU.1-IRF(ETS:IRF) 1.00E-06 6.18% 
HLH-1(bHLH) 1.00E-26 6.08% 
Rbpj1(?) 1.00E-06 6.08% 
Oct6(POU,Homeobox) 1.00E-06 6.02% 
NPAS2(bHLH) 1.00E-14 5.96% 
FOXP1(Forkhead) 1.00E-13 5.86% 
ERG(ETS) 1.00E-11 5.84% 
ETV1(ETS) 1.00E-03 5.77% 
PIF5ox(bHLH) 1.00E-04 5.51% 
MITF(bHLH) 1.00E-04 5.40% 
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Gata1(Zf) 1.00E-04 5.34% 
TEAD(TEA) 1.00E-02 5.20% 
Ascl1(bHLH) 1.00E-07 4.72% 
Pax7(Paired,Homeobox) 1.00E-15 4.69% 
Ap4(bHLH) 1.00E-16 4.55% 
Brn1(POU,Homeobox) 1.00E-08 4.50% 
Atf7(bZIP) 1.00E-02 4.27% 
ETS1(ETS) 1.00E-09 4.23% 
Atoh1(bHLH) 1.00E-09 4.21% 
E2A(bHLH) 1.00E-10 4.05% 
MafF(bZIP) 1.00E-06 4.03% 
Fosl2(bZIP) 1.00E-97 3.97% 
PRDM1(Zf) 1.00E-07 3.82% 
Hoxb4(Homeobox) 1.00E-13 3.73% 
KLF10(Zf) 1.00E-98 3.71% 
MafA(bZIP) 1.00E-03 3.60% 
STAT6(Stat) 1.00E-03 3.58% 
DPL-1(E2F) 1.00E-03 3.57% 
Esrrb(NR) 1.00E-05 3.57% 
MyoG(bHLH) 1.00E-13 3.57% 
E-box 1.00E-25 3.56% 
Etv2(ETS) 1.00E-09 3.54% 
PAX3 (Paired,Homeobox) 1.00E-17 3.53% 
SFP1 1.00E-07 3.46% 
Max(bHLH) 1.00E-08 3.45% 
Tcf21(bHLH) 1.00E-14 3.43% 
ELF5(ETS) 1.00E-02 3.38% 
CLOCK(bHLH) 1.00E-09 3.31% 
NeuroD1(bHLH) 1.00E-10 3.14% 
n-Myc(bHLH) 1.00E-06 3.08% !!!!!!!
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Table vii: Top motifs found in the specific posterior 48hR intergenic open regions 
using Homer. The transcription factors mentioned in the Chapter 4 are highlighted. Motifs 
shown have a p-value<0.01 and are sorted by the % of target sequences with motifs. 
Motif Name P-value 
% of Target with 
Motif 
Nanog(Homeobox) 1.00E-05 32.82% 
Lhx3(Homeobox) 1.00E-03 21.49% 
Isl1(Homeobox) 1.00E-04 16.00% 
HOXD13(Homeobox) 1.00E-02 14.57% 
GATA3(Zf) 1.00E-03 13.30% 
Nkx2.1(Homeobox) 1.00E-03 12.37% 
Bapx1(Homeobox) 1.00E-13 11.75% 
Nkx2.5(Homeobox) 1.00E-09 10.69% 
Nkx3.1(Homeobox) 1.00E-02 10.03% 
Nkx2.2(Homeobox) 1.00E-04 8.12% 
Gata4(Zf) 1.00E-02 7.88% 
SEP3(MADS) 1.00E-02 7.32% 
Mef2a(MADS) 1.00E-03 3.31% 
Rfx5(HTH) 1.00E-12 3.02% 
Nr5a2(NR) 1.00E-09 3.00% 
Esrrb(NR) 1.00E-05 2.85% 
PRDM1(Zf) 1.00E-02 2.52% 
Pax7(Paired,Homeobox) 1.00E-02 2.41% 
MafF(bZIP) 1.00E-04 2.39% 
Nr5a2(NR) 1.00E-08 2.29% 
Egr1(Zf) 1.00E-08 1.70% 
GATA3(Zf),DR4 1.00E-09 1.37% 
Fosl2(bZIP) 1.00E-05 1.15% 
HNF4a(NR),DR1 1.00E-02 1.10% 
Egr2(Zf) 1.00E-12 1.01% 
Jun-AP1(bZIP) 1.00E-08 0.97% 
ZNF136(Zf) 1.00E-06 0.94% 
IRF1(IRF) 1.00E-03 0.89% 
GEI-11(Myb?) 1.00E-05 0.84% 
Rfx1(HTH) 1.00E-02 0.81% 
MafK(bZIP) 1.00E-10 0.76% 
IRF2(IRF) 1.00E-02 0.69% 
Bach2(bZIP) 1.00E-03 0.66% 
ISRE(IRF) 1.00E-05 0.63% 
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Bach1(bZIP) 1.00E-09 0.53% 
NF-E2(bZIP) 1.00E-15 0.53% 
Nrf2(bZIP) 1.00E-13 0.43% 
NRF(NRF) 1.00E-03 0.40% 
NRF1(NRF) 1.00E-04 0.28% 
ZNF692(Zf) 1.00E-02 0.25% 
ZNF382(Zf) 1.00E-02 0.20% !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Regulation of gene expression at the level of transcriptional elongation has been shown to be important
in stem cells and tumour cells, but its role in the whole animal is only now being fully explored. Neural
crest cells (NCCs) are a multipotent population of cells that migrate during early development from the
dorsal neural tube throughout the embryo where they differentiate into a variety of cell types including
pigment cells, cranio-facial skeleton and sensory neurons. Speciﬁcation of NCCs is both spatially and
temporally regulated during embryonic development. Here we show that components of the tran-
scriptional elongation regulatory machinery, CDK9 and CYCLINT1 of the P-TEFb complex, are required to
regulate neural crest speciﬁcation. In particular, we show that expression of the proto-oncogene c-Myc
and c-Myc responsive genes are affected. Our data suggest that P-TEFb is crucial to drive expression of c-
Myc, which acts as a ‘gate-keeper’ for the correct temporal and spatial development of the neural crest.
& 2016 Elsevier Inc. All rights reserved.
1. Introduction
RNA polymerase pausing and transcriptional elongation is im-
portant in the speciﬁcation of many types of cells including em-
bryonic stem (ES) cells. In order for genes to undergo transcription,
RNA polymerase II (Pol II) must be recruited to the promoter re-
gion (Hochheimer and Tjian, 2003). Subsequent to this, RNA Pol II
may undergo regulation to temporally control the expression of
genes in speciﬁc cell types. Such regulation includes the promoter
proximal pausing of Pol II, the process by which Pol II undergoes
stalling or poising at the 5′ end of a gene just downstream of the
transcription start site (Core and Lis, 2008). This occurs due to
binding of pause factors, DRB-sensitivity inducing factor (DSIF),
negative elongation factor (NELF) and Gdown1 (Cheng et al., 2012;
Wada et al., 1998; Yamaguchi et al., 1999). In order for transcrip-
tional elongation to commence the positive transcription elonga-
tion factor (P-TEFb) must be recruited to the transcription elon-
gation complex. P-TEFb is known to be a complex composed of
cyclin dependent kinase 9 (CDK9) and cyclin T1 (Bres et al., 2008;
Fujita et al., 2009; Jonkers and Lis, 2015; Kohoutek, 2009). To in-
itiate transcriptional elongation, P-TEFb phosphorylates serine2 of
the c-terminal domain (CTD) of Pol II and the SPT5 subunit of DSIF.
After this phosphorylation, NELF dissociates from the complex and
transcriptional elongation begins (Fujita et al., 2009). This process
occurs when P-TEFb is in its active form and part of a collective of
several proteins, termed the super elongation complex (SEC),
which is known to regulate transcriptional elongation (Luo et al.,
2012; Zhou et al., 2012).
The SEC is recruited to the promoter region of genes when
rapid transcription is required in response to speciﬁc develop-
mental signals, changes to available nutrition or even acute tem-
perature change. It is because of this that the genes primarily
regulated by RNA polymerase pausing are master regulator genes
and/or rapid response genes such as heat shock and serum in-
ducible genes (Fuda et al., 2009; Luo et al., 2012). It has also been
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suggested that the main function of SEC recruitment to paused
genes is not necessarily to allow rapid induction but also to syn-
chronise genes in development (Boettiger and Levine, 2009). Work
in Drosophila and ES cells has shown that transcription elongation
is not important globally within the genome but is found to reg-
ulate 10–40% of genes. Some of these genes have been identiﬁed as
crucial developmental control genes (Gaertner and Zeitlinger,
2014; Zeitlinger et al., 2007).
The neural crest is a transient embryonic cell population found
exclusively in vertebrates. Neural crest cells (NCCs) migrate from
the dorsal neural tube to various parts of the embryo where they
differentiate to give rise to a diverse set of cell types (Milet and
Monsoro-Burq, 2012; Pegoraro and Monsoro-Burq, 2013; Sauka-
Spengler and Bronner-Fraser, 2008). These include enteric ganglia,
neuroendocrine cells, melanophores, and craniofacial skeletal and
connective tissue, thus NCCs are multi-potent progenitors. Their
induction and speciﬁcation begins during the early gastrula stage
of development and continues throughout organogenesis. This
process depends on multi-module gene regulatory networks act-
ing between the neural plate, non-neural ectoderm and paraxial
mesoderm (Buitrago-Delgado et al., 2015; Hoppler and Wheeler,
2015; Huang and Saint-Jeannet, 2004; Sauka-Spengler and Bron-
ner-Fraser, 2008). Multiple signals and transcription factors are
responsible for neural crest (NC) properties such as multipotency,
induction, speciﬁcation, migration and differentiation (Sauka-
Spengler and Bronner-Fraser, 2008).
Once the neural plate border is fully speciﬁed and NCCs have
been induced, neural crest speciﬁers begin to act (Milet and
Monsoro-Burq, 2012). These include the transcription factors
Snail1, Snail2 (Slug), Sox8, Sox9, Sox10, FoxD3, and c-Myc. After
speciﬁcation morphological changes in the neural crest cells in-
cluding changes to shape, adhesion and cell motility enable the
cells to migrate from the dorsal neural tube (Sauka-Spengler and
Bronner-Fraser, 2008). Neural crest speciﬁers can be separated into
two groups; early and late NC speciﬁers. Expression of early neural
crest speciﬁers, including c-Myc, and Snail1, is ﬁrst identiﬁed at the
neural plate border, whilst expression of slightly later neural crest
speciﬁers such as Snail2 and FoxD3 is seen in pre-migrating neural
crest and can continue throughout migration. Only after these
have all started to be expressed does expression of members of the
SoxE family such as Sox10 start (Sauka-Spengler et al., 2007). It has
been suggested that the early neural crest speciﬁer c-Myc may
have a role in maintaining neural crest cell multipotency and
proliferation by maintaining a balance between cell death and
proliferation following NC speciﬁcation (Bellmeyer et al., 2003;
Kee and Bronner-Fraser, 2005; Light et al., 2005).
Using chemical genetic screens we have previously identiﬁed
small molecules that affect pigment cell development (Tomlinson
et al., 2005, 2009a, 2009b). One of these, the small molecule le-
ﬂunomide, inhibits pigment cell development in Xenopus and
Zebraﬁsh (Elworthy et al., 2003; Tomlinson et al., 2009b; White
et al., 2011). In addition, leﬂunomide inhibits melanoma tumour
growth in tissue culture and in mouse xenografts. Leﬂunomide
inhibits the enzyme dihydroorotate dehydrogenase, a rate limiting
enzyme in the pyrimidine biosynthesis pathway. It acts to inhibit
transcriptional elongation of genes required for neural crest de-
velopment and melanoma growth by limiting the pool of pyr-
imidines in the cell (White et al., 2011).
Here we further investigate leﬂunomide's ability to inhibit
transcriptional elongation during neural crest development and
show that it prevents expression of both, early and late neural
crest speciﬁers such as Snail2, Sox10 and FoxD3 and c-Myc. As le-
ﬂunomide acts through inhibiting transcriptional elongation we
speculated that regulation of transcriptional elongation could be
crucial for neural crest development. We therefore characterised
the temporal and spatial expression of components of the Positive
Transcription Elongation Factor B (P-TEFb) complex, Cdk9 and
CyclinT1, during neural crest development in Xenopus laevis. CDK9
and CYCLINT1 loss-of-function analyses by morpholino knock-
down closely mimic the phenotypes induced by leﬂunomide
treatment. Interestingly, we identify c-Myc as a gene susceptible to
regulation of transcriptional elongation in the early NC and show
that it is able to rescue CDK9 and CYCLINT1 morphant phenotypes.
This is backed up by ChIP sequencing data of Xenopus embryos
which shows the c-Myc gene to be one of the most ‘paused’ genes
in the genome. We thus propose regulation at the level of tran-
scriptional elongation to be important in NC development through
the driving of c-Myc expression.
2. Results
2.1. The expression of the P-TEFb complex components during Xe-
nopus laevis development
We have previously shown that inhibition of transcriptional
elongation leads to defects in neural crest development (White
et al., 2011). An important regulator of transcriptional elongation is
the P-TEFb complex. We therefore decided to investigate the role
of the components of the P-TEFb complex during Xenopus devel-
opment. The P-TEFb complex is comprised of CDK9 and CYCLINT1.
Expression analysis showed Cdk9.S, Cdk9.L and CyclinT1 to be ex-
pressed in the neural plate and neural plate border of neurula
stage embryos (Fig. 1). In tailbud stage embryos at stages 26 and
32 expression was seen in the NC derived branchial arches. To
determine if their expression overlapped with the NC, we carried
out double in situ hybridisations at st16 for all three P-TEFb com-
ponents with the neural crest marker Sox10. Expression of the
Cdk9.S, Cdk9.L and CyclinT1 overlapped with expression of Sox10,
indicating that the P-TEFb complex is expressed in neural crest
cells (Fig. 1).
2.2. Leﬂunomide treatment affects the development of neural crest
derivatives
Leﬂunomide was identiﬁed as an inhibitor of NC as a result of
chemical screens carried out with the aim to look for small mo-
lecules that affect pigment cell development. Our previous results
concentrated on the effects of leﬂunomide on zebraﬁsh neural
crest (White et al., 2011). Here we look at the effects of le-
ﬂunomide in more detail on Xenopus neural crest. Leﬂunomide
inhibits the formation of Xenopus laevis melanophores in a dose
dependent manner and causes a loss of melanophores when ad-
ded to the embryo after gastrulation (Fig. 2A and B). Initially, a
leﬂunomide dose response was used to establish the general
phenotype induced by the compound. DMSO treated embryos
served as a control. Embryos were treated at a range of con-
centrations from stage 15 and analysed at stage 38 (Fig. 2Ai). Le-
ﬂunomide treatment led to a loss of melanocytes in the underside
of the tail, head and lateral stripe of the embryo (Fig. 2Ai black
arrow heads). This phenotype was dose dependent, with 60 μM
leﬂunomide demonstrating the most severe phenotypes occurring
in a signiﬁcant number of embryos (Fig. 2Bi). Treating Xenopus
embryos at earlier stages showed a stronger effect on pigment cell
development along with a shortened axis (Fig. 2Aii and Bii).
2.3. Leﬂunomide inhibits transcription of neural crest speciﬁer genes
Next, we looked at how leﬂunomide treatment affects the ex-
pression of genes known to play a role at different stages of neural
crest development. Embryos were treated with 60 μM leﬂunomide
or DMSO from fertilisation and examined by in situ hybridisation
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for different markers of neural crest development (Fig. 2C and D).
The expression of the neural plate border markers Zic1, Zic3 and
Pax3 did not change after leﬂunomide treatment when compared
to the DMSO control (Fig. 2C). This suggests that leﬂunomide does
not interfere with these early stages of neural crest development.
There was also no signiﬁcant change seen in Sox2 expression
throughout the neural plate (Fig. 2C) suggesting that neural de-
velopment is largely unaffected by leﬂunomide treatment. We
next tested genes known to play a role in neural crest speciﬁca-
tion. The earliest neural crest speciﬁer gene, which showed a loss
in expression was c-Myc. This gene gave an interesting expression
pattern as it appeared that leﬂunomide-mediated inhibition of c-
Myc expression was restricted to the areas fated to become neural
crest (Fig. 2D black arrows). Loss of c-Myc expression was not
observed in more posterior neural domains. Later neural crest
speciﬁers, such as Sox10, were also signiﬁcantly reduced after
Fig. 1. The expression of the P-TEFb complex components during Xenopus laevis development. Transcripts for the P-TEFb components were detected using NBT/BCIP and
expression of CDK9.S, CDK9.L and CyclinT1 appeared blue in the sectioned neurula stage embryo. Sox10 was detected using fast red and ﬂuorescence microscopy. (A) CDK9.S
expression at stage 16 and 18 in the neural plate and neural plate border and expression at stages 26 and 32 in the branchial arches. Scale bar¼100 mm (Bi) 10" mag-
niﬁcation section of a stage 16 embryo showing CDK9.S expression in the neural plate and neural plate border (blue) and Sox10 expression in the neural crest (red). (ii) 20"
magniﬁcation section shows overlap of the blue CDK9.S expression with the red Sox10 expression. Expression of CDK9.S is outlined with a dashed white line and overlaid
onto the Sox10 expression image. Scale bar¼100 mm (C) CDK9.L expression at stage 16 and 18 in the neural plate and neural plate border and expression at stages 26 and 32
in the branchial arches. Scale bar¼100 mm (Di) 10" magniﬁcation section of a stage 16 embryo showing CDK9.L expression in the neural plate and neural plate border (ii)
20" magniﬁcation section shows overlap of the blue CDK9.L expression with the red Sox10 expression. Expression of CDK9.L is outlined with a dashed white line and
overlaid onto the Sox10 expression image. Scale bar¼100 mm (E) CyclinT1 expression at stage 15 and 18 in the neural plate and neural plate border and expression at stages
26 and 32 in the branchial arches. Scale bar¼100 mm (Fi) 10" magniﬁcation section of a stage 15 embryo showing CDK9.S expression in the neural plate and neural plate
border (blue) and Sox10 expression in the neural crest (red). (ii) 20" magniﬁcation section shows overlap of the blue CDK9.S expression with the red Sox10 expression.
Expression of CDK9.S is outlined with a dashed white line and overlaid onto the Sox10 expression image. Scale bar¼100 mm. Npb¼Neural plate border, ba¼branchial arches.
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Fig. 2. Leﬂunomide treatment affects the development of neural crest derivatives expression of neural crest genes. (Ai) Top to bottom shows DMSO treated control embryo,
20 μM, 40 μM and 60 μM leﬂunomide treated Xenopus laevis embryos. Leﬂunomide is applied at stage 15. Scale bar¼500 mm (ii) Top to bottom shows DMSO treated control
embryo, 60 μM leﬂunomide applied at stage 1, 8 and 12. Phenotype is observed at stage 38. Black arrow heads indicate pigment cell loss. Scale bar¼300 mm (Bi) Graph
showing the percentage of embryos displaying a pigment loss phenotype after treatment of DMSO n¼155, 20 μM n¼158, 40 μM n¼164 and 60 μM leﬂunomide n¼141.
*Po0.05 by Kruskall Wallis statistical test. (ii) Graph showing the percentage of embryos displaying a pigment loss phenotype after treatment of DMSO and 60 μM
leﬂunomide applied at stage 1 (DMSO n¼60 leﬂunomide n¼72), 8 (DMSO n¼67 leﬂunomide n¼73) and 12 (DMSO n¼63 leﬂunomide n¼67). *Po0.05 by Kruskall Wallis
statistical test. (C) Whole mount in situ hybridisation carried out on embryos treated with either DMSO or 60 μM leﬂunomide from stage 4 until stage 13 (Zic1, Zic3 and Pax3)
or stage 15 (Sox2). The neural plate border markers Zic1, Zic3 and Pax3 show no change in expression. Similarly, no change is seen for neural plate marker Sox2. Scale bar
¼200 mm (D) Whole mount in situ hybridisation carried out on embryos treated with either DMSO or 60 μM leﬂunomide from stage 4 until stage 13 (c-Myc) or stage 15
(Sox10, Slug/Snail2 and FoxD3). Speciﬁc loss of c-Myc expression is seen in the anterior region of the embryo (black arrows) and no loss of expression is seen in the posterior
neural tissue. Loss of Sox10 expression can be seen (black arrows) and some loss or alteration of expression on Slug/Snail2 and FoxD3. Scale bar¼200 mm (E) RNA sequencing
carried out on animal caps injected with Wnt-8 and noggin and treated with DMSO or leﬂunomide. The change in expression seen in speciﬁc genes found in the animal cap
sample by RNA sequencing is shown. Green¼neural crest specifying genes, Orange¼neuroectoderm genes, Blue¼neural plate border speciﬁers, Grey¼heat shock protein.
The complete list of genes affected can be seen in Supplementary data 1.
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leﬂunomide treatment (Fig. 2D black arrows) and also shown to be
only affected in the NC as expression in the otic vesicle (ear) was
not affected (Fig. S8). In addition we examined the neural crest
speciﬁers Slug/Snail2 and FoxD3 (Fig. 2D). Many embryos showed a
partial loss or an alteration in the expression of these genes.
Quantiﬁcation of these results (Fig. S1A) showed that c-Myc and
Sox10 show the strongest loss of expression. These results were
conﬁrmed by qRT-PCR on whole embryos (Fig. S1B). Using this
technique we found that neural plate border markers Zic1, Zic3,
Pax3 and the neural plate marker Sox2 displayed no signiﬁcant
change in expression level (Fig. S1B). Similarly to the in situ hy-
bridisation data we saw a signiﬁcant decrease in expression of
neural crest specifying genes c-Myc, Sox10, Slug/Snail2, and Sox9
(Fig. S1B).
2.4. RNA sequencing carried out on animal caps treated with
leﬂunomide
To characterise the tissue speciﬁc effects of leﬂunomide treat-
ment we carried out RNA sequencing on animal cap explants in-
duced to become neural crest, neuroectoderm or ectoderm. Ani-
mal caps were cut at stage 9 and immediately immersed into ei-
ther 60 μM leﬂunomide or DMSO and allowed to develop until
stage 15. The genes predominantly down-regulated in the neural
crest animal cap sample were genes involved in neural crest spe-
ciﬁcation and general development (Fig. 2E and Fig. S1C). Most of
these genes, were previously identiﬁed to be affected by in situ
hybridisation such as c-Myc, Sox10, FoxD3, Slug/Snail2 and Sox9.
Interestingly Snail1 expression was not affected by leﬂunomide. In
agreement with our in situ data, we saw no change in neural plate
markers, such as Sox1 and Sox2, or neural plate border markers,
such as Zic1, Zic3 and Pax3. Other categories of down regulated
genes included genes involved in eye development and metabo-
lism, both of which are closely associated with neural crest de-
velopment. Interestingly we saw down-regulation of heat shock
genes (Hsp90aa1.1, Hsp105 and Hsp110), which were some of the
ﬁrst genes suggested to be controlled by RNA polymerase pausing
and transcriptional elongation (Andrulis et al., 2000; Keegan et al.,
2002; Lis et al., 2000). The neuroectoderm sample showed a de-
crease in the expression of genes, which restrict neuroectoderm
fate e.g. Grainyhead-like 3, suggesting an increase in neuroecto-
derm cell fate. The ectoderm sample showed no signiﬁcant in-
crease or decrease in any other genes suggesting that regulation of
transcriptional elongation is not important for ectoderm devel-
opment. These results indicate that interference with transcrip-
tional elongation in this system mostly affects neural crest de-
velopment. We found expression of c-Myc to be slightly down-
regulated in the neural crest sample with no change seen in the
neuroectodem sample and it only shows low expression in the
ectoderm. This result agrees with the in situ hybridisation results
obtained (Fig. 2D). The small decrease in the NC sample is likely
due to a masking of any decrease by contaminating neural tissue,
which is always found in the NC animal caps. A full list of all genes
affected in all three sample types can be found in Supplementary
data 1. Overall, this data conﬁrmed our ﬁndings that leﬂunomide
acts to inhibit NC development and that this could be due to in-
hibition of transcriptional elongation.
2.5. Knockdown of the P-TEFb components leads to defects in neural
crest development
To determine the requirement of the P-TEFb complex and
subsequent transcriptional elongation for NCC development, we
carried out knockdown studies of the individual components. We
obtained morpholinos (MO) for CDK9.S, CDK9.L and CYCLINT1.
Morpholino sequences and controls are shown in Fig. S2. CDK9
MOs were injected individually and in combination at the one or
two cell stage. Embryos injected with these morpholinos were left
to develop until stage 38. The phenotype obtained after knock-
down of the P-TEFb components was comparable to that obtained
after leﬂunomide treatment. The MO-injected embryos displayed
neural crest defects including loss of pigment cells (Fig. 3A and Fig.
S3A) comparable to those shown in Fig. 2 and disorganisation of
cranial cartilage (Fig. S3B).
We next carried out in situ hybridisation using neural plate
border genes, neural crest speciﬁer genes and a neural plate
marker. Embryos were injected with a standard control Morpho-
lino, CDK9.S morpholino or the CYCLINT1 morpholino along with
300 pg of LacZ cRNA into one cell of a two-cell stage, with the non-
injected half serving as control (Fig. 3B, Fig. S3D and Fig. S7). The
expression of neural plate border markers Zic1, Zic3 and Pax3 were
not affected (Fig. 3B). The Neural plate marker Sox2 and other
neural genes were not affected (Fig. 3B and S5). c-Myc and Sox10
however, showed a striking knockdown after CDK9.S-MO or CY-
CLINT1-MO (Fig. 3B). Loss of c-Myc was seen speciﬁcally in the
anterior patches, which give rise to NC (black arrows Fig. 3B).
Complete loss of Sox10 expression was seen in the NC (black ar-
rows Fig. 3B). These results were conﬁrmed using qRT-PCR (Fig.
S4C). The same experiment was carried out after injection of the
CDK9.L MO, or a combination of the CDK9.S and CDK9.L MOs and
this data is shown in Fig. S4A and B. When embryos were allowed
to progress to stage 26 an effect on Sox10 expression in the cranial
NC can be seen but no change in expression of Sox10 is seen in the
otic vesicle (Fig. S8). In Leﬂunomide treated embryos Sox10 ex-
pression in the otic vesicle is also not affected while there is a loss
of expression in the cranial NC and pigment cells (Fig. S8). Other
neural crest markers Slug/Snail2, FoxD3 and Sox9 show some al-
teration and partial loss of expression, but very little complete loss
of expression (Fig. 3B and Fig. S4). In support of the RNA-Seq data
expression of Snail1, which is also an early speciﬁer of NC, was not
affected by knockdown of P-TEFb components (Fig. S7). The phe-
notypes after P-TEFb knock-down were strikingly similar to those
obtained after leﬂunomide treatment (Fig. 2C and D).
c-Myc is also known to regulate the development of trigeminal
placodes in the anterior region of the embryo. We therefore looked
at the expression of placodal markers by WISH. The placode
markers we used include Tbx2, NeuroD and ElrD, which are ex-
pressed in the trigeminal placodes and the neural tube (Green and
Vetter, 2011; Schlosser and Ahrens, 2004; Showell et al., 2006). We
were able to detect a loss of expression of all three markers, spe-
ciﬁcally in the trigeminal placode region, but not in any of the
other tissues in which they are expressed (Fig. 3C and Fig. S4D).
2.6. c-Myc is a paused gene during development
As c-Myc is the earliest gene to be affected by Leﬂunomide and
the knockdown of the P-TEFb components, we looked at the RNA
pol II occupancy proﬁle of c-Myc and compared it to the promoter
histone modiﬁcation H3K4me3 and the processive elongation
mark H3K36me3. These data suggest that c-Myc is in a paused or
poised state during mid to late gastrula just before the NC are
speciﬁed (Fig. 4A). We next carried out RNA Pol II ChIP-seq on
embryos injected with CDK9.S morpholino compared to embryos
injected with control morpholino. Knockdown of Cdk9 causes an
increase in RNA Pol II occupance, the effect of which is the
strongest on the promoter, suggesting that there is an increase in
pausing of c-Myc (Fig. 4A, blue tracks). We determined the pausing
index values for all annotated genes and Fig. 4Bi shows that there
is an overall increase in pausing. This would be expected given
that transcriptional elongation is effectively being suppressed.
Fig. 4Bii highlights that the loss of CDK9 causes an increase in the
amount of RNA Pol II bound to the promoter compared to the rest
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of the gene body. The position of c-Myc is shown by the blue spot.
While the RPKM on its gene body is increased from 5 to 10, the
RPKM on its TSS goes from 11 to 50. This suggests that c-Myc is
particularly sensitive to control of expression at the level
of transcriptional elongation and is therefore in a more ‘paused’
state.
Fig. 3. Knockdown of P-TEFb components leads to loss of expression of neural crest specifying genes. (A) All embryos were injected with 100 ng standard control mor-
pholino, 100 ng CDK9.S morpholino and 60 ng CYCLINT1 morpholino in both cells of a two cell stage embryo and ﬁxed at stage 38. Loss of melanocytes in the tail head and
lateral stripe are indicated by black arrow heads. (B) All embryos were injected in one cell of a two cell stage embryo with either a control morpholino CoMo, 100 ng CDK9.S
morpholino or 60 ng CYCLINT1 morpholino. 300 pg of Lac-Z cRNA was co-injected with morpholinos and β-gal activity was detected using a red gal stain to monitor lineage
tracing. in situ hybridisation was then carried out on these embryos for neural crest specifying, neural plate border and neural plate genes. c-Myc (stage 13) shows tissue
speciﬁc loss of expression (black arrows). Sox10 (stage 15) shows loss of expression (black arrows). Slug/Snail2 expression (stage 15) and FoxD3 expression (stage 15) appear
partially lost or altered. Zic1 expression (stage 12), Zic3 expression (stage 12), Pax3 expression (stage 12) and Sox2 expression (stage 15) appear unchanged. Quantiﬁcation of
these results can be found in Fig. S5D. Scale bar¼200 mm. (C) Knockdown of P-TEFb components leads to a loss of trigeminal placode markers. All embryos were injected in
one cell of a two cell stage embryo with either 100 ng control morpholino (CoMo), 100 ng CDK9.S morpholino or 60 ng CYCLINT1 morpholino. 300 pg of Lac-Z cRNA was co-
injected with morpholinos and β-gal activity was detected using a red gal stain to monitor lineage tracing. in situ hybridisation was then carried out on these embryos for
trigeminal placode markers. Tbx2 expression (stage 18) shows loss of expression speciﬁcally in the trigeminal placode region (black arrow). Expression in the otic placode
and dorsal root ganglia in not altered. NeuroD expression (stage 18) shows speciﬁc loss of expression in the trigeminal placode region (black arrow). ElrD expression (stage
18) is lost speciﬁcally in the trigeminal placode region (black arrow). Expression in the dorsal root ganglia remains unaltered.
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2.7. c-Myc is regulated by transcriptional elongation in neural crest
cells
We postulated that c-Myc could be the primary gene regulated
by transcriptional elongation in neural crest cells. We therefore
examined if loss of Sox10 expression after P-TEFb morpholino in-
jection could be rescued by co-injecting c-Myc RNA. For this ex-
periment CDK9.S morpholino and CYCLINT1 morpholinos were
injected alone or with 100 pg of c-Myc and 500 pg of c-Myc RNA.
As before, knockdown of CDK9.S and CYCLINT1 led to a high
number of embryos displaying loss of Sox10 expression (Fig. 5A
and B). Co-injection of these morpholinos with 100 pg of c-Myc
resulted in a reduction of the number of embryos displaying a loss
of expression phenotype. The majority of embryos displayed a
partial loss phenotype or wild type phenotype. After injection of
500 pg of c-Myc RNA a greater number of embryos displayed a
wild type phenotype (Fig. 5A and B). Injection of 500 pg of c-Myc
alone had very little effect on Sox10 expression and injection of the
standard control MO did not affect Sox10 expression (Fig. 5B). In-
jection of c-Myc RNA into one blastomere was also shown to
rescue leﬂunomide treated embryos on the injected side (Fig. S6).
3. Discussion
The molecular mechanisms controlling NCC speciﬁcation and
differentiation are complex and consist of many layers of regula-
tion to ensure the cells decide upon the correct lineage and form
the correct cell types. Other multipotent cell types such as em-
bryonic stem cells and haematopoietic stem cells are thought to
undergo regulation at the level of transcriptional elongation (Bai
et al., 2010; Lin et al., 2011). It has previously been shown that
Foggy mutant Zebraﬁsh, which are deﬁcient in the SPT5 subunit of
DSIF, display pigmentation and cardiac defects suggesting a
Fig. 4. c-Myc is a paused gene and CDK9 MO causes c-Myc to become more paused during development. (A) Histone methylation and RNA polymerase II (RNAPII) binding at
the c-Myc gene. Proﬁles of H3K4me3 (marking active promoters and 5′ ends of gene bodies, green), H3K36me3 (showing active transcription, light green) and RNA Pol II
(RNAPII, purple) (Hontelez et al., 2015) are visualised using the UCSC Genome Browser for the c-Myc gene on scaffold_6:7844903–7863621 (X. tropicalis genome assembly
version 7.1). The transcriptional proﬁle shows c-Myc to be a paused gene in Xenopus blastula and gastrula-stage embryos. RNA Pol II proﬁle of the c-Myc gene at stage 16 from
embryos injected with control MO or Cdk9s MO (blue). Note that the c-Myc gene is proportionately more paused in the cdk9 MO treated embryos. (B) RNA Pol II ChiP-seq on
whole embryos injected with Control MO or Cdk9.S MO. i) Histogram plots showing the distribution of the Pausing Index values (RPKM TSS 7150 bp divided by the RPKM
on the gene body) in log2 space for Control MO-injected (grey) and Cdk9.S MO-injected embryos (orange). The populations were shown to be signiﬁcantly different from
each other (Mann-Whitney P-valueo2.2"10#16), indicative of RNAPII redistribution. ii) c-Myc is more highly paused in Cdk9 MO treated embryos. Scatter plots of RPKM on
the gene body versus the transcriptional start site (tss) in Control MO (left panel) and Cdk9.S MO-injected embryos (right panel). The loss of Cdk9 causes an increase in the
amount of RNA Pol II bound to the promoter compared to the rest of the gene body. The c-Myc gene is shown by the blue spot. Genes with the strongest increase in gene
body RNAPII have the lowest increase in PI, suggesting that RNAPII stalls either at the promoter or in the gene body. The effects of RNAPII inhibition on transcript levels is
shown in Fig. 3B.
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disruption in neural crest development (Keegan et al., 2002). In
addition the Xenopus tropicalis mutant cyd vicious, which displays
pigmentation defects, is also mutated in the Spt5 gene (Lyle Zim-
merman, personal communication). Here we provide evidence for
direct regulation of the speciﬁcation of NC at the level of tran-
scriptional elongation by the P-TEFb complex. In addition, we
show that in the NC, c-Myc is the crucial gene regulated at the
level of transcriptional elongation.
The methods used in this study were ﬁrstly to use leﬂunomide
as an inhibitor of transcriptional elongation and secondly, through
the use of morpholino knockdowns of components of the P-TEFb
complex to block transcriptional elongation. Both of these meth-
ods gave comparable results (Figs. 2 and 3, Fig. S1–4). Both de-
monstrate a disruption in the development of neural crest deri-
vatives including melanophores, sensory neurons and cranio-facial
cartilage. When looking at the levels of expression of genes in-
volved in the neural crest gene regulatory network the two genes
demonstrating the greatest level of knockdown by WISH, qRT-PCR
or RNAseq were c-Myc, an early NC speciﬁer and Sox10, a NC
speciﬁer downstream of c-Myc also expressed in the migrating NC.
Furthermore, we showed that the loss of Sox10 gene expression in
the NC was rescued by injecting embryos with c-Myc RNA (Fig. 5).
To investigate whether c-Myc expression was directly regulated
by the P-TEFb complex and transcriptional elongation, we looked
at cell types other than neural crest cells, which are known to have
c-Mycwithin their gene regulatory network. We reasoned that if c-
Myc is a direct target a loss in expression of markers for these
other cell types should be observed. Our in situ hybridisation data
suggested that c-Myc expression in the placodal regions is lost
after knockdown of P-TEFb components (Fig. 3B), as opposed to
more posterior neural expression, which was not affected. We
therefore looked at the trigeminal placodes, which are similar to
NC and which express c-Myc in the early stages of their gene
regulatory network (Bellmeyer et al., 2003; Grocott et al., 2012).
We were able to detect a loss of expression of three markers,
speciﬁcally in the trigeminal placode region, but not in any of the
other tissues in which they are expressed (Fig. 3C and Fig. S4D).
This provides further evidence for c-Myc itself being directly
regulated by transcriptional elongation in speciﬁc tissues. Inter-
estingly we also see a loss of Rohon-Beard cell markers (Runx1,
Islet1 and Ngnr1) upon knockdown of the P-TEFb complex (Fig.
S4E). It is currently not known whether c-Myc signalling is re-
quired for the development of these cells. The combination of the
loss of neural crest cells, trigeminal placodes and Rohon-Beard
cells causes embryos treated with leﬂunomide or CDK9 morpho-
lino to become insensitive to touch response assays as shown in
(Fig. S3C and Supplementary movies 1–3).
Our ChIP-Seq analysis (Fig. 4) shows c-Myc to be a paused gene
during early development and that the inhibition of transcrip-
tional elongation by Cdk9 morpholino causes c-Myc to become
even more paused compared to the rest of the genome. This is
consistent with studies using human 293 T embryonic kidney cell
lines, which have also shown c-Myc to be a paused gene (Taka-
hashi et al., 2011). Rahl et al. (2010) have previously shown in
tissue culture that c-MYC can directly regulate the activity of
P-TEFb. This suggests the activation of c-Myc by signals such as
WNT (Bellmeyer et al., 2003) could lead to a positive feedback
system where c-MYC activates P-TEFb which in turn promotes
Fig. 5. c-Myc can rescue the effect of Cdk and CyclinT1 morpholino knockdown (A) Embryos were co-injected into one cell of a two cell stage embryo with a morpholino and
c-Myc RNA. 300 pg of Lac-Z cRNA was co-injected with morpholinos and RNA. β-gal activity was detected using a red gal stain to monitor lineage tracing. Embryos then
underwent Sox10 in situ. Injection of 100 ng Cdk9.S morpholino and 60 ng CyclinT1 morpholino results in a loss of Sox10 expression on the injected side. Co-injection of Cdk9.
S and CyclinT1 morpholino with 100 pg c-Myc RNA results in a partial rescue of Sox10 expression. Co-injection of Cdk9.S and CyclinT1 morpholino with 500 pg c-Myc RNA
results in a greater rescue of Sox10 expression. Scale bar¼200 mm. These results are quantiﬁed in Fig. S6D. (B) Graph showing the percentage of embryos displaying an
expansion, wild type, partial loss or loss of Sox10 expression pattern by in situ hybridisation after injection of Cdk9.S morpholino alone (n¼51) and co-injected with 100 pg
(n¼114) and 500 pg of c-Myc RNA (n¼61). CyclinT1 morpholino alone (n¼46) and co-injected with 100 pg (n¼61) and 500 pg of c-Myc RNA (n¼52). 500 pg of c-Myc RNA
alone (n¼34) and 100 ng of a standard control morpholino alone (n¼33).
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transcriptional elongation of the c-Myc gene. Our rescue experi-
ments in Fig. 5 and Fig. S6 suggests c-Myc overexpression can
overcome the effect of loss of P-TEFb activity. However we cannot
exclude the possibility that the increased amount of c-MYC in
these embryos may increase any residual P-TEFb activity to over-
come the loss of activity from the MO. Either way it still underlines
the crucial role for regulation at the level of transcriptional elon-
gation and the role of c-Myc in this process.
Our RNA-Seq results using animal cap explants show that when
the three cell types NC, neuroectoderm and ectoderm have in-
hibited transcriptional elongation the only cell type to show spe-
ciﬁc changes was the NC. We show down regulation of c-Myc
expression in the neural crest sample and observed little change in
the neural and ectoderm samples (Supplementary data 1). This
gives us further reason to suggest that regulation of c-Myc ex-
pression by transcriptional elongation is occurring only in speciﬁc
tissues, in this case the NC.
Overall, these results provide evidence that c-Myc is the ‘gate-
keeper’ regulated by transcriptional elongation in both, the NC and
trigeminal placodes, and that expression of the downstream
marker Sox10 in the NC is lost as a secondary effect of this. This is
consistent with previous analysis of microarrays from melanoma
tumours where many c-Myc responsive genes were affected by
leﬂunomide treatment (White et al., 2011). Our results are sum-
marised as a model in Fig. 6. We propose that the c-Myc gene is
held in a paused state within NCCs and not in all tissues. This
paused state is then speciﬁcally released in a wild type NC cell by
the P-TEFb complex to allow normal c-Myc transcription and
therefore promote synchronous transcription of downstream
genes such as Sox10 and the subsequent differentiation of neural
crest derivatives (Fig. 6 top route). MYC is known to actually sti-
mulate recruitment of P-TEFb to promoters of active genes thus
leading to increased expression in a process called transcriptional
ampliﬁcation (Rahl and Young, 2014). The results obtained from
our P-TEFb knockdown studies and leﬂunomide treated embryos
suggest that when the function of P-TEFb is impaired c-Myc is no
longer expressed at a high enough level and this in turn leads to
incorrect expression of downstream NC speciﬁers such as Sox10
and the synchronicity of maintaining multipotency, proliferation
and differentiation of neural crest is lost (Fig. 6 bottom route).
Recently it has been shown that regulation of transcriptional
elongation to be important for genes regulating cell cycle and
signal transduction (Williams et al., 2015). c-Myc is an important
regulator for such processes and as we show here it is clearly
important in the regulation of the neural crest.
To conclude, we provide evidence that the P-TEFb activation of
transcriptional elongation is an important step regulating the
correct expression of neural crest genes and that this is mediated
through the action of c-Myc. It is possible that a polymerase
pausing step is acting to prime c-Myc for transcription to ensure
the correct temporal expression of NC genes and therefore a
synchronous development of this cell type into its derivatives.
Polymerase pausing has previously been shown to be important in
cells, which undergo synchronous gene expression and develop-
ment. Compared to stochastic uncoordinated gene expression in
the whole embryo, the development of the NC requires such
synchronous gene expression (Boettiger and Levine, 2009). c-Myc
has been shown here to be particularly sensitive to inhibition of
transcriptional elongation and so it is possible that c-Myc is a
paused gene in prospective NC cells (Bai et al., 2010). There has
been much debate in recent literature as to whether this phe-
nomenon of RNA polymerase pausing and regulation of tran-
scriptional elongation is (1) common to all genes and (2) whether
it might be speciﬁc to certain cell types (Luo et al., 2012). Our data
contributes to this debate by providing evidence that regulation of
transcriptional elongation is focussed on c-Myc and is particularly
important in developing neural crest.
4. Materials and methods
4.1. Embryos, capped RNA synthesis, morpholinos, microinjection
and animal capping
All experiments were performed in compliance with the re-
levant laws and institutional guidelines at the University of East
Anglia. The research has been approved by the local ethical review
committee according to UK Home Ofﬁce regulations. Xenopus
laevis embryos were obtained as previously described (Harrison
et al., 2004). Embryos were staged using the Nieuwkoop and Faber
normal table of Xenopus development (Nieuwkoop, 1994). Full
length cDNAs for Xenopus laevis CDK9.S (IMAGE:5156812) and
CyclinT1 (IMAGE:7207389) were obtained from the IMAGE Clone
collection. CDK9.L was obtained from Dr Paul Mead. The cDNA
clones were all completely sequenced before subcloning into re-
levant vectors. Capped RNA was synthesised using the SP6
mMESSAGE mMACHINE™ (Ambion) kit for Wnt1, Noggin, c-Myc
(from Carole Labonne), LacZ and mutagenesis rescue constructs for
CDK9.S, CDK9.L and CyclinT1. Mutagenesis was carried out using
the QuickChange II XL Site-Directed Mutagenesis kit (Agilent
Technologies). Morpholino oligos (MOs) were designed and made
by Gene Tools. Morpholino sequences are: Standard control
(CoMO) 5′-CCTCTTACCTCAGTTACAATTTATA-3′, CDK9.S 5′-ATGGC-
CAAGAACTACGACTCGGTGG-3′, CDK9.L 5′-ATGGTAAAGAACTA-
CGACTCTGTTG-3′ and CyclinT1 5′-GACATCGTACTTTATGGCAA-
CAAAC-3′. These were tested by in vitro translation using the TNTs
Coupled Reticulocyte Lysate System (Promega) following manu-
facturers instructions. Capped RNA and morpholinos were co-in-
jected with 300 pg LacZ. Microinjections were carried out in 3%
Ficoll PM400 (Sigma). Embryos were injected at the 2 cell stage in
either 1 or both cells. β-Galactosidase activity was detected by
colorimetric reaction using Red-Gal (Sigma). Embryos were staged
and ﬁxed for 2 h at room temperature in MEMFA. Animal capping
Fig. 6. Model displaying the mechanism by which c-Myc is paused in neural crest
cells. On the left c-Myc is shown in a paused state with Pol ll bound to NELF, DSIF
and Gdown1. We have shown that a knockdown of the P-TEFb components CDK9
and CYCLINT1 leads to a loss of c-Myc expression and a subsequent loss of Sox10
expression and incorrect development of neural crest derivatives (bottom scenar-
io). This suggests in a wild type neural crest cell, P-TEFb is promoting transcrip-
tional elongation of c-Myc. P-TEFb in its active form bound to the SEC will phos-
phorylate DSIF, NELF, Gdown1 and serine2 of the C terminal of RNA Pol ll. This
promotes pause release on the c-Myc gene and allows the subsequent expression of
Sox10 leading to correct synchronous development of neural crest derivatives (top
scenario). S2¼Serine2, S5¼Serine5, P¼phosphorylation mark, NELF¼Negative
elongation factor, DSIF¼DRB sensitivity inducing factor, Pol ll¼RNA polymerase II,
CDK9¼Cyclin dependent kinase 9, SEC¼Super elongation complex.
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was carried out as previously described (Garcia-Morales et al.,
2009).
4.2. Wholemount in situ hybridisation
Single and double in situ hybridisation was carried out as pre-
viously described (Harrison et al., 2004). Probes were synthesised
for c-Myc (IMAGE:4884683), Sox10, Zic1, Zic3, Pax3, Sox2, Slug/
Snail2, FoxD3, Sox9, CDK9.S, CDK9.L and CyclinT1.
4.3. Cryosectioning
Embryos were ﬁxed in MEMFA for 1 h, washed twice for 5 min
in PBST and then put in 30% sucrose for 4 h at room temperature.
Embryos were then transferred to cryomoulds ﬁlled with optimal
cutting temperature (OCT) compound and left at 4 °C overnight.
Embryos were then positioned appropriately for sectioning and
left at #20 °C overnight. Embryos were sectioned using the LEICA
CM 1950 Cryostat and sections were placed on 5% TESPA slides.
Slides were then washed for 5 min in PBST and covered with a
coverslip using hydromount. Images were taken using a Zeiss CCD
upright microscope with colour camera.
4.4. Alcian blue staining
Embryos were ﬁxed for 1 h at room temperature, dehydrated
with 5 washes of 100% ethanol (EtoH) for 5 min each at RT and
then left in Alcian blue staining solution for 3 nights. After this
they were washed 3 times for 15 min in 95% ethanol at RT then
rehydrated in 2% KOH. This was done gradually using 10 min wa-
shes of 75% EtoH in 2% KOH, 50% EtoH in 2% KOH, 25% EtoH in 2%
KOH then 3 2% KOH washes. Embryos were then stored in glycerol
to make embryos more transparent. Facial cartilage was then
dissected out before imaging.
4.5. RNA extraction, PCR, Q-PCR and RNA sequencing
For the PCR, Q-PCR and RNA-sequencing experiments animal
caps were cut at stage 8 and allowed to develop to stage 15. Ap-
proximately 200 caps were required for each condition tested to
generate enough RNA for sequencing. Caps were collected in
batches of approx. 30 and RNA puriﬁed. Each batch was tested by
RT_PCR or QPCR to make sure the caps were expressing the re-
levant NC, neural or ectodermal markers. Total RNA was extracted
using TRIzols (15596-026, Life technologies, UK) and DNAse
treated. Reverse transcription was performed using SuperScripts II
reverse transcriptase (18064-014, Invitrogen, CA, USA), with 1 μg
total RNA and random primers (C1181, Promega, Southampton,
UK). Brightwhite 96 well plates (BW-FAST) and high quality optical
plate seals (BW-ADVSEAL) were used (PrimerDesign Ltd, South-
ampton, UK). Gene-speciﬁc nucleotide sequences were detected
using Precision™ FAST-LR 2" mastermix (PrimerDesign Ltd,
Southampton, UK). Quantitative RT-PCR was performed in a ﬁnal
volume of 20 μL using a 7500 FAST real-time PCR instrument
(Roche) under the following cycling conditions: 95 °C for 20 s, 40
cycles at 95 °C for 3 s, 60 °C for 30 s. After cycling, a melting curve
was recorded between 60 °C and 95 °C under the following 95 °C
for 15 s, 60 °C for 1 min, 95 °C for 15 s, 60 °C for 15 s with a ramp
rate of 0.11 °C s#1. Detection primers were designed using Primer3
software (http://biotools.umassmed.edu/bioapps/primer3_www.
cgi) and custom designed by PrimerDesign Ltd, UK where in-
dicated (Rozen and Skaletsky, 2000). Their oligonucleotide se-
quences are provided in Supplementary Table 1. In-house de-
signed primers were synthesised by euroﬁns (Norwich, UK) and
custom primers were designed by and purchased from Pri-
merDesign Ltd (PrimerDesign Ltd, Southampton, UK).
For the RNA seq experiments to determine whether we get a
similar loss of neural crest specifying genes compared to the whole
embryo data, the animal cap samples were initially tested by
in situ hybridisation and RT-PCR. RNA sequencing was carried out
to investigate which genes were affected by leﬂunomide across the
whole genome in the three sample types.
For RNA sequencing total RNA was fragmented before under-
going cDNA library preparation. cDNA was end-repaired, A-tailed
and adapter-ligated before ampliﬁcation and size selection. The
prepared libraries undergo quality control by running on a gel and
using a bioanalyser to check library fragment size distribution
before 100 bp paired end sequencing over one lane of a ﬂow cell.
Samples were multiplexed 2"3 and ran on one lane each to yield
approximately 25 million paired reads per sample. Reads were
aligned to the Xenopus laevis transcriptome (xlaevisMRNA.fasta)
downloaded from Xenbase (release 28/09/12) (Bowes et al., 2008;
Langmead and Salzberg, 2012). Mapping was carried out with
bowtie2 on paired-end samples using default parameters. A cus-
tom Perl script was used to parse the bowtie results and count the
number of sequences in each sample mapping to every mRNA
sequence in the transcriptome ﬁle. The table of raw abundances
for each mRNA was then read into R and differential expression
between untreated and leﬂunomide treated samples was calcu-
lated using the DEseq package (Anders and Huber, 2010). Any
transcript with a p-value of r0.05 was classed as being differ-
entially expressed between untreated and leﬂunomide treated
samples. The data has been uploaded to the NCBI SRA, accession
number PRJNA325078.
The data for quantitative RT-PCR experiments were analysed
using the 7500FAST software. Measured Ct values for quantitative
RT-PCR technical and biological replicates for each gene of interest
were analysed using the NORMA-gene algorithm (Heckmann et al.,
2011). NORMA-gene reduces systematic and artiﬁcial between-
replicate bias utilising the entire data-set of the target genes being
studied. NORMA-gene is applicable to small data sets greater than
ﬁve genes of interest and is used as our primary analysis tool as it
produces equal or better normalisation compared to the delta-
delta ct method. Leﬂunomide affects gene transcription thus im-
pacting upon metabolic and neural crest pathways. Therefore,
using reference vs. target normalisation is not appropriate to
measure gene expression.
4.6. ChIP-sequencing
Morpholinos were injected at 2 cell stage embryos and in-
cubated at 26 °C in 0.05" Marc’s Modiﬁed Ringer’s (MMR). Ap-
proximately 50 embryos per sample were ﬁxed at stage 16 in 1%
formaldehyde for 30 min. Samples were then washed in 125 mM
glycine solution 30 min and then transfer gradually to 0.1" MMR.
Embryos were homogenized in sonication buffer (20 mM TrisHCl
pH¼8, 70 mM KCl, 1 mM EDTA, 10% glycerol, 5 mM DTT, 0.125%
NP40, protease inhibitors (Roche #04693132001) and stored at
#80 °C. ChIP was prepared as previously described (Jallow et al.,
2004). After sonication, chromatin samples were incubated with
RNA Pol II antibody (diagenode C15200004) 1 mg per 15 embryo
equivalent in IP buffer overnight (50 mM TrisHCl pH¼8, 100 mM
NaCl, 2 mM EDTA, 1%NP40, 1 mM DTT and protease inhibitors)
followed by incubation with Dynabeads Protein G for 1 h. Beads
where subsequently washed in ChIP 1 buffer (IP buffer þ0.1%
deoxycholate), ChIP 2 buffer (ChIP 1 buffer þ400 mM NaCl), ChIP
3 buffer (ChIP 1 buffer þ250 mM LiCl) and TE buffer. Material was
digested with proteinase K and DNA was puriﬁed using a QIAGEN
kit. Q-PCR was performed pre and post library preparation for
quality checking and DNA libraries were prepared using Kapa
Hyper Prep kit (Kapa Biosysistem). Sequencing was done on the
Illumina HiSeq2000 platform and reads were mapped to the
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reference X. tropicalis genome JGI7.1 using BWA allowing one
mismatch. The CDK9 MO tracks are uploaded on the GEO database
and have GEO accession number GSE82153.
4.7. Small molecule compound treatment
The small molecule compound leﬂunomide (Sigma) was dis-
solved in DMSO to make a 10 mM stock. This was then diluted
directly into the embryos media 0.1" MMR. DMSO was added to
the media as a control (Tomlinson et al., 2012).
Author contributions
VH, CF, NW, MT, MM, ID, SH, IK and AH performed experiments.
VH, CF, SM, MT, GV, MM, AM and GW designed experiments,
discussed and analysed data. GW directed the research. VH and
GW wrote the manuscript.
Acknowledgements
We would like to thank members of the Münsterberg and
Wheeler labs past and present for their help and support during
this project. We would also like to thank Stefan Hoppler, Tim
Grocott and Richard White for helpful discussions, Paul Mead for
sending us his Cdk9 plasmid and other colleagues for various
plasmids. VH and GW acknowledge the help provided by the Cold
Spring Harbor Xenopus course. This work was supported by a
BBSRC, United Kingdom Grant (BB/I022252) to GW, a UEA Dean's
studentship to VH, by the People Programme (Marie Curie Actions)
of the European Union’s Seventh Framework Programme FP7 un-
der REA Grant agreement number 607142 (DevCom) to MM and ID
and by the UEA, United Kingdom, the John Innes Centre, United
Kingdom and AstraZeneca, United Kingdom (R18873) to AH.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.ydbio.2016.06.012.
References
Anders, S., Huber, W., 2010. Differential expression analysis for sequence count
data. Genome Biol. 11, R106.
Andrulis, E.D., Guzman, E., Doring, P., Werner, J., Lis, J.T., 2000. High-resolution
localization of Drosophila Spt5 and Spt6 at heat shock genes in vivo: roles in
promoter proximal pausing and transcription elongation. Genes Dev. 14,
2635–2649.
Bai, X., Kim, J., Yang, Z., Jurynec, M.J., Akie, T.E., Lee, J., LeBlanc, J., Sessa, A., Jiang, H.,
DiBiase, A., Zhou, Y., Grunwald, D.J., Lin, S., Cantor, A.B., Orkin, S.H., Zon, L.I.,
2010. TIF1gamma controls erythroid cell fate by regulating transcription
elongation. Cell 142, 133–143.
Bellmeyer, A., Krase, J., Lindgren, J., LaBonne, C., 2003. The protooncogene c-myc is
an essential regulator of neural crest formation in xenopus. Dev. Cell 4,
827–839.
Boettiger, A.N., Levine, M., 2009. Synchronous and stochastic patterns of gene ac-
tivation in the Drosophila embryo. Science 325, 471–473.
Bowes, J.B., Snyder, K.A., Segerdell, E., Gibb, R., Jarabek, C., Noumen, E., Pollet, N.,
Vize, P.D., 2008. Xenbase: a Xenopus biology and genomics resource. Nucleic
Acids Res. 36, D761–D767.
Bres, V., Yoh, S.M., Jones, K.A., 2008. The multi-tasking P-TEFb complex. Curr. Opin.
Cell Biol. 20, 334–340.
Buitrago-Delgado, E., Nordin, K., Rao, A., Geary, L., LaBonne, C., 2015. NEURODE-
VELOPMENT. Shared regulatory programs suggest retention of blastula-stage
potential in neural crest cells. Science 348, 1332–1335.
Cheng, B., Li, T., Rahl, P.B., Adamson, T.E., Loudas, N.B., Guo, J., Varzavand, K., Cooper,
J.J., Hu, X., Gnatt, A., Young, R.A., Price, D.H., 2012. Functional association of
Gdown1 with RNA polymerase II poised on human genes. Mol. Cell 45, 38–50.
Core, L.J., Lis, J.T., 2008. Transcription regulation through promoter-proximal
pausing of RNA polymerase II. Science 319, 1791–1792.
Elworthy, S., Lister, J.A., Carney, T.J., Raible, D.W., Kelsh, R.N., 2003. Transcriptional
regulation of mitfa accounts for the sox10 requirement in zebraﬁsh melano-
phore development. Development 130, 2809–2818.
Fuda, N.J., Ardehali, M.B., Lis, J.T., 2009. Deﬁning mechanisms that regulate RNA
polymerase II transcription in vivo. Nature 461, 186–192.
Fujita, T., Piuz, I., Schlegel, W., 2009. The transcription elongation factors NELF, DSIF
and P-TEFb control constitutive transcription in a gene-speciﬁc manner. FEBS
Lett. 583, 2893–2898.
Gaertner, B., Zeitlinger, J., 2014. RNA polymerase II pausing during development.
Development 141, 1179–1183.
Garcia-Morales, C., Liu, C.H., Abu-Elmagd, M., Hajihosseini, M.K., Wheeler, G.N.,
2009. Frizzled-10 promotes sensory neuron development in Xenopus embryos.
Dev. Biol. 335, 143–155.
Green, Y.S., Vetter, M.L., 2011. EBF factors drive expression of multiple classes of
target genes governing neuronal development. Neural Dev. 6, 19.
Grocott, T., Tambalo, M., Streit, A., 2012. The peripheral sensory nervous system in
the vertebrate head: a gene regulatory perspective. Dev. Biol. 370, 3–23.
Harrison, M., Abu-Elmagd, M., Grocott, T., Yates, C., Gavrilovic, J., Wheeler, G.N.,
2004. Matrix metalloproteinase genes in Xenopus development. Dev. Dyn. 231,
214–220.
Heckmann, L.H., Sorensen, P.B., Krogh, P.H., Sorensen, J.G., 2011. NORMA-Gene: a
simple and robust method for qPCR normalization based on target gene data.
BMC Bioinform. 12, 250.
Hochheimer, A., Tjian, R., 2003. Diversiﬁed transcription initiation complexes ex-
pand promoter selectivity and tissue-speciﬁc gene expression. Genes Dev. 17,
1309–1320.
Hontelez, S., van Kruijsbergen, I., Georgiou, G., van Heeringen, S.J., Bogdanovic, O.,
Lister, R., Veenstra, G.J., 2015. Embryonic transcription is controlled by mater-
nally deﬁned chromatin state. Nat. Commun. 6, 10148.
Hoppler, S., Wheeler, G.N., 2015. DEVELOPMENTAL BIOLOGY. It’s about time for
neural crest. Science 348, 1316–1317.
Huang, X., Saint-Jeannet, J.P., 2004. Induction of the neural crest and the oppor-
tunities of life on the edge. Dev. Biol. 275, 1–11.
Jallow, Z., Jacobi, U.G., Weeks, D.L., Dawid, I.B., Veenstra, G.J., 2004. Specialized and
redundant roles of TBP and a vertebrate-speciﬁc TBP paralog in embryonic gene
regulation in Xenopus. Proc. Natl. Acad. Sci. USA 101, 13525–13530.
Jonkers, I., Lis, J.T., 2015. Getting up to speed with transcription elongation by RNA
polymerase II. Nat. Rev. Mol. Cell Biol. 16, 167–177.
Kee, Y., Bronner-Fraser, M., 2005. To proliferate or to die: role of Id3 in cell cycle
progression and survival of neural crest progenitors. Genes Dev. 19, 744–755.
Keegan, B.R., Feldman, J.L., Lee, D.H., Koos, D.S., Ho, R.K., Stainier, D.Y., Yelon, D.,
2002. The elongation factors Pandora/Spt6 and Foggy/Spt5 promote tran-
scription in the zebraﬁsh embryo. Development 129, 1623–1632.
Kohoutek, J., 2009. P-TEFb-the ﬁnal frontier. Cell Div. 4, 19.
Langmead, B., Salzberg, S.L., 2012. Fast gapped-read alignment with Bowtie 2. Nat.
Methods 9, 357–359.
Light, W., Vernon, A.E., Lasorella, A., Iavarone, A., LaBonne, C., 2005. Xenopus Id3 is
required downstream of Myc for the formation of multipotent neural crest
progenitor cells. Development 132, 1831–1841.
Lin, C., Garrett, A.S., De Kumar, B., Smith, E.R., Gogol, M., Seidel, C., Krumlauf, R.,
Shilatifard, A., 2011. Dynamic transcriptional events in embryonic stem cells
mediated by the super elongation complex (SEC). Genes Dev. 25, 1486–1498.
Lis, J.T., Mason, P., Peng, J., Price, D.H., Werner, J., 2000. P-TEFb kinase recruitment
and function at heat shock loci. Genes Dev. 14, 792–803.
Luo, Z., Lin, C., Shilatifard, A., 2012. The super elongation complex (SEC) family in
transcriptional control. Nat. Rev. Mol. Cell Biol. 13, 543–547.
Milet, C., Monsoro-Burq, A.H., 2012. Neural crest induction at the neural plate
border in vertebrates. Dev. Biol. 366, 22–33.
Nieuwkoop, P., Faber, J., 1994. Normal Table of Xenopus laevis (Daudin). Garlan
Publishing, New York.
Pegoraro, C., Monsoro-Burq, A.H., 2013. Signaling and transcriptional regulation in
neural crest speciﬁcation and migration: lessons from xenopus embryos. Wiley
Interdiscip. Rev. Dev. Biol. 2, 247–259.
Rahl, P.B., Young, R.A., 2014. MYC and transcription elongation. Cold Spring Harb.
Perspect. Med. 4, a020990.
Rahl, P.B., Lin, C.Y., Seila, A.C., Flynn, R.A., McCuine, S., Burge, C.B., Sharp, P.A., Young,
R.A., 2010. c-Myc regulates transcriptional pause release. Cell 141, 432–445.
Rozen, S., Skaletsky, H., 2000. Primer3 on the WWW for general users and for
biologist programmers. Methods Mol. Biol. 132, 365–386.
Sauka-Spengler, T., Bronner-Fraser, M., 2008. A gene regulatory network orches-
trates neural crest formation. Nat. Rev. Mol. Cell Biol. 9, 557–568.
Sauka-Spengler, T., Meulemans, D., Jones, M., Bronner-Fraser, M., 2007. Ancient
evolutionary origin of the neural crest gene regulatory network. Dev. Cell 13,
405–420.
Schlosser, G., Ahrens, K., 2004. Molecular anatomy of placode development in Xe-
nopus laevis. Dev. Biol. 271, 439–466.
Showell, C., Christine, K.S., Mandel, E.M., Conlon, F.L., 2006. Developmental ex-
pression patterns of Tbx1, Tbx2, Tbx5, and Tbx20 in Xenopus tropicalis. Dev.
Dyn. 235, 1623–1630.
Takahashi, H., Parmely, T.J., Sato, S., Tomomori-Sato, C., Banks, C.A., Kong, S.E.,
Szutorisz, H., Swanson, S.K., Martin-Brown, S., Washburn, M.P., Florens, L.,
Seidel, C.W., Lin, C., Smith, E.R., Shilatifard, A., Conaway, R.C., Conaway, J.W.,
2011. Human mediator subunit MED26 functions as a docking site for tran-
scription elongation factors. Cell 146, 92–104.
Tomlinson, M.L., Field, R.A., Wheeler, G.N., 2005. Xenopus as a model organism in
V.L. Hatch et al. / Developmental Biology 416 (2016) 361–372 371
developmental chemical genetic screens. Mol. Biosyst. 1, 223–228.
Tomlinson, M.L., Hendry, A.E., Wheeler, G.N., 2012. Chemical genetics and drug
discovery in Xenopus. Methods Mol. Biol. 917, 155–166.
Tomlinson, M.L., Rejzek, M., Fidock, M., Field, R.A., Wheeler, G.N., 2009b. Chemical
genomics identiﬁes compounds affecting Xenopus laevis pigment cell devel-
opment. Mol. Biosyst. 5, 376–384.
Tomlinson, M.L., Guan, P., Morris, R.J., Fidock, M.D., Rejzek, M., Garcia-Morales, C.,
Field, R.A., Wheeler, G.N., 2009a. A chemical genomic approach identiﬁes ma-
trix metalloproteinases as playing an essential and speciﬁc role in Xenopus
melanophore migration. Chem. Biol. 16, 93–104.
Wada, T., Takagi, T., Yamaguchi, Y., Ferdous, A., Imai, T., Hirose, S., Sugimoto, S., Yano,
K., Hartzog, G.A., Winston, F., Buratowski, S., Handa, H., 1998. DSIF, a novel
transcription elongation factor that regulates RNA polymerase II processivity, is
composed of human Spt4 and Spt5 homologs. Genes Dev. 12, 343–356.
White, R.M., Cech, J., Ratanasirintrawoot, S., Lin, C.Y., Rahl, P.B., Burke, C.J., Langdon,
E., Tomlinson, M.L., Mosher, J., Kaufman, C., Chen, F., Long, H.K., Kramer, M.,
Datta, S., Neuberg, D., Granter, S., Young, R.A., Morrison, S., Wheeler, G.N., Zon,
L.I., 2011. DHODH modulates transcriptional elongation in the neural crest and
melanoma. Nature 471, 518–522.
Williams, L.H., Fromm, G., Gokey, N.G., Henriques, T., Muse, G.W., Burkholder, A.,
Fargo, D.C., Hu, G., Adelman, K., 2015. Pausing of RNA polymerase II regulates
mammalian developmental potential through control of signaling networks.
Mol. Cell 58, 311–322.
Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J.,
Handa, H., 1999. NELF, a multisubunit complex containing RD, cooperates with
DSIF to repress RNA polymerase II elongation. Cell 97, 41–51.
Zeitlinger, J., Stark, A., Kellis, M., Hong, J.W., Nechaev, S., Adelman, K., Levine, M.,
Young, R.A., 2007. RNA polymerase stalling at developmental control genes in
the Drosophila melanogaster embryo. Nat. Genet. 39, 1512–1516.
Zhou, Q., Li, T., Price, D.H., 2012. RNA polymerase II elongation control. Annu. Rev.
Biochem. 81, 119–143.
V.L. Hatch et al. / Developmental Biology 416 (2016) 361–372372
Nanoscale
PAPER
Cite this: DOI: 10.1039/c7nr06020c
Received 14th August 2017,
Accepted 6th December 2017
DOI: 10.1039/c7nr06020c
rsc.li/nanoscale
Unravelling the mechanisms that determine the
uptake and metabolism of magnetic single and
multicore nanoparticles in a Xenopus laevis
model†
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Multicore superparamagnetic nanoparticles have been proposed as ideal tools for some biomedical appli-
cations because of their high magnetic moment per particle, high speciﬁc surface area and long term col-
loidal stability. Through controlled aggregation and packing of magnetic cores it is possible to obtain not
only single-core but also multicore and hollow spheres with internal voids. In this work, we compare toxi-
cological properties of single and multicore nanoparticles. Both types of particles showed moderate
in vitro toxicity (MTT assay) tested in Hep G2 (human hepatocellular carcinoma) and Caco-2 (human
colorectal adenocarcinoma) cells. The inﬂuence of surface chemistry in their biological behavior was also
studied after functionalization with O,O’-bis(2-aminoethyl) PEG (2000 Da). For the ﬁrst time, these nano-
particles were evaluated in a Xenopus laevis model studying their whole organism toxicity and their
impact upon iron metabolism. The degree of activation of the metabolic pathway depends on the size
and surface charge of the nanoparticles which determine their uptake. The results also highlight the
potential of Xenopus laevis model bridging the gap between in vitro cell-based assays and rodent models
for toxicity assessment to develop eﬀective nanoparticles for biomedical applications.
Introduction
Iron oxide magnetic nanoparticles (IOMNPs) are extensively
studied nowadays for their potential in biomedical appli-
cations.1,2 Their surface chemistry can be modified, adding
functionality to the material and enabling their use for gene
therapy, tissue regeneration and drug delivery, to specifically
target tumours using external magnetic fields.3 Their magnetic
properties can be exploited for magnetic resonance imaging
and magnetic-fluid hyperthermia, which has raised hope for
improved imaging techniques4 and cancer treatment.5,6
However, in spite of their potential, few of these biomaterials
have reached clinical practice.7
A crucial issue for magnetic nanoparticle utilization in bio-
medicine and their approval by regulatory agencies depends
on their biotransformation and toxicity. The course and fate of
the nanoparticles once they deliver their imaging or thera-
peutic objective needs to be studied. Thus, the metabolism of
the particles and degradation by-products must be assessed
and assured. Since iron is involved in diverse cellular pro-
cesses,8 organisms display mechanisms to transport and store
iron in non-toxic forms.9 Therefore, IOMNPs are predicted to
be safely incorporated into biological systems. Increasing
evidence demonstrates that IOMNPs trigger iron-coping
mechanisms in cells and that the degradation products of
these materials are incorporated into normal iron metabolic
routes.10–16 However, nanoparticle coating has been shown to
be a determinant of the IOMNPs uptake and degradation path-
ways.17,18 In order to establish solid conclusions about
IOMNPs toxicity and biodistribution and their cellular eﬀects,
it would be ideal to have biologically pertinent models.
Xenopus laevis is an amphibian model ideal to study the
course and fate of the nanoparticles as it is an easy and flexible
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system in which to evaluate vertebrate embryology, basic cell
and molecular biology, genomics, neurobiology and toxi-
cology.19 Recently, this model was used to identify the risk of
exposure to contaminated water.20 The mortality, malfor-
mations and growth inhibition of Xenopus laevis were studied,
after challenge with metal oxide-based nanomaterial contami-
nants (γ-Fe2O3, TiO2, ZnO and CuO). Notably, γ-Fe2O3 did not
pose risks to amphibian populations up to 1 mg mL−1 where it
causes developmental abnormalities. In contrast, the other
nanoparticles caused gastrointestinal, spinal, and other
abnormalities at concentrations of ∼3 mg L−1. Furthermore, it
was shown that nanoparticle sizes above 200 nm had toxic
eﬀects.21 Despite available literature on the eﬀects of many
compounds on the larval development of X. laevis in environ-
mental studies, there are only few reports evaluating nano-
particles toxicity and biodistribution designed for biomedical
applications,22,23 and there is still a lack of knowledge bridging
biotransformation studies in cell-based assays with data gener-
ated from rodent in vivo systems.
In this work, we report the eﬀect of γ-Fe2O3 magnetic single
and multicore nanoparticles suitable for bioapplications in
X. laevis embryos. The particles have uniform size in the nano-
scale and are coated with biocompatible shells. IOMNPs col-
loids used in this work can be classified as single-core (with
only one magnetic core per particle) and multicore (with
several magnetic cores per particle).24 Single-core superpara-
magnetic nanoparticles have been proposed as ideal tools in
biomedicine, since they display longer circulation times post-
injection.25 Indeed, this may favour their uptake in leaky vas-
culature regions such as tumors.26 In contrast, for some
medical applications, such as bioseparation or magnetic fluid
hyperthermia, it can be advantageous to use larger multicore
particles that have a large magnetic moment per particle.27
Few in vitro and in vivo studies have been dedicated to the
comparison of single-core and multicore nanoparticles28 and
there is a lack of knowledge still on how the aggregation of
magnetic cores forming multicore nanoparticles aﬀects the
nanoparticle uptake and degradation.
Here we report for the first-time toxicity and metabolism
of single-core and multicore nanoparticles using a combi-
nation of in vitro cell culture models and an in vivo X. laevis
embryo model. The application of AC magnetic susceptibility
measurements has proven to be an excellent tool to study mag-
netic nanoparticles in complex matrices, since the diamag-
netic signal coming from tissues does not interfere with the
superparamagnetic signal of the NPs.29 This way it was poss-
ible to follow the signal of the magnetic nanoparticles in
animal models30–32 and to quantify the iron content. This is
one of the greatest challenges in the nanomaterials area nowa-
days, i.e. determining how best to characterize nanoparticles
and follow their transformation/degradation.33 The study of
in vivo fate of IOMNPs is imperative to develop successful bio-
medical applications. In this paper, we present for the first
time, a study, by means of AC magnetic susceptibility measure-
ments, of the intake of iron-containing particles in X. laevis
embryos.
Results and discussion
Nanoparticles synthesis and characterization
Two diﬀerent types of iron oxide nanoparticles were syn-
thesized in this work. Single-core nanoparticles (SC) were
obtained by thermal decomposition of the iron(III) oleate pre-
cursor in 1-octadecene (Fig. 1A and B). Particles were 13 nm
(±1 nm) in diameter, uniform in size (Fig. 1C), relatively round
and well dispersed, owing to the presence of oleic acid around
the particles. In a diﬀerent approach, multicore nanoparticles
(MC) were obtained by polyol mediated reduction of iron(III)
chloride. MC are composed of spherical 142 nm (±23 nm)
nanoparticles with a well-defined size and shape (Fig. 1D and F).
These MC nanoparticles consist of smaller cores of approxi-
mately 10 nm. HRTEM and X-ray diﬀraction patterns have
already been reported.34 Particle structure and size were
selected intentionally, since they are two key parameters that
directly influence in vivo biological behavior. The size of intra-
venously injected nanoparticles greatly aﬀects their in vivo bio-
distribution, e.g. particles from 60 to 150 nm in size are taken
up by the reticuloendothelial system leading to rapid uptake in
the liver and spleen in humans. Intravenously injected nano-
particles with diameters of 10–40 nm allow longer blood circu-
lation and can cross capillary walls, and they are often phago-
cytosed by macrophages which traﬃc to lymph nodes and
bone marrow.35 However, how these parameters aﬀect the
greater picture of toxicity and biodegradability mechanisms is
still poorly understood.
Iron oxide nanoparticles obtained by thermal decompo-
sition are hydrophobic. To stabilize them in aqueous media
and make them suitable for biological applications, oleic acid
on the surface of the nanoparticle was removed with DMSA via
ligand exchange reaction (SC-DMSA). Polyol mediated processes
render hydrophilic nanoparticles along with polyvinylpyrroli-
done (PVP40), present in the reaction, however an extra
capping agent like citric acid enhances the electrostatic repul-
sion and facilitates the final dispersion of the MC nano-
particles in aqueous media (MC-Cit). Hydrodynamic sizes are
always higher than sizes measured by TEM, indicating the
presence of the coating or some degree of agglomeration after
surface modification, but both types of particles remain below
200 nm (34 and 181 nm were obtained for SC-DMSA and
MC-Cit, respectively), an important requirement for bio-
medical applications. Both particles have high negative surface
charge at pH 7 (Z-potential equal to −38 and −25 mV for
SC-DMSA and MC-Cit, respectively). In order to evaluate the
influence of the surface charge in particle absorption and bio-
degradation, we conjugated covalently a diamine PEG deriva-
tive to the carboxylic groups (from both DMSA and citric acid)
to the surface of the nanoparticles. After PEG conjugation,
average hydrodynamic size at pH 7 increased from 34 to 65 nm
and from 181 to 183 nm for SC-DMSA and MC-Cit, respectively
(SC-DMSA-PEG and MC-Cit-PEG) and net surface charge
decreased from approximately −38 to −24 mV for
SC-DMSA-PEG samples and from −25 to −18 mV for MC-Cit-
PEG. Colloidal properties of aqueous suspensions of the nano-
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particles at pH 7 are summarized in Table 1. Also, hydrodyn-
amic sizes of the particles have been studied in diﬀerent bio-
logical media (Fig. 1S†).
Nanoparticle surface modification was also confirmed by
FTIR (Fig. 1G and H). For all the samples, the typical bands of
metal skeleton vibration (Fe–O) in the region of 550–600 cm−1
and a broad peak between 3000 and 3500 cm-1 due to surface
–OH groups are observed. After PEG conjugation, some peaks
appeared at 1354 and 1102 cm−1, indicating asymmetric and
symmetric stretching of C–O–C, and out-of-plane bending of
the –CH of the PEG chains at 956 cm−1. TGA of the unconju-
Fig. 1 Transmission electron microscopy (TEM) images of single and multicore nanoparticles. (A, B) SC-DMSA. (D, E) MC-Cit. (C, F) Size distribution
histograms. Red lines indicate the log-normal ﬁtting function of TEM particle size data. Physical chemical characterization of the nanoparticles after
conjugation with PEG. FTIR spectra of (G) single-core nanoparticles. (H) Multicore nanoparticles. (I) Thermogravimetric analysis of four formulations.
Table 1 Colloidal properties of aqueous suspensions of the nano-
particles at pH 7. Hydrodynamic sizes, PDI (= standard deviation/mean
size) and surface charge of single and multicore nanoparticles after PEG
conjugation
Sample Hydrodynamic size (nm) PDI ζ-Potential (mV)
SC-DMSA 34 0.054 −38 ± 12
SC-DMSA-PEG 65 0.084 −24 ± 7
MC-Cit 181 0.201 −25 ± 9
MC-Cit-PEG 183 0.225 −18 ± 9
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gated nanoparticles reveals a weight loss of ∼15% and 8%
for SC-DMSA and MC-Cit respectively, due to the removal of
physical and chemical water and capping molecules (DMSA or
citric acid) (Fig. 1I). Particles modified with diamine PEG
nonetheless showed a larger amount of conjugated polymer
(∼20% in the case of SC-DMSA-PEG and 13% for MC-Cit-PEG)
which indicates greater reaction eﬃciency. In the case of
SC-DMSA-PEG, the presence of ∼2 molecules of PEG per nm2
was calculated. In the case of MC-Cit-PEG is not possible to
make an accurate calculation of the number of PEG molecules
bounded to the surface because is not a homogeneous spheri-
cal surface due to their multicore structure. A notable decrease
in the surface charge of the particles is observed after PEG con-
jugation, however not all carboxyl groups are modified during
the reaction. The surface is not saturated probably due to the
steric hindrance caused by the PEG chains, and therefore we
have a limited balance of the negative surface charge coming
from the DMSA or citric acid.
Toxicity in vitro
In vitro toxicological characterization of the nanoparticles was
evaluated through the degree of cell survival by means of the
standard MTT assay. The cell lines used, Hep G2 and Caco-2,
represent the liver and the intestine, which are two important
target organs to encounter the NPs after oral exposure or intra-
venous injection in a biomedical application. The analysis of
cytotoxicity after incubation with the nanoparticles showed
that viability of cell culture is not significantly reduced by the
presence of the nanoparticles up to 160 µg mL−1 Fe concen-
tration after 24 h of treatment (80–100% viability compared
with the control) (Fig. 2A and B). At iron concentrations of
320 µg mL−1, SC decreased the viability of both cell lines down
to values of 20%. In the case of MC, viability percentage of
both cell lines is in the range of 60–80%, indicating lower tox-
icity even at high iron concentrations. The eﬀect of PEG
coating is not very clear at high iron concentration. In the case
of Hep G2 cells, PEG functionalization improved the cyto-
toxicity for SC while in Caco-2 it had no eﬀect. For MC, PEG
functionalization reduces the viability to 60% in Caco-2 cells
(Fig. 2A and B). Even though this method needs further refine-
ment and standardization for toxicity evaluation of nano-
materials, it oﬀers a quick, inexpensive and high-throughput
methodology to perform in vitro cytotoxicity screens.36
In order to characterize the absorption and biotransform-
ation of the nanoparticles, we determined by ELISA the ferritin
formation in Caco-2 cells as a measure of iron uptake
(Fig. 2C). Single-core nanoparticles seem to be internalized by
the cells more eﬃciently than multicore nanoparticles as
evidenced by a 5.4-fold increase in intracellular ferritin (cf.
control) compared with a 3.7-fold increase for MC-Cit probably
due to the smaller size of the SC. PEGylated MC particles
failed to alter (p > 0.05) the ferritin levels in Caco-2 cells. The
surface modification with PEG in both types of nanoparticles
reduces the internalization by the cells. The coating with
short-chain PEG molecules of iron oxide nanoparticles was
found to shield their surface charge and decreases their
internalization.37
In vivo evaluation of nanoparticles
To characterize the general toxicity of the nanoparticles,
embryos were treated with four diﬀerent concentrations, 0.25,
0.5, 0.75 and 1 mg mL−1. In these experiments, nanoparticles
were added at stage 38 and survival was evaluated every 24 h
until embryos reach stage 45, after approximately 72 h of
exposure. None of the conditions was found lethal for the
Fig. 2 Evaluation of cell viability by MTT assay. (A) Hep G2 cells.
(B) Caco-2 cells. Cells were treated with the nanoparticles for 24 h.
(C) Ferritin formation measured by ELISA in Caco-2 cells exposed to
40 µg mL−1 of single or multicore nanoparticles. Data represent
means ± SD (n = 3). * shows statistically-signiﬁcance compared with the
control (t test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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embryos, therefore we decided to perform the rest of the
experiments comparing a low and a high dose of nanoparticles
(0.5 and 1 mg mL−1). The use of the Xenopus model has advan-
tages with respect to other animal models. First, embryos
develop externally, allowing experiments to be performed prior
to, or directly following fertilization. Also, they have a rapid
embryo growth and development. A larval tadpole has a fully
functional set of organs, and it can be examined to determine
if any experimental intervention (in this case a solution con-
taining nanoparticles) has had an eﬀect.
Tadpoles treated with SC-DMSA and MC-Cit at 1 mg mL−1
displayed some general body toxicity compared with the
control, characterized by defects in embryo body shape like
bent spine or enlarged ventral fin (Fig. 3B). In the case of
SC-DMSA, 20% of the animals showed enlarged ventral fin and
MC-Cit provokes a significant increase (27%) of embryos with
bent spine.
Interestingly, the eﬀect of the PEG coating for each type of
NPs reduced the toxicological eﬀect as evidenced in a 2.6-fold
decrease of embryos with bent spine and a 2-fold decrease of
mild gut inflammation for MC; and a significant reduction in
the enlarged ventral fin phenotype for SC treated tadpoles
(Fig. 3A). In the case of embryos treated with 0.5 mg mL−1,
defects were subtler. These results suggested a dose-dependent
uptake of the NPs by the embryos. We next evaluated gut mor-
phology as it is the main organ involved in NPs’ absorption
after oral ingestion. Diﬀerent degrees of inflammation were
observed according to the dose of the nanoparticles, but also
Fig. 3 Xenopus laevis phenotypic nanotoxicity assay after 72 h of exposure from stage 38–45. (A) Quantiﬁcation of embryonic abnormalities.
Histograms shown are of 30 embryos per group (chi-square test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). (B) Representative images from
the X. laevis phenotypic nanotoxicity assay.
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according to their chemical structure. Mild inflammation is
observed in 43% of animals treated with SC-DMSA at
1 mg mL−1. The intestine coiled structure is preserved
although it is visibly enlarged. Embryos treated with MC-Cit at
the same dose showed more drastic eﬀects (20% mild and
36% severe inflammation). In the case of severe inflammation,
the gut is not maintained or not well formed, as we are unable
to see the intestinal loops. Regarding the eﬀects on inflam-
mation we didn’t observed significant diﬀerences in PEGylated
particles compared with the uncoated ones. In addition, 30%
of the animals treated with MC showed a significant decrease
of touch response after 72 hours of exposure (Fig. 3A).
Electron microscopy analysis of pharynx sections (Fig. 4),
taken from diﬀerent embryos, aﬀords the localization of the
ingested particles. The presence of the NPs in the tissue
sample is evidenced by the Energy Dispersive X-ray (EDS)
elemental mapping which delivers spots with brighter contrast
in areas of NP accumulation, due to the higher Z atomic
number of iron. NP intake is visibly detected in the images of
pharynx sections of the embryos because the EDS spectra
clearly showed K electron shell (K-α and K-β lines) of iron,
whereas in the case of control these peaks are absent (Fig. 4).
EDS analysis confirmed that only at the dose of 1 mg mL−1,
SC-DMSA and MC-Cit, could be detected in the upper body
tissue sections, in contrast with the control. PEGylated nano-
particles (SC or MC) were undetectable in all organisms. We
also observed SC-DMSA in the gills of the embryos (Fig. 2S†).
These results agree with the size-dependent deposition in the
intestine and/or the gills in Zebrafish observed for silver nano-
particles where particles from 10–20 nm showed increased bio-
availability compared with 140 nm particles.38 In our case, the
deposition of SC-DMSA in the gills is directly related to the
smaller size and larger surface area compared with MC-Cit,
providing increased adherence, penetration, and deposition in
the organism.
Iron quantification. AC magnetic susceptibility and ICP-OES
In order to quantify the iron present in the samples through
SEM-EDS analysis, the application of quantitative correction
procedures is needed, which are sometimes referred to as
matrix corrections.39 As SEM only provides local information,
the quantitative analysis of NP intake, was performed through
magnetic characterization of freeze-dried tissue samples and
iron elemental analysis of acid digested embryos. Moreover,
these techniques allow the comparison of the accumulation
depending on the coating and the surface charge (DMSA, citric
acid, and PEG functionalization).
In order to evaluate the accumulation of the nanoparticles
in the animals, we performed AC susceptibility of pools of
seven animals. Magnetic measurements, especially AC mag-
netic susceptibility, are extremely sensitive being able to dis-
tinguish the contribution from the magnetic nanoparticles
from that of other endogenous iron-containing species,
usually present in a bigger concentration but with weaker mag-
netic signal than the nanoparticles. The presence of magnetic
nanoparticles can be identified by a maximum in the in-phase
magnetic susceptibility (χ′) accompanied by a maximum at
slightly lower temperatures in the out-of-phase susceptibility
(χ″). The temperature location of the maxima depends on the
nanoparticle (material, size, aggregation degree, etc.). The
height of the maxima is a surrogate measurement of the con-
centration of nanoparticles.
In our case, a dose-dependent amount of nanoparticles is
observed in the animals treated with particles without PEG
coating (Fig. 5), independently if they are SC or MC.
Interestingly PEG coated nanoparticles, both SC and MC, were
below the detection limits of the technique. These results are
in agreement with what we observed by SEM-EDS. In this
work, the presence of ferritin, the iron storage protein with an
out-of-phase susceptibility maxima located at around 10 K,18
has not been observed. The absence of a substantial paramag-
netic contribution, usually observed at the lowest tempera-
tures, indicates that the concentration of free iron atoms is
very low, indicating that NP degradation process is limited if
not absent in the timescale of these experiments.
Through AC magnetic susceptibility measurements, dose-
dependent amounts of nanoparticles (SC-DMSA and MC-Cit)
were detected. In addition, a quantitative analysis of NP intake
was performed by ICP-OES (Fig. 6). Elemental analysis results
evidenced a dose-dependent iron absorption, which is in
agreement with the iron content detected by AC magnetic sus-
ceptibility. The absorption of SC-DMSA detected in the
Fig. 4 Scanning electron microscopy (SEM) images of pharynx sections
from diﬀerent embryos. (A) Schematic representation of the transversal
section analyzed. (B) Control. (C) Embryos exposed to SC-DMSA nano-
particles (1 mg mL−1, 72 h). (D) Embryos exposed to MC-Cit nano-
particles (1 mg mL−1, 72 h). Right panel shows elemental analysis of red
selected areas in the images obtained by Energy Dispersive X-ray
Spectrometry (SEM-EDS).
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embryos has been confirmed by ICP-OES, a three or five-fold
increase in comparison with MC-Cit for iron concentrations of
0.5 and 1 mg mL−1, respectively. Interestingly, the iron content
in the animals treated with PEGylated NPs is comparable to
the control indicating a very low absorption of these NPs.
One possible explanation for the visual disturbance of the
intestine structure of the embryos treated with MC-Cit-PEG,
could be that the particles are rapidly excreted by the organism
and therefore the iron content in these animals is seen as low.
As we previously observed in Caco-2 cells, PEG functionali-
zation reduces net surface charge of the particles and this
eﬀect could reduce the absorption of the particles in the gut
favouring their excretion. Surface functionalization with PEG
has been reported to enable particles to diﬀuse through
mucus in the gastrointestinal tract at a rate similar to
diﬀusion through water. It has been hypothesized that this
occurs by reduction of particle–mucus interactions.40 There is
also evidence that PEG-coating can decrease macrophage or
HeLa uptake of iron particles where the polymer increases
uptake hindrance compared with uncoated NPs.41 Another
possible explanation for the morphological alterations
observed at higher doses of nanoparticles could be the pres-
ence of polyol used during the MC synthesis. Other studies
have shown that polyol-made nanoparticles produce in vitro
(10 µg mL−1) and in vivo (0.8 mg kg−1) toxicity.42
Iron metabolism
Since iron resulting from NP degradation is predicted to be
processed by iron metabolic pathways, we next studied the
expression of diﬀerent genes involved in iron metabolism and
Fig. 5 AC magnetic susceptibility measurement of embryo tissue samples. In-phase (χ’(T )) and out-of-phase ( χ’’(T )) components of the magnetic
susceptibility, per mass of sample, corresponding to freeze-dried tissues from diﬀerent embryos after exposure (72 h): (A, C) embryos exposed to
SC. (B, D) Embryos exposed to MC (n = 7 per group).
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oxidative stress. The expression of genes linked to both pro-
cesses was assessed by real-time quantitative PCR (RT-qPCR)
in embryos treated with SC-DMSA and MC-Cit after 72 h of
treatment with the nanoparticles at 1 mg mL−1, taking into
account that only at highest doses could we detect a significant
amount of absorbed nanoparticles (Fig. 7A).
In the case of SC-DMSA treated embryos, transferrin and
dmt1 increased 2.6 and 2-fold respectively (cf. control) coupled
with a 70% downregulation of hepcidin. In contrast, the
MC-Cit treated embryos displayed marginal increases (p <
0.05) in hepcidin, and transferrin and dmt1 levels remained
unchanged. In both cases the transcription of ferritin is
increased after nanoparticle treatment, 2.9-fold change for
SC-DMSA and 1.9-fold change for MC-Cit treated embryos
(Fig. 7A).
From these data, we can describe diﬀerences in the meta-
bolic activation pathway of single-core or multicore nano-
particles. After iron ingestion, ferrous ions (Fe2+) are absorbed
in the enterocytes through the divalent metal transporter-1
(DMT1). In the apical membrane of the enterocytes, the cyto-
chrome B facilitates the reduction of ferric to ferrous ions
enabling the absorption of iron.
In the basolateral membrane of the enterocytes the ferro-
portin transporter is located together with hephaestin which
oxidize ferrous ions and allows transferrin to bind iron and
carry it in the bloodstream through the diﬀerent organs.
Hepcidin negatively regulates the entry of iron into circulation
through inhibiting ferroportin in case of iron overload
(Fig. 8A). Ferritin is the most important protein involved in
iron storage within cells, and the levels of Fe2+ present in the
organism regulates its expression.43
From magnetic measurements and elemental analysis, we
detected a higher absorption of SC-DMSA compared with
MC-Cit. We propose that the rate of particle internalization
into the embryos will dictate the time at which iron metabolic
pathway activation is measurable. In the case of SC-DMSA
Fig. 6 Iron quantiﬁcation though ICP-OES of acid digested tissues from
embryos treated at diﬀerent concentrations of IOMNPs. Striped pattern:
0.5 mg mL−1. Solid pattern: 1 mg mL−1 (n = 7 per group).
Fig. 7 Eﬀect on the expression of diﬀerent genes in X. laevis embryos exposed to SC-DMSA or MC-Cit after 72 h at 1 mg mL−1. (A) Genes involved
in iron metabolism. (B) Genes involved in oxidative stress response (n = 7 per group). * shows statistically-signiﬁcance compared with the control
(t test, ns > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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treated embryos, dmt-1, transferrin and ferritin have the highest
levels of transcription. The increase in ferritin in embryos
treated with SC-DMSA compared with MC-Cit, follows the
same pattern observed in Caco-2 cells where the protein was
detected by ELISA suggesting a higher iron bioavailability from
single-core nanoparticles. Hepcidin is downregulated for
SC-DMSA, which implies a saturation of the metabolic
pathway of iron. In the case of MC-Cit only ferritin and hepcidin
are upregulated corroborating a slower activation of the iron
metabolic pathway depending on the amount of internalized
particles after 72 h of treatment.
Oxidative stress
In embryos treated with SC-DMSA or MC-Cit at 1 mg mL−1 we
observed a 2.2 and 2.96-fold increase in hmox1 (cf. control)
respectively after 72 h of exposure (Fig. 7B). Increases in tran-
script levels of hmox1 have been described in macrophages
treated with iron oxide hybrids nanomaterials.44 Hmox1 is
induced after oxidative stress, reactive oxygen species or heavy
metals, thus degrading heme group to form biliverdin and
Fe2+. The production of Fe2+ leads to the activation of iron
regulatory protein (IRP) which is able to control the translation
of iron sensitive proteins such as ferritin. In the absence of
iron, IRP binds to ferritin mRNA and inhibits its translation.
However, when iron ions are available, they bind to IRP and
release it from ferritin mRNA, thus allowing its translation
(Fig. 8B).45 The increase in Fe2+ in the embryos 72 h after the
treatment, activates iron response proteins, which activates the
translation of proteins involved in iron metabolism such as
ferritin. We show in vivo the activation by Hmox-1 of iron regu-
latory proteins and their eﬀect in the transcription of ferritin
mRNA associated to the treatment with iron oxide nano-
particles (Fig. 7A and B).
Other oxidative stress response genes showed an increase in
expression in the case of embryos treated with SC-DMSA (sod
1.35-fold, catalase 3.27-fold and gsr 2.85-fold) compared with
MC-Cit (sod 0.5-fold, catalase 0.67-fold and gsr 1.14-fold)
(Fig. 7B). These results suggest the activation of protective
mechanisms depending on nanoparticle uptake in order to
reduce reactive oxygen species (ROS) generated during the bio-
degradation process. This is the early response of the organism
when nanoparticle clearance induces the formation of ROS.
However, we are not in the presence of an acute state of oxi-
dative stress when a general decrease of antioxidant enzymes
takes place.46
With these results, we provide evidence that an early devel-
opmental vertebrate model such as Xenopus laevis is a rapid
and inexpensive system for NP toxicity assessment, compared
with adult mammalian models. Because most theranostic
applications need nanoparticles to be taken up by the cells,
intracellular nano-biodegradation in an in vitro model needs
to correlate with in vivo observations. In the case of IONPs
degradation in vitro and their bioavailability by the cells trans-
lated into an increase of ferritin levels (Fig. 2C), should corre-
late with the corresponding activation of the iron metabolic
pathway as shown in Fig. 7A.
Here we demonstrated for the first time the study, by
means of AC magnetic susceptibility measurements, of the
intake of iron-containing particles in X. laevis embryos. We
postulate that the rate of particle internalization into the
embryos will dictate the time at which iron metabolic pathway
activation is measurable. Also, the NP deposition and uptake
likely depends on the physico-chemical characteristics of the
nanoparticles in terms of structure, size, and chemical modifi-
cation of the surface. We can consider Xenopus as the bridge
between cell-based assays and mammalian models taking into
account that the activation of the iron metabolic pathway,
especially with SC-DMSA, correlates with previous results in
diﬀerent murine models tracking IONPs biodegradation.18,32,47
The significant increase of transcript levels of ferritin or dmt1
correlates with previous observations in a Wistar rat animal
Fig. 8 Schematic representation of iron metabolic pathway. (A)
Enterocyte uptake and transfer of iron: ferrous ions (Fe2+) are absorbed
in the enterocytes through the divalent metal transporter-1 (DMT1). In
the apical membrane of the enterocytes, the cytochrome B (DcytB)
facilitates the reduction of ferric to ferrous ions enabling the absorption
of iron. In the basolateral membrane of the enterocytes the ferroportin
transporter (Fpn) is located together with hephaestin (Hp), which oxidize
ferrous ions and allows transferrin to bind iron and carry it in the blood-
stream through the diﬀerent organs. In the liver iron will be stored in
complex with ferritin (Ftn). In the case of iron overload Hepcidin tran-
scription is activated and it will regulate the entry of iron into circulation
through inhibiting ferroportin. (B) Regulation of ferritin mRNA translation
by Hmox1 and IRP: iron overload induces ROS generation. Hmox1 is
induced after oxidative stress, thus degrading heme group to form bili-
verdin and ferrous ions. The production of Fe2+ leads to the activation of
iron regulatory protein (IRP) which is able to control the translation of
iron sensitive proteins such as ferritin. In the absence of iron, IRP binds
to ferritin mRNA and inhibits its translation. However, when iron ions are
available, they bind to IRP and release it from ferritin mRNA, thus allow-
ing its translation.
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model where these proteins were quantified by ELISA in tissue
samples from the liver, spleen and kidneys, 24 hours after
SC-DMSA intravenous injection.18 Also, multicore nano-
particles degradation has been described in vitro recently,
starting with the dissociation of the multigrain structure and
following with the massive dissolution of the iron oxide
cores.48 These results highlight the necessity to study at longer
times the nanoparticle biotransformation in X. laevis.
Conclusions
In this work, the toxicity and metabolization of DMSA, citric
acid and PEG coated single and multicore iron oxide magnetic
nanoparticles have been studied in Hep G2 and Caco-2 cell
lines, and in an amphibian animal (Xenopus laevis) model
during its embryo development. The viability of both cell lines
is preserved in all cases when treated with the nanoparticles
up to an iron concentration of 160 µg mL−1. Above that con-
centration, only PEGylated nanoparticles didn’t cause toxicity
on Hep G2 cells but Caco-2 cells were more sensitive. In the
case of the in vivo viability, although none of the single-core
nor multicore coated nanoparticles were found lethal for the
embryos, more dramatic eﬀects were observed in the treatment
with multicore nanoparticles. Single-core nanoparticles are
absorbed (three or five-fold increase for doses of 0.5 and
1 mg mL−1, respectively) in comparison with multicore ones
suggesting size-dependent diﬀerences in the deposition an
uptake of the nanoparticles. Monitoring nanoparticle bio-
degradation is critical for therapeutic eﬃciency and safety
issues. Depending on their structural organization (single or
multicore) and surface chemistry, the embryos will trigger the
iron metabolic pathway to varying degrees. These findings
advance the understanding of iron oxide nanoparticle meta-
bolization in an early developmental vertebrate model like
Xenopus laevis, which oﬀers a quick, inexpensive and high-
throughput alternative prior toxicity assessment of nanothera-
peutics in rodent models.
Materials and experimental methods
Materials
Commercial products: iron(III) chloride hexahydrate, oleyl-
amine, oleic acid, meso-2,3-dimercaptosuccinic acid (DMSA),
1-octadecene, toluene, dimethyl sulfoxide, O,O′-bis(2-amino-
ethyl)PEG, 2000 Da, polyvinylpyrrolidone PVP40, sodium
acetate trihydrate, and citric acid (Sigma-Aldrich), sodium
oleate (Riedel-de Haen), n-hexane (Scharlau), ethyl-3-(3-di-
methylaminopropyl)-carbodiimide, ethylene glycol (Fluka),
and ethanol (Panreac). Dialysis tubing cellulose membranes
were purchased from Sigma-Aldrich and washed prior to use.
Nanoparticles synthesis
Synthesis of iron oxide single-core nanoparticles (SC). The syn-
thesis of iron oxide nanoparticles has been based on a pre-
vious work described in the literature.49 The reaction was
carried out under nitrogen. In a round-bottomed flask
(500 mL), equipped with a mechanical stirrer (glass stirrer
shaft), thermometer, entry for nitrogen flow and reflux conden-
ser, iron(III) oleate (4.54 g) was mixed with oleic acid (0.724 g)
in 1-octadecene (50 mL). The mixture was stirred (100 rpm)
and slowly heated (5 °C min−1 for T < 100 °C, and 2 °C min−1
for T > 100 °C) until reflux (325 °C) with a heating mantle. The
heating mantle was withdrawn, and the system was cooled
down to room temperature. The resulting black mixture was
washed with ethanol several times by centrifugation (RCF =
7500) and magnetic decantation. The resulting dried black
solid was redispersed in hexane.
Synthesis of iron oxide multicore nanoparticles (MC). The
synthesis of iron oxide nanoparticles has been based on a pre-
vious work described in the literature50 but the experimental
procedure and the concentration of NaAc have been varied.
Typically, 2.62 mmol iron(III) chloride were dissolved with
ultrasound in 109 mL of ethylene glycol. Then, 140 mmol
PVP40 were added slowly under vigorously magnetic stirring
(>1000 rpm) and mild heating until completely dissolved.
Then, 26.2 mmol of NaAc·3H2O were added to the solution.
The mixture was sealed in a Teflon-lined autoclave (125 mL)
and maintained at 200 °C for 16 h for solvothermal crystalliza-
tion, following cooling inside oven. The precipitated solid
product was washed with ethanol and distilled water through
centrifugation (RCF = 7500) several times.
Surface modification
Ligand exchange with dimercaptosuccinic acid on single-core
NPs (SC-DMSA). For DMSA ligand exchange, a standard pro-
cedure was used.51 In a typical experiment, ethanol (20 mL)
was added to a volume of SC dispersed in hexane containing a
mass of Fe3O4 of 50 mg. The mixture was sonicated and then
placed on a magnet to separate the liquid from the black solid
residue of nanoparticles. The residue was washed with more
ethanol (5 × 10 mL) following the same procedure, until the
discarded liquid had a clean appearance. The remaining black
residue was dispersed in toluene (20 mL) and the dispersion
added to a solution of DMSA (90 mg) in dimethyl sulfoxide
(5 mL). The resulting black suspension was then shaken in a
laboratory tube rotator. After 2 days, SC-DMSA nanoparticles
were precipitated as a black powder stuck to the glass tube and
the liquid phase was transparent and pale yellow. The liquid
was discarded and the nanoparticles were washed with
ethanol (4 × 10 mL), sonicating and centrifuging (RCF = 7500).
The final black solid was air dried and redispersed in distilled
water. KOH 1 M was added to increase the pH to 10 and HNO3
0.01 M was used to lower the pH to 7. The dispersion was then
placed in a cellulose membrane and dialyzed for 5 days in dis-
tilled water, to remove any excess of unreacted DMSA and any
other small impurities that may be present in the dispersion
without being attached to the nanoparticles.
Surface coating with citric acid on multicore NPs (MC-Cit).
For citric acid coating a standard procedure was used.24,52
First, sample volume equivalent to 20 mg of Fe was adjusted to
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pH 2 and then dispersed in 13 mL of a solution of citric acid
0.1 M. Afterwards, the mixture was heated at 80 °C for 30 min.
The solution was centrifuged and washed with distilled water.
Finally, the pH was adjusted first to 11 with KOH 1 M and
then to 7 with HNO3 0.01 M.
Surface coating with polyethylene glycol (SC-DMSA-PEG
and MC-Cit-PEG). PEG conjugation reaction has been based
on a previous work described in the literature.37 Amine-func-
tionalized PEG was attached to SC-DMSA or MC-Cit via an
ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)-mediated
coupling reaction using the polymer O,O′-bis(2-aminoethyl)
PEG, 2000 Da (Fig. 3S†). PEGylation reaction was carried out in
a refrigerated ultrasonic bath; an aqueous solution containing
10 mg SC-DMSA or MC-Cit was mixed with the PEG derivative
(4 mg). The total amount of EDC (1 mg) was divided into five
aliquots, one of which was added every 1 h, and the fifth 4 h
after the previous addition. The molar ratio of COOH groups/
amine groups/EDC was 1 : 1.5 : 1; pH was adjusted to 6, and
the mixture was sonicated (4 h, 25 °C), followed by extensive
dialysis.
Nanoparticle structural characterization
The particle sizes and morphologies were determined by trans-
mission electron microscopy (TEM) with a JEM1010 micro-
scope (JEOL, Peabody, USA) operating at 100 kV. Samples were
prepared by placing a drop of the uncoated particles
suspended in water onto a carbon coated copper grid and
allowing it to dry at room temperature. The size distributions
were determined by manual measurement of more than 100
particles using the public domain software ImageJ. The pres-
ence of the coating and the washing process was also con-
firmed and studied by Fourier transform infrared spectroscopy
(FTIR) in the range of 4000–250 cm−1 by use of a Bruker (USA)
IFS 66VS. The samples for FTIR were prepared diluting the
dried powder in KBr at 2% by weight and pressing it into a
pellet. The presence of the coating was also studied by thermo-
gravimetric analyses (TGA). They were performed in a Seiko
TG/DTA 320U thermobalance, whose temperature scanning
range is from room temperature up to 900 °C. For this work,
samples were heated from room temperature to 700 °C at
10 °C min−1 under an air flow of 100 mL min−1. Platinum
pans were used and α-Al2O3 was used as reference. Colloidal
properties were studied in a Zetasizer Nano S, from Malvern
Instruments (UK). The hydrodynamic size was determined by
Dynamic Light Scattering (DLS) and the zeta potential was
measured as a function of pH at 25 °C, using HNO3 and KOH
to change the pH of the suspensions. Hydrodynamic size is
given as the intensity-weighted mean.
Cell culture
Caco-2 cells (HTB-37) and HepG2 (HB-8065) were obtained
from American Type Culture Collection (Manassas, VA, USA)
and stored in liquid nitrogen. Hep G2 (human hepatocellular
carcinoma) and Caco-2 (human colorectal adenocarcinoma)
cells were cultured as mono-layers in Dulbecco’s modified
Eagle medium supplemented with 2% penicillin–streptomycin
and 10% fetal bovine serum, in a humidified incubator (37 °C,
5% CO2). For toxicity experiments, cells were seeded in 96-well
plates (approximately 1 × 104 cells per well, 200 μL per well).
For iron uptake experiments, Caco-2 cells between passages
30–36 were seeded onto collagen-coated 12-well plates (Bio-
Greiner, UK) at a density of 2 × 105 cells per well suspended in
1 mL of supplemented DMEM which was replaced every 2
days. Cells were used on confluence at days 13–15 post-
seeding. In order to ensure a low basal media iron levels,
24 hours prior to the initiation of the nanoparticles treat-
ments, the DMEM medium was replaced by Eagle’s minimum
essential medium (MEM) without foetal bovine serum sup-
plemented with 10 mmol L−1 PIPES [piperazine-N,N′-bis-(2-
ethanesulfonic acid)], 26.1 mM NaHCO3, 19.4 mmol L−1
glucose, 1% antibiotic–antimycotic solution, 11 µmol L−1
hydrocortisone, 0.87 µmol L−1 insulin, 0.02 µmol L−1 sodium
selenite (Na2SeO3), 0.05 µmol L−1 triiodothyronine and 20 µg
L−1 epidermal growth factor.53 The day of the experiment, the
nanoparticles were diluted in the low-iron MEM to obtain a
40 µg mL−1 final iron concentration and subsequently Caco-2
cells were exposed for 24 hours with the treatments. Ferritin
formation was measured 24 h after treatment. Cells were
rinsed with Milli-Q (18.2 MΩ) H2O and subsequently lysed by
scraping in 100 μL (12 well plates) of CelLytic M (Sigma-
Aldrich, Gillingham, UK). Cell lysates were kept on ice for
15 min and stored at −80 °C. For analysis, samples were
thawed and centrifuged at 14 000g for 15 min. Cellular debris
was discarded and the supernatant containing the proteins
was analysed for ferritin using the Spectro Ferritin ELISA assay
(Ramco Laboratories Inc., Staﬀord, TX, USA). The ferritin con-
centration in the samples was determined using a microplate
reader at an excitation wavelength of 500 nm according to the
manufacturer’s protocol. Ferritin concentrations were normal-
ized to total cell protein using the Pierce Protein BCA protein
assay (ThermoFisher Scientific, Loughborough, UK).
Cytotoxicity assay (MTT)
Cell viability was determined using the standard 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay 24 h after exposure to NP. Cells were seeded in 96-well
plates at (approximately 1 × 104 cells per well, 200 μL per well).
In total 60 wells were seeded per plate (6 rows × 10 columns)
as the outer wells were left empty to avoid errors due to evapor-
ation. Each row was used as a replicate (3 wells per condition)
and serial dilutions went across the columns of the plate. Cells
were left to grow until 70–80% confluency. NP-containing
medium was removed after 24 h, cells were rinsed three times
with PBS, and MTT solution in medium (final MTT concen-
tration 50 μg mL−1) was added and incubated (2 h, 37 °C). The
MTT solution was removed without disturbing cells, 0.2 mL
per well of DMSO and 0.025 mL per well of Sorensen buﬀer
were added, the plates were shaken gently to dissolve formazan
crystals, and the absorbance was read on a microplate reader
at 550 nm. Cell viability (%) was calculated as [(A − B)/A × 100],
where A and B are the absorbance of control and treated cells,
respectively. Values represent mean ± SD (n = 3).
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In vivo test
All experiments were performed in compliance with the rele-
vant laws and institutional guidelines at the University of East
Anglia. The research has been approved by the local ethical
review committee according to UK Home Oﬃce regulations.
Xenopus laevis embryo toxicity assays were carried out as
described before.54,55 Briefly, adult females were primed with
PMSG (Pregnant Mare’s Serum Gonadotropin) and induced
with Chorulon. Eggs were obtained manually and fertilized in
a petri dish by adding male sperm (male testis incubated with
2 mL 1× MMR (Marc’s modified ringers) + 8 mL FBS). The fer-
tilized embryos were dejellied via cysteine, and the embryos
were plated in BSA-coated petri dishes covered with 0.1× MMR.
Embryos were left at 23 °C until they reached stage 38, and
then plated in 24-well plates (7 embryos per well) in 0.1× MMR
medium containing the nanoparticles and incubated at 23 °C.
Non-treated embryos were used as control. The mortality and
the morphological changes of the embryos were recorded every
24 h until embryos reached stage 45.
Histological evaluation
When the embryos reached the appropriate stage, they were
fixed in MEMFA (3.7% Formaldehyde, 1× MEM salts and
DEPC H2O) overnight at 4 °C. Samples were washed in PBS,
dehydrated and kept in 100% ethanol. To embed embryos in
wax, they were directly washed in a 65 °C oven first in histo-
clear, then in 1 : 1 histoclear : wax and finally wax 30 min to
1 h each wash. Then the embryos were and placed in molds
with wax. Embryos were sectioned using a microtome generat-
ing 10 µm slices. Slices were then hydrated in water and dried
to be analyzed by Scanning electron microscopy.
Magnetic characterization
The resulting freeze-dried samples were placed into gelatin
capsules for their magnetic characterization in a Quantum
Design MPMS-XL SQUID magnetometer with an AC suscepti-
bility option. The measurements were performed with AC
amplitude of 0.41 Oe, in the temperature range between 1.8
and 300 K and at a frequency of 11 Hz.
Iron content analysis
Groups of 7 embryos were pooled. Animals were weighed and
lyophilized 72 hours in a Telstar lyoquest lyophilizer, and the
iron content was measured by Inductively Coupled Plasma-
Optical Emission Spectrometry (ICP-OES) in an Optima 2100
DV from PerkinElmer, after acid digestion, with concentrated
HNO3 during 1 h; or kept freeze-dried for magnetic character-
ization, respectively. The sample manipulation was performed
using disposable plastic material to avoid ferromagnetic
contamination.
RNA extraction and quantitative PCR
Groups of 7 embryos were snap frozen in liquid nitrogen. RNA
was extracted using High Pure RNA isolation kit (Roche) and
1 µg of RNA was taken to synthetize cDNA using Maxima First
Strand cDNA synthesis kit (Thermofisher). RT-PCR was per-
formed using SYBER Green detection method. Primers were
designed targeting both copies of X. laevis genes. Gapdh have
been used as a control.
Primers Sequence 5′–3′
fth1_F tggagtaacaccctggaagc
fth1_R aggatcaaccttgtcggatg
tf_F agaaagggcaagtgggtttt
tf_R tctggcaaagtgacaacagc
dmt1_F cagaggatgaaacgcactca
dmt1_R atcctgccactgatccagac
hepcidin_F aaatcaaccccaatctgctg
hepcidin_R gtttgttgattgccgaaggt
hmox1_F ggagacctctcaggtggaca
hmox1_R atggagttcatacgggaacg
sod2_F tgtgcaggctcagtgtttgt
sod2_R gctgcagagcaccataatca
gsr_F gcaaagaggagaaggtggtg
gsr_R cggaggaagtcggatgaata
cat1_F cttctgcccagatgcttttc
cat1_R agttgcccagagcgacttta
gapdh_F ctttgatgctgatgctggaa
gapdh_R gaagaggggttgacaggtga
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